Host-pathogen Interactions in Guillain-Barré Syndrome by Kuijf, M.L. (Mark)
Host-pathogen Interactions in Guillain-Barré Syndrome
Gastheer-pathogeen interacties in het Guillain-Barré syndroom
ISBN-13: 978-90-73436-88-6
No part of this thesis may be reproduced or transmitted in any form by any means, electronic or 
mechanical, including photocopying, recording or any information storage and retrieval system, 
without permission in writing from the publisher (M.L. Kuijf, Department of Immunology, 
Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands).
Host-pathogen Interactions in Guillain-Barré Syndrome
Gastheer-pathogeen interacties in het Guillain-Barré syndroom
PROEFSCHRIFT
ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
prof.dr. H.G. Schmidt
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
donderdag 5 november 2009 om 13.30 uur
door
Mark Laurens Kuijf
geboren te Arnhem
PROMOTIECOMMISSIE
Promotor: prof.dr. P.A. van Doorn
Overige leden: prof.dr. J.D. Laman
 prof.dr. A. van Belkum
 dr. E.E.S. Nieuwenhuis
Copromotor: dr. B.C. Jacobs
The studies described in this thesis were 
performed at the Departments of Neurology 
and Immunology, Erasmus MC, Rotterdam, 
The Netherlands.
 
The studies were financially supported by an Mrace grant from the Erasmus MC.
Illustrations :  Mark Kuijf
Printing :  Ridderprint Offsetdrukkerij B.V., Ridderkerk
Cover :  Studiokuijf-Vormgeving-DTP
Lay-out :  Wendy Netten and Marcia IJdo-Reintjes

Host-pathogen Interactions in Guillain-Barré Syndrome
Gastheer-pathogeen interacties in het Guillain-Barré syndroom
CONTENTS
 
Chapter 1 Introduction   9
   
Chapter 2   Preceding infections in Guillain-Barré syndrome (GBS) 37
Chapter 2.1  Presence or absence of cytomegalovirus in the cerebrospinal 39 
	 fluid	of	patients	with	Guillain-Barré	syndrome?
  (J. Infect. Dis. 2006; 193:1471-2)
Chapter 2.2  Epidemiology of Campylobacter-related Guillain-Barré 43
 syndrome in the Netherlands
  (Submitted for publication)
Chapter 3 Campylobacter jejuni and molecular mimicry in GBS  57
Chapter 3.1  Structural characterization of Campylobacter jejuni  59
	 lipo-oligosaccharide	outer	cores	associated	with	
 Guillain-Barré and Miller Fisher syndrome
  (Infect. Immun. 2007; 75:1245-54)
Chapter 3.2  Origin of ganglioside-complex antibodies in 89
 Guillain-Barré syndrome
  (J. Neuroimmunol. 2007; 188:69-73)
 
Chapter 4 Immune response to Campylobacter jejuni and  99
 antigen presentation in GBS
 
Chapter 4.1  Susceptibility to Guillain-Barré syndrome is not associated 101
 to CD1A and CD1E gene polymorphisms
  (J. Neuroimmunol. 2008; 205:110-2)
Chapter 4.2  Sialylation of lipo-oligosaccharide from Guillain-Barré  109
 syndrome-related Campylobacter jejuni modulates DC 
 and B-cell responses
  (Submitted for publication)
Chapter 5 Serum anti-neural antibodies in GBS and other  131 
immune-mediated neuropathies 
Chapter 5.1  Diagnostic value of anti-GQ1b antibodies in relapsing  133
 dysarthria and ataxia
  (BMJ Case Reports 2009 [doi:10.1136/bcr.08.2008.0783])
Chapter 5.2  Diagnostic value of anti-GM1 ganglioside serology and 141
 validation of the INCAT ELISA
  (J. Neurol. Sci. 2005; 239:37-44)
Chapter 5.3  Detection of anti-MAG antibodies in polyneuropathy  155
	 associated	with	IgM	monoclonal	gammopathy
  (Neurology 2009; 73:688-695)
Chapter 6 General Discussion   171
 
Summary    195 
   
Samenvatting    198
List of abbreviations    201
Appendices     203
     
Dankwoord    213 
  
Curriculum Vitae    216
 
List of Publications    217
Portfolio    218
   
     

1
Introduction
Chapter 1
10
GuILLAIN-BARRé SyNDROME
Guillain-Barré syndrome (GBS) is a neurological illness in which patients become rapidly 
paralyzed and require long-term rehabilitation. At present, it is the world’s most frequent 
cause of acute ascending paralysis in those countries where poliomyelitis has been eradicated 
(1). GBS is a post-infectious immune-mediated disease and in the last twenty years much 
progress has been made in elucidating the immune response to infections and peripheral 
nerves, the types of infection and the mechanism of nerve damage (2). As a consequence, 
GBS is regarded a model disease for other post-infectious diseases. 
The aim of the following paragraphs is to present a comprehensive framework for reading 
the remaining chapters of this thesis. It will focus on the role of infections, antibodies to neural 
antigens and the presumed immunological and molecular factors that determine why some 
individuals may develop GBS after infections whereas most do not. A general introduction 
about the history and clinical aspects of GBS and related disorders will be presented first. 
Next, the pathogenesis of GBS will be addressed in more detail. The role of serum anti-
neural antibodies in the diagnosis of GBS and other immune-mediated neuropathies will be 
discussed separately. 
Central to this thesis is the thought that interactions between patients (the host) and 
microorganisms (pathogens) contribute to the development of this post-infectious syndrome. 
At the end of this chapter the outline and aims of the studies described in this thesis will be 
presented. 
History
 
When modern medicine roots were shaped during the 19th century different authors have 
described cases resembling GBS. The most detailed description of  “acute ascending paralysis” 
during that time was written by J. B. Landry de Thézillat in 1859 (3). His superior suggested 
a relationship with preceding diphtheria in such patients, a common cause for gastroenteritis. 
During the First World War, G. Guillain and J.-A. Barré were serving doctors in the French 
army and performed lumbar punctures in two soldiers who had developed an acute partial 
paralysis that resembled Landry’s ascending paralysis. In 1916 the radiologist and physicist 
A. Strohl described in a French journal that both soldiers had reduced tendon reflexes in 
electrophysiological examination (4). He also found an elevated protein content in the 
cerebrospinal fluid (CSF) of these patients but without pleiocytosis. Together with Guillain and 
Barré they called this phenomenon the “dissociation albuminocytologique” and published this 
observation in the same edition of the journal (5). At the time these were relevant discoveries 
since they discriminated the syndrome from poliomyelitis and other prominent febrile causes 
of paralysis. 
At a meeting in 1927, H. Draganesco and J. Claudian introduced the eponym Guillain-
Barré syndrome, neglecting Landry and Strohl in the discovery of this syndrome (6). Today 
GBS is divided into different subgroups with different acronyms and is considered to be an 
immune-mediated polyneuropathy. 
11
Introduction
Clinical features
Diagnosis
Clinical symptoms of GBS
In essence, GBS is an acute generalized polyradiculopathy affecting limbs proximally and 
distally that commonly spreads to cranial nerves (7). The initial hallmark of GBS is progressive 
muscle weakness with or without numbness. In some patients progressive shortness of breath 
indicates involvement of respiratory muscles, which can lead to respiratory failure. Double 
vision and difficulties with swallowing indicate cranial nerve involvement. Sensory symptoms 
include numbness, paresthesia, pain and ataxia. Pain particularly occurs at the beginning of 
the disease and is more frequently present in children. In some patients autonomic dysfunction 
causes blood pressure disturbances and cardiac arrhythmias. In neurological examination a 
symmetrical distribution of sensory and motor deficits is usually found although asymmetric 
distribution of symptoms does not rule out the diagnosis. Tendon reflexes are low or absent 
in affected muscles. 
An increased protein level in CSF is usually found by the second week of disease. 
Electrophysiology may demonstrate signs of a demyelinating or axonal polyneuropathy and 
polyradiculopathy and is also best performed in the second week (8). Diagnostic criteria have 
been proposed that are generally used for inclusion of GBS patients in clinical trials and 
summarize these characteristics (9) (Appendix 1). 
Disease course and prognosis
A trigger precedes the onset of GBS, which is usually an infection in the days or weeks before 
(Figure 1). Subsequently, symptoms progress within days or weeks but sometimes within 
hours. The maximum level of weakness is reached within 4 weeks after onset of symptoms and 
is followed by a plateau phase, which can persist for weeks or months. Usually spontaneous 
recovery will take place that is often incomplete and may take years. In principle, GBS is a 
monophasic disorder although clinical fluctuations sometimes occur termed treatment-related 
fluctuations, which suggest a relationship with a temporarily response to treatment (10). 
A retrospective study showed that secondary deterioration nine weeks after onset of symptoms 
is suggestive for chronic inflammatory demyelinating polyneuropathy (CIDP) instead of 
GBS (11). 
Several prognostic factors are associated with poor outcome, including increased age (12-14), 
artificial ventilation (13), rapid onset of symptoms (15), absent motor responses and axonal 
involvement in initial electromyography (12-14), previous diarrhea or Campylobacter 
jejuni (C. jejuni) infection and antecedent cytomegalovirus (CMV) infection (13). Recently 
a clinically easy to use prediction model based on these prognostic factors was proposed 
that could be used to inform patients in an early stage (16). Retrospective analysis reveals 
that most patients will eventually function independently. However, 15-20% of patients are 
still unable to walk unaided after 6 months. In addition, 4-15% of patients die, mostly due 
to complications such as pneumonia, although this also depends on demographical factors 
such as geography and social economic factors. Residual symptoms constitute a challenge for 
patients and a lasting fatigue occurs in 70% of patients after stabilization (17). 
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Treatment 
The most important cornerstone for GBS treatment is supportive care, which generally 
requires a multidisciplinary approach (18). Regular monitoring of vital capacity, cardiac 
arrhythmias, blood pressure, urinary retention, pain, ileus and deep vein thrombosis are 
particularly important. Monitoring in an intensive care unit is indicated in patients with rapid 
progressive disease course, respiratory failure and patients with autonomic dysfunction. 
Intravenous immunoglobulin (IVIg) is the first choice of treatment and is similarly effective 
as plasmapheresis, but easier to be administered, better tolerated and is associated less often 
with complications (19). Addition of intravenous corticosteroids to IVIg may be beneficial in a 
selection of patients but is ineffective as monotherapy (20,21). In some patients a second course 
of IVIg may be given when patients deteriorate after an initial improvement. In developing 
countries therapies are hardly implemented presumably because they are expensive and only 
shorten disease duration of a self-limiting disease. However, prognosis of GBS is poor in 
more than 20% of patients; more effective, cheaper and more easily manufactured drugs are 
therefore desirable. New promising trials will investigate the beneficial use of complement 
inhibitors and additional courses of IVIg in a selection of patients with poor prognosis. 
Furthermore, many patients benefit from patient support groups such as the international 
GBS/CIDP foundation and the Dutch Vereniging Spierziekten Nederland (VSN). 
Classification and heterogeneity 
A syndrome is often defined as a spectrum of symptoms that characterizes a disease without 
reference to its cause. Accordingly, GBS is considered a syndrome with several distinct 
Infection / trigger
symptoms / weakness
monthsweeks
se
ve
rit
y
plateau phase
Production of anti-ganglioside antibodies
Progression of disease
recovery
residual deficits
Figure 1. Disease course of GBS. The subsequent phases of disease are shown in relation to the severity and 
time course of GBS.
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subtypes and not a unitary disorder. The different features that determine this heterogeneity 
are illustrated in Figure 2. This heterogeneity is presumably caused by different host genetic 
and environmental factors.
Accordingly, GBS can be classified in various ways. The most commonly used classification 
is based on electrophysiological findings, which are supposed to reflect the histological damage 
and is related to geographical areas. Acute inflammatory demyelinating polyneuropathy 
(AIDP) is the predominant form of GBS in Europe and in Northern America (22). In 1993, a 
collaborative study from Chinese and American researchers reported a primary axonal form 
of GBS occurring as an epidemic in a rural area in Northwest China (23). This form was called 
acute motor axonal neuropathy (AMAN) when a pure motor syndrome was found (without 
sensory symptoms) and acute motor and sensory axonal neuropathy (AMSAN) when sensory 
and motor involvement were both found. AMAN later appeared to be the most common type 
of GBS in China, Japan, Central and South America (23-25) and was highly associated with 
preceding C. jejuni infections and anti-ganglioside antibodies. 
In 1956, Charles Miller Fisher reported three patients with acute ophthalmoplegia, ataxia and 
areflexia. This clinical triad was subsequently termed the Miller Fisher syndrome (MFS)(26). 
The clinical symptoms in MFS are often supplemented by bulbar or oropharyngeal signs. 
Preceding event or infection
Electrophysiology
– demyelinating
– axonal
CSF abnormalities
–  or  protein content
– ± pleiocytosis
Specificity of anti-neural
antibodies
Physical examination Additional examination
A. Distribution of symptoms
– distal > proximal
– pure motor
– pure sensory
– sensory-motor
B. Cranial nerve involvement
± ataxia
C. Autonomic dysfunction
D. Severity and prognosis
A. B.
C. D.
Figure 2. Heterogeneity in GBS in clinical practice. The variability of several factors in relation to clinical 
deficits and additional examination determines the heterogeneity in GBS. 
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Some extent of muscle weakness is occasionally found in which cases it is sometimes referred 
as an overlapping form of GBS with ophthalmoplegia. In the original publication, Miller 
Fisher already considered the triad a variant of GBS as the clinical course of MFS is also 
very similar to GBS. In the current literature it is generally accepted that the syndromes are 
associated with each other. 
Epidemiology 
Extrapolation of available data from 40 years of research reveals an estimated annual 
incidence between 0.8 and 2.0 GBS cases per 100.000 individuals (15). The syndrome is 
found worldwide with possibly a slightly higher incidence of MFS in Japan. Generally, in 
most studies more males are observed with an estimated ratio of 3:2 (male: female). GBS 
occurs more frequently in higher age categories with a smaller second peak between 20-30 
years of age (15,27). A seasonal fluctuation of GBS incidence with more cases during summer 
and early winter has been reported in several countries (15,27,28). In countries like China, 
this pattern of increased incidence during summer is related to the seasonal fluctuation of 
C. jejuni infections, being more prevalent during warmer periods (28,29). Endemic forms of 
C. jejuni-related GBS have been reported in China, Curaçao and Bangladesh (1, 28,30). 
Pathogenesis 
Histopathology
Only limited autopsy studies in GBS cases are available but the results of individual cases 
showed that AMAN and AIDP presumably have different histopathological characteristics. 
Macrophages appear to play a critical role in both but act at different anatomical localizations. 
Table 1. Classification of most important variants of GBS.
Classification Clinical syndrome Electrophysiology Geographical relative frequency
AIDP Pure motor or
Sensory motor
Demyelinating Western countries: 80%
Asian countries: < 20%
AMAN / AMSAN Pure motor / Sensory motor Axonal Western countries: 5-10%
Asian countries: 30-50%
MFS Ophthalmoplegia
Ataxia
Areflexia
Absent SNAP in SFEMG Western countries: <5%
Japan: 10-15%
Overlapping forms Ophthalmoplegia 
Sensory motor
Various patterns <5%
Abbreviations: AIDP: acute inflammatory demyelinating polyneuropathy, AMAN: acute motor axonal neuropathy, 
AMSAN: acute motor and sensory axonal neuropathy, MFS: Miller Fisher syndrome, SNAP: sensory nerve action 
potential, SFEMG: single fiber electrophysiology. 
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In AIDP, macrophages invade the Schwann cell basement membrane and strip off the abaxonal 
Schwann cell cytoplasm (7,31) In AMAN, macrophages are located at the nodes of Ranvier 
where they insert their processes in between the axon and the Schwann cell axolemma (31) 
(Figure 3). The myelin initially appears untouched, but secondary demyelination as well as 
Wallerian degeneration is found at later stages of the disease and when the ventral root is 
affected, the entire axon is destroyed (22,31). Interestingly, T-cell infiltration is not observed 
in AMAN patients suggesting a different pathophysiology from AIDP (31). Both in AMAN 
and AIDP complement activation plays a prominent role (32). 
Anti-ganglioside antibodies in GBS
Anti-ganglioside antibodies were first described in patients with a paraproteinaemic 
polyneuropathy (33) but soon also in cases of GBS patients (34). Antibodies to several other 
types of gangliosides including GD1a, GD1b, GalNAc-GD1a and GQ1b were subsequently 
reported in large case-control studies that confirmed the association with GBS (35).
axon
AMAN macrophage
C5b-9Abs
macrophage
C5b-9 Abs
AIDP
axon
myelin
myelin
Figure 3. Histopathology of GBS and role of macrophages. 
Histological examination in patients with AMAN (acute motor axonal neuropathy) and AIDP (acute inflammatory 
demyelinating polyneuropathy) variants showed the presence of macrophages at different localizations. Abs: 
antibodies, C5b-9 complement complex.
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The term gangliosides refers to a group of glycosphingolipids that express sialic acid. 
The nomenclature of gangliosides is based on the number of carbohydrate molecules in the 
oligosaccharide chain and the position and number of sialic acid residues (36). The lipid tail 
of gangliosides is a ceramide that is immersed into the lipid membrane. The carbohydrate part 
is hereby exposed extracellularly and serves as an autoantigen for antibodies. The molecular 
structure of relevant gangliosides and glycolipids is given in Table 2.
 Gangliosides can be found in so called glycosynapses; organized molecular assemblies 
present in microdomains of the cellmembrane that are involved in cell adhesion, signal 
transduction events and altering cell phenotypes. Gangliosides are present in almost any cell 
type of the body but are highly concentrated in myelin sheaths and the axolemma of the 
nervous system. For example, GM1 is particularly concentrated in peripheral motor nerve 
myelin (37) whereas GQ1b is found in high concentrations in the oculomotor nerve (38). 
The distribution of the neurological deficits found in GBS patients shows a remarkable 
association with antibody specificity and the distribution of these glycoconjugates. Antibodies 
to GM1 and GD1a are typically associated with motor deficits in GBS patients, whereas anti-
GQ1b antibodies are highly associated with oculomotor deficits (35). 
With current techniques, in around 40-50% of GBS patients serum antibodies to one or 
more gangliosides are detected but in the remaining patients the target antigens are unknown. 
In 2004, a new concept was proposed that opens a new field of research for this seronegative 
group of patients. Gangliosides are lipid molecules that accumulate in specialized domains 
of the cell membrane called lipid rafts (39). The fluidity of this environment generates the 
possibility that single gangliosides may form complexes with other gangliosides when they 
reside in each other’s proximity. Accordingly, it was hypothesized that GBS patients without 
detectable anti-ganglioside antibodies may have antibodies to ganglioside complexes. This 
was demonstrated in a GBS patient having antibodies to a complex formed by GD1a and 
GD1b (40). The serum of this patient did not react to GD1a or GD1b alone in thin-layer 
chromatography but clearly showed a band present in between these lipids. Antibodies to other 
ganglioside complexes have been described in other GBS as well as in MFS patients (41). 
The clinical correlate of anti-ganglioside complex antibodies in GBS is under current 
investigation.
Pathogenicity of anti-ganglioside antibodies in GBS
In concept, the presence of anti-ganglioside antibodies in GBS and other immune-mediated 
neuropathies was first linked to the presence of high amounts of gangliosides in peripheral 
nerves. However, antibodies found in GBS patients could in theory be induced secondary 
to peripheral nerve damage and represent an epiphenomenon. Instead, compelling evidence 
indicates that anti-ganglioside antibodies are induced during antecedent infection and in GBS 
directly cause peripheral nerve damage (35,42). Antibody deposits are found in peripheral 
nerves of GBS patients and are neurotoxic for mouse perisynaptic Schwann cells, nodes of 
Ranvier, peripheral nerve endings and neuromuscular junctions (43-46). Disruption of these 
structures is mediated by local complement activation (Figure 4). Anti-ganglioside antibodies 
may induce leucocyte degranulation via Fc-receptors (47,48). Passive transfer of serum 
from GBS patients with anti-GQ1b antibodies results in nerve dysfunction in vitro as well as 
neurological symptoms in mice, which can be prevented by addition of IVIg and complement 
17
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inhibitors (49,50). Furthermore, immunization of rabbits with gangliosides and C. jejuni 
results in anti-ganglioside antibody responses and neurological symptoms resembling GBS 
in mice and rabbits (42,51). In GBS patients, there is a significant association between the 
specificity of antibodies and clinical deficits that further suggests a crucial role of anti-
ganglioside antibodies in the pathogenesis of GBS (52-54). Collectively these observations 
have firmly established the concept that anti-ganglioside antibodies are pathogenic and induce 
GBS. However, GBS patients have antibodies to different forms of gangliosides, of which the 
pathogenicity has not yet been demonstrated in all cases. In addition, in about half of GBS 
patients no serum antibodies to gangliosides can be detected at all.
Preceding infections and other triggers
One to three weeks prior to development of GBS, symptoms of an upper respiratory tract 
infection (URTI) or flu or diarrhea are reported in two thirds of GBS patients. Initial case reports 
Table 2. Schematic representation of relevant glycolipids in thesis and GBS. 
(1-1)(1-4)
(2-3)
GM1
GA1
GM1b
GD1a
GD1b
GQ1b
(1-4) (1-4)
(1-1)(1-4) (1-4) (1-4)
(2-3)
(1-1)(1-4) (1-4) (1-4)
(2-3)
(1-1)(1-4) (1-4) (1-4)
(2-3)
(2-8)
(1-1)(1-4) (1-4) (1-4)
(2-3)
(2-8)
(1-1)(1-4) (1-4) (1-4)
(2-3)
(2-8)
(2-3)
(1-1)GalC
(1-1)(1-4)GA3
(1-1)GA2 (1-4) (1-4)
(2-3)
GM2 (1-1)(1-4) (1-4)
(2-3)
GM3 (1-1)(1-4)
(2-3)
GD3 (1-1)(1-4)
(2-8)
Legend:      galactose,       sialic acid,       glucose, N-acetyl-galactosamine,  ceramide tail, GA1: asialo-GM1, GA2: asialo 
GM2, GA3: asialo-GM3, GalC: galactocerebroside. 
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suggested C. jejuni infections as a cause for the antecedent diarrhea in GBS patients (55). 
Large case control studies using serological techniques confirmed that around 30 to 40% of GBS 
patients have recent infections caused by C. jejuni and also indicated that other pathogens are 
associated with GBS such as CMV, Epstein-Barr virus (EBV) and Mycoplasma pneumoniae 
(Table 3) (56,57). Haemophilus influenzae is frequently isolated from GBS patients but is 
also isolated from controls (58,59). Nevertheless, indirect evidence suggests that H. influenza 
may be the precipitating factor in a similar proportion as those having antecedent C. jejuni 
infections (60). Several other types of infections have been associated with GBS in single 
cases or small case series of which the significance is unclear.
It is an intriguing question what triggers GBS in the remaining one third of patients not 
reporting infections. Most likely, a considerable proportion of these are caused by subclinical 
infections. In addition to subclinical infections other factors may also provoke GBS. 
For example, an increased incidence of GBS after vaccination programs for rabies (61) and 
swine-flu (62) was reported during the 1970s and 1980s although the significance of this 
association has been debated (63). Other possible triggers suggested by case reports include 
intravenous ganglioside mixture therapy, pregnancy, surgery and cancer, of which some 
may be related to an infection as well (64). GBS thus appears to be a typical post-infectious 
syndrome with or without a defined trigger. In the next paragraphs, the role of C. jejuni as 
most important pathogen for GBS will be discussed further.
Lipid raft
C1q
Classical pathway of complement
activation
C5b-9
Ca2+
GM1 ganglioside
Axon
Myelin sheath
Axonal damage and 
nerve disruption
Figure 4. Anti-ganglioside antibodies induce complement-mediated nerve injury. 
Gangliosides residing in lipid rafts in axons serve as targets for antibody binding. Subsequently, C1q complement 
binds to the Fc-part of antibodies and is activated through the classical pathway resulting in the formation of the 
C5b-9 or membrane attack complex (MAC). This leads to disruption of sodium channels, Ca2+ influx and axonal 
nerve injury.
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The role of C. jejuni infections in GBS
C. jejuni infection is the leading bacterial cause of diarrhea in the industrialized world and 
is the most frequent cause of infection preceding the development of GBS (65). Reported 
frequencies in GBS range between 30 to 40% (66). Based on current serological techniques, 
the annual incidence of C. jejuni-related GBS cases for The Netherlands with around 17 million 
inhabitants has been estimated 60 cases per year (67). From this, it has been deduced that the 
risk of getting GBS after a C. jejuni enteritis is around 1 per 1.300 (68). Since only about 
60-75% of culture confirmed cases of C. jejuni gastroenteritis also have positive serology, 
this may still be an underestimation. It is important to know which risk factors determine 
the susceptibility of developing GBS after C. jejuni-related gastroenteritis and why the large 
majority of individuals do not develop this disabling sequel. Comparing the demography of 
C. jejuni-related gastroenteritis and GBS may identify predisposing factors for development 
of GBS after C. jejuni infection. 
C. jejuni infections induce cross-reactive anti-ganglioside antibodies
A breakthrough in GBS research was made in 1993 when the mechanism by which anti-
ganglioside antibodies arise was postulated to occur through molecular mimicry with microbial 
lipo-oligosaccharide structures (LOS) present in the outer cell wall of C. jejuni (Figure 5). 
Chemical and structural analysis of C. jejuni LOS purified from the strain that infected a 
GBS patient with anti-GM1 antibodies, demonstrated a carbohydrate structure resembling 
GM1 (2). This suggested that an immune response was induced, in which serum antibodies 
cross-react to C. jejuni LOS and peripheral nerves. Other observations further supported the 
idea that anti-ganglioside antibodies in GBS arise in response to infections by pathogens 
expressing ganglioside-like structures. These observations include:
1.  The presence of GD1a, GD3, and GT1a-like moieties in LOS of C. jejuni strains 
isolated from other GBS patients with anti-ganglioside antibodies (69,70). 
2.  Serum reactivity to gangliosides was inhibited by pre-incubation with purified 
C. jejuni LOS containing ganglioside-like structures demonstrating that these 
antibodies cross-react (71,72).
3.  Ganglioside-like structures in LOS were more frequently found in GBS-associated 
C. jejuni strains compared to strains isolated from uncomplicated C. jejuni enterits 
patients (52). 
4.  Rabbits repeatedly immunized with C. jejuni LOS in the presence of adjuvant showed 
similar clinical, electrophysiological and histopathological findings as found in 
AMAN patients (51).
Table 3. Preceding infections and their relative frequency in GBS.
Pathogen Estimated frequency
C. jejuni 30-40%
Cytomegalovirus 15%
Epstein-Barr virus 5-10%
M. pneumoniae 10%
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Molecular mimicry has been suggested to be the critical pathogenic mechanism for other 
types of infections in GBS although this has not been demonstrated as convincingly as for 
C. jejuni and gangliosides. For example, H. influenza isolated from a GBS patient was associated 
with a GM1-like epitope in LOS and cross-reacted with IgM, IgG and IgA of other GBS patients 
with predominantly preceding respiratory tract infections (73). In addition, serum reactivity to 
GM2 was inhibited by incubation with fibroblasts infected with a GBS-associated CMV strain 
(74). Furthermore, serum antibodies to galactocerebroside, GM1b and GM1 cross-reacted 
to M. pneumoniae antigens in patients with preceding M. pneumoniae infections (75-77). 
These examples suggest a more common pathway for the immunopathogenesis of GBS of 
which the structural nature is unclear.
Host-pathogen interactions
Characterization of the post-infectious autoimmune response in GBS
In GBS, an aberrant humoral immune response in patients (the hosts) is triggered by a pathogen 
that results in anti-neural antibody response and nerve damage. This process is subject to 
Cell membraneCell wall
ceramide
GM1 gangliosideLipid A GM1-like LOS outer core
Pathogen
Campylobacter jejuni
Host
Peripheral nerve
antibodies cross-react
Figure 5. The concept of molecular mimicry in GBS. 
Carbohydrate structures in the cell wall of C. jejuni resemble gangliosides present in the cell membrane of host 
peripheral nerves. This mimicry is thought to induce cross-reactive antibodies that cause GBS.
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interactions between host and pathogen and the factors that determine the outcome of these 
interactions are unknown. To further reflect on the mechanism involved in this molecular 
mimicry driven autoimmunity, the following observations in GBS may be relevant: 
a)  Antibody titers to gangliosides rapidly decay in weeks to months. 
b)  The anti-ganglioside antibodies arise in response to carbohydrate antigens such as 
C. jejuni LOS.
c)  Anti-ganglioside antibodies are mainly of IgA and IgG isotypes. The IgG subclass 
distribution is predominantly IgG1 and IgG3.
d)  Anti-ganglioside antibodies are affinity matured antibodies.
Based on immunological observations in mice, it has been suggested that C. jejuni LOS 
functions as a thymus-independent antigen activating B-1 and marginal zone (MZ) 
B-cells (78). Some of the above mentioned observations could be explained by this hypothesis, 
such as the absence of immunological memory and isotype and subclass distribution. To 
class-switch to IgG however, B-1 or MZ cells require accessory signals from other cell types. 
Theoretically, in the mucosal compartment this help could come from T-cells, dendritic cells 
(DCs), epithelial cells or other adjacent cells. In the next paragraphs, the potential role of 
T-cells and DCs will be discussed. 
The possible role of T-cells in GBS
Different T-cell subsets exist that each have specific functions in adaptive immunity. 
A highly variable pattern of activated T-cell subsets in peripheral blood and CSF samples from 
GBS patients was found (79-86). Anti-ganglioside specific T-cells have not been isolated from 
GBS patients thus far. In one cohort of GBS patients a restricted usage of Vβ chain genes in 
activated T-cells suggested a response to a common antigen but this could not be reproduced 
in a different GBS cohort (87). Sural nerve biopsies of GBS patients showed the presence 
of CD8+ as well as γδ-T-cells, although the latter observation was not disease-specific since 
these cells were also found in biopsies from vasculitic neuropathy patients (88,89). γδ-T-cells 
show a limited diversity of receptors that are encoded by a few common rearrangements. 
γδ-T-cells probably constitute an ontogenetic early form of T-cells that function to defend 
mucosal surfaces. This location makes them an interesting candidate cell to interact with 
e.g. B-1 cells. They do not generally recognize peptides presented by MHC molecules, but 
rather seem to recognize their target antigens directly or via CD1 molecules. They have the 
capacity to respond to glycolipid antigens and expand in vitro to infection with C. jejuni in 
healthy controls but not in GBS patients (90,91). This interesting finding however, was only 
studied in a small cohort of GBS patients and has not been confirmed by others. The results 
of studies addressing the role of T-cells in GBS do not demonstrate a consistent pattern yet to 
give direction for further exploring the role of T-cells.
Although a role for T-cell mediated autoimmunity in GBS cannot be excluded, there 
are other observations that suggest T-cells unlikely are involved as a central factor in GBS 
pathogenesis. Adaptive T-cell mediated immunity generally induces immunological memory. 
For GBS, the low recurrence rate of less than 5% and the high yearly rate of encountering 
potential pathogens able to induce GBS indicate that generation of immunological memory is 
unlikely. Second, T-cell mediated autoimmune diseases are often genetically linked to HLA-
class II polymorphisms, which could not be demonstrated for GBS (92). Third, monotherapy 
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with corticosteroids especially suppresses T-cell function and is an ineffective treatment when 
given as monotherapy. A role for T-cell mediated immunity in GBS pathogenesis is unclear 
and therefore it may be interesting to focus first on other cell types interacting with B-cells.
Dendritic cell function and their potential role in GBS
In this thesis the role of DCs in the human immune response to GBS-associated 
C. jejuni will be addressed as a candidate cell to interact with B-cells. In the next paragraph 
an immunological introduction about DCs will be given. 
DCs are professional antigen presenting cells (APC) and are abundantly present in the gut 
directly underneath the epithelial cell layer (93). Here they generate networks of extending 
dendrites scavenging for microbes. DCs sample luminal antigens through these dendrites by 
opening tight junctions that hold together the epithelial cell layer (93). They are specialized 
in uptake of antigens through various pattern-recognition receptors (PRRs) including Toll-
like receptors (TLRs), C-type lectins, sialic-acid Ig binding lectin’s (Siglec’s), complement 
receptors and Fc-receptors (94). Amongst others, the binding of antigens to these receptors 
results in the release of cytokines and chemokines such as IL-8 that recruit neutrophils and 
monocytes from the bloodstream to the site of infection. In addition, antigen uptake by 
DCs initiates the migration of DCs to organized lymphoid tissues where adaptive immune 
responses are coordinated.
Protein antigens from degraded pathogens within DCs are loaded on specialized antigen 
presenting molecules such as MHC-I and MHC-II. When these antigens are recognized in 
the context of MHC by antigen specific T-cells, this induces adaptive and highly specific 
immune responses. CD1 molecules expressed on DCs share the β2-microglobulin with MHC 
molecules but have a much longer antigen-binding groove that fits the long fatty-acid tails of 
self- and foreign lipid antigens. Lipid antigens such as gangliosides are thus presented through 
CD1 and are recognized by γδ-T-cells and NK-T cells (95,96). Interestingly, signalling 
through PRRs on DCs may alter the type of these adaptive immune responses. PRRs scavenge 
antigens (Figure 6) and induce the release of specific cytokine profiles by DCs that may skew 
the immune response to either humoral immune responses (Th2), cellular immune responses 
(Th1) or other newer concepts of regulatory immune responses (Th3, Th17). Thus, DCs play 
a pivotal role as bridge between innate and adaptive immunity (94,97). 
Interestingly, in the last decade various reports have indicated important interactions 
occuring between DCs and B-cells, which may have implications for understanding the cross-
reactive anti-carbohydrate antibody response in GBS (98-101). DCs have the capacity to 
retain antigens in their native state and directly present these for engagement of the B-cell 
receptor (101). Thymus independent antigens opsonized by DCs can enhance humoral 
responses in FcγRIIB and complement dependent fashion (102). They additionally produce 
several cytokines and chemokines influencing B-cells (99,102). DCs can also synthesize entire 
antigens and hereby increase the epitope density that is required for optimal B-cell activation 
(103). Furthermore, DCs can induce direct class-switching in B-cells via expression of B-cell 
activating factor (BAFF) and a proliferation-inducing ligand (APRIL) and skew adaptive 
immune responses by TLR-dependent mechanisms (101,104). Whether B-cell responses are 
influenced by DCs in relation to C. jejuni LOS or other GBS-associated pathogens, however, 
remains to be established. Because DCs are localized in the gut they are likely one of the 
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first immune cells responding to C. jejuni. In fact, it has been shown that DCs are activated 
by C. jejuni and produce several types of pro-inflammatory cytokines (105). Various host- or 
pathogen-related factors may influence the outcome of these initial steps that eventually lead 
to development of GBS. It is of specific relevance to further assess DC interactions with GBS-
associated C. jejuni isolates to obtain an immunological model for GBS immunopathogenesis 
that may enable the development of new therapeutic or preventative strategies.
Host related genetic factors
Several families were reported in which clustering of GBS occurred that suggested GBS 
to be a complex genetic disorder (106). In a case report of a family outbreak of C. jejuni 
gastroenteritis, only one family member developed GBS with high titres of anti-ganglioside 
antibodies (107). As all family members were likely infected with the same C. jejuni strain, 
host-related factors may have played an important role. Furthermore, in an estimated 1 to 5% 
of GBS patients recurrences occur, suggesting a common general (host-related) factor within 
these episodes (108).
More specific genetic associations for GBS have been published that were the result of 
candidate gene studies for single nucleotide polymorphisms (SNPs) in GBS cohorts. SNPs are 
mutational variations in genes, are widely distributed throughout the genome and are present 
in at least 1% of the general population (109). SNPs in the pattern recognition receptor MBL2 
were associated on the allele and the haplotype level with susceptibility to develop GBS and 
severity of GBS patients (110). Moreover, severity of GBS expressed as muscle weakness was 
Figure 6. Host-pathogen molecular interactions at the cellular surface. 
Pattern recognition receptors (PRRs) recognize evolutionary conserved repetitive structures such as lipid A in 
LPS and flagellin present in various micro-organisms. Various adaptor molecules downstream of these PRRs are 
involved, depending on the type of LPS (smooth or rough LPS) that result in NF-κB activation and cell activation. 
LPS: lipopolysaccharide, MD2: MD-2 protein also referred to as lymphocyte antigen 96, TLR4: toll-like receptor 4, 
TLR5: toll-like receptor 5, MAL: MyD88 adaptor-like, TRAM: TRIF-related adaptor molecule, TRIF: TIR domain-
containing adaptor-inducing IFN-β, NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells.
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associated with high MBL concentrations and high MBL complex activity in sera from GBS 
patients (110). Two SNPs in CD1A and CD1E have also been associated with susceptibility 
to develop GBS. The functional implication of these SNPs in GBS immunopathogenesis 
was not demonstrated but may be theoretically feasible (111). Various other SNPs (Table 4) 
have been studied in relation to GBS susceptibility, production of cross-reactive antibodies, 
severity of GBS and outcome of GBS (112). Although promising results have been reported 
in these studies, finding a general genetic factor is difficult because of the many possible 
simultaneously active pathways, heterogeneity of the disease and unknown interactions 
between pathogen- and host (Table 4 and Figure 7). 
Pathogen related factors
C. jejuni strains can be serotyped according to their heat-stable antigens being LPS or LOS, 
which is denominated as the O serotyping or Penner serotyping system. Several reports 
suggest that specific serotypes are associated with GBS (66). This led to the concept that 
specific clones of C. jejuni strains were associated with post-infectious development of 
GBS. However, collections of C. jejuni strains within restricted timeframes and geographic 
areas displayed extensive diversity of clonality. This may indicate that associating strains 
or clones with GBS could lead to an underestimation of the capacity of strains to induce 
GBS (113,114). 
The interest in the heat-stable antigen as the basis for serotyping different strains 
consequently led to more insight in the chemical structure of C. jejuni LOS. First, the presence 
Figure 7. Selection of open research fields in GBS pathogenesis dealing with interactions between pathogen- 
and host.
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of N -acetylneuraminic acid (Neu5Ac), also termed sialic acid, in LOS of C. jejuni was 
discovered (115). This supported the concept of molecular mimicry since sialic acid residues 
are also present in gangliosides (2). However, serotypes with ganglioside-like moieties were 
also described in C. jejuni isolates from uncomplicated enteritis patients, suggesting that other 
pathogen or host-related factors possibly determines the development of GBS.
Next, the focus of research moved towards the genes encoding the enzymes responsible 
for the biosynthesis of LOS. By comparative genomics technologies, the cst-II gene was 
discovered and was found to be related to the presence of GQ1b epitopes in C. jejuni LOS and 
development of MFS (116). This gene encodes the sialyltransferase that attaches sialic acid 
residues to the LOS backbone. C. jejuni cst-II mutant knock-out strains have been developed 
for further immunological studies. Mice immunized with mutant C. jejuni cst-II LOS were 
unable to mount anti-ganglioside antibody responses in contrast to mice immunized with 
wild-type LOS (117). Interestingly, the presence and functionality of the cst-II gene in 
C. jejuni strains is also dependent on horizontal transfer of genes from other sources which 
can lead to substantial variation in LOS structures (118). In addition, polymorphisms in 
the cst-II gene influence the presence of either GM1 or GD1a mimics in LOS (119-121). 
These observations may at least partially explain why ganglioside-expressing strains in 
enteritis patients generally do not lead to GBS development. It remains to be established to 
what extent LOS variation is related to clinical variants and neurological deficits.
DIAGNOSTIC VALuE OF ANTI-NEuRAL ANTIBODIES IN 
IMMuNE-MEDIATED NEuROPATHIES
The previous paragraphas concerned the role of antibodies induced by infections in GBS. 
The next paragraphs discuss the role of anti-neural antibodies in GBS and other 
polyneuropathies in clinical practice.
Table 4. Host and pathogen-related factors implicated in GBS.
C. jejuni-related factors GBS patient-related factors
Clonality (66) Demography (age, gender, geography)
Presence of sialylated LOS (35,115) Cross-reactive anti-ganglioside antibody reponse 
(35)
Presence of C. jejuni LOS biosynthesis locus class A 
(117,118)
SNPs in HLA-DR1 and mechanical ventilation (92)
Transcription and presence of sialyltransferase (cst-II 
gene) in GBS-associated strains (116,117)
SNPs in MBL2 and severity and susceptibility of 
GBS (110)
SNPs Asn51 and Thr51 in cst-II gene (120) 
Presence of anti-ganglioside antibodies
Clinical deficits in GBS patients
SNPs in immune response genes CTLA4, CD40, 
Fc-γ III, TNF-α, Fas and MMP-9 (122-124)
Severity of GBS and muscle weakness
Presence of anti-ganglioside antibodies
Infection with specific serotypes including O:19, O:4, 
O:41 (66)
SNPs in CD1A and CD1E and GBS susceptibility 
(111)
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The prevalence of polyneuropathy is estimated around 1-7% of the general population and 
depends on clinical definitions (125). The prevalence increases with age and both sexes can 
be affected. Many causes and associated conditions have been identified. Underlying diabetes 
is most frequently found. Other frequent causes for polyneuropathy include excessive use of 
alcohol, hereditary causes, metabolic disturbances, use of toxic drugs or substances, vitamin 
deficiency and the presence of paraproteins (125). 
In an outpatient clinic around 5-12% of all polyneuropathy patients have an immune-
mediated cause for their neuropathy (125). Recognition of immune-mediated neuropathies 
in an early stage is clinically relevant because this group of patients may well respond to 
immunosuppressive therapy. 
Anti-neural antibodies in immune-mediated neuropathies
In 1980 Latov et al. reported the first patient with a demyelinating neuropathy and an 
IgM-κ gammopathy in which serum antibodies reacted with myelin associated glycoprotein 
(MAG) (127). Ganglioside antibodies were first described in a case of IgM paraproteinaemic 
neuropathy in 1985 (33). Currently, more than 20 glycoconjugates have been identified and 
characterized as target antigens for serum antibodies in mainly demyelinating neuropathies 
(35) (Tables 5 and 6). In clinical practice, the diagnostic value of the antibodies in most of 
these polyneuropathies is uncertain.
Table 5. Classification of immune-mediated polyneuropathies according to clinical course (35,126).
Onset of disease Disease Association with autoantibodies
Acute 
Vasculitis (systemic or non-systemic) ANA, ANCA, ENA, dsDNA
GBS and variants Gangliosides 
Paraneoplastic Hu
Chronic
MMN GM1
IgM MGUS polyneuropathy MAG, gangliosides, SGPG
CANOMAD GQ1b
Pareneoplastic Hu
CIDP Sulfatide 
Chronic sensory neuropathy Sulfatide
MADSAM
DADS
Abbreviations: GBS, Guillain-Barré syndrome, CIDP, chronic inflammatory demyelinating polyneuropathy, MMN, 
multifocal motor neuropathy, IgM MGUS, IgM monoclonal gammopathy of unknown significance, MADSAM, 
multifocal acquired demyelinating sensory and motor neuropathy, DADS, distal acquired demyelinating sensory 
neuropathy, CANOMAD, chronic ataxic neuropathy, ophthalmoplegia, IgM paraproteinemia, cold agglutinin and 
disialosyl antibodies. 
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Antibodies to myelin associated glycoprotein 
MAG is a cell membrane molecule (also called Siglec-4) that functions as a receptor for 
sialic acid containing moieties such as gangliosides. It is expressed in peripheral nerve myelin 
sheaths and Schwann cells and is involved in the process of myelination. Antibodies to MAG 
react with the HNK-1 carbohydrate epitope that is shared with the peripheral nerve acidic 
glycolipid sulfate-3-glucuronyl paragloboside (SGPG) (128). Anti-MAG antibodies also 
cross-react with other myelin glycoproteins such as P0 and PMP22 (129).
Patients with an anti-MAG polyneuropathy are a homogeneous subgroup of polyneuropathy 
patients predominantly occurring in the elderly (>65 years). Characteristically, the patients 
have a slowly progressive distal form of mixed motor-sensory polyneuropathy, but generally 
with more sensory symptoms and frequently also sensory ataxia. This form of neuropathy is 
associated with the presence of an IgM- or biclonal IgM/IgG gammopathy. In most patients the 
malignant cause for the gammopathy is not found and subsequently denominated gammopathty 
of unknown significance (MGUS). Testing for these antibodies may be clinically relevant 
since patients with an anti-MAG neuropathy tend to respond poorly to immunosuppressive 
Table 6. Characteristics of anti-neural antibodies in immune-mediated neuropathies.
Clinical syndrome Antigen Frequency Main isotype
GBS GM1 20-30% IgG > IgM
GD1a 10-20% IgG > IgM
GM2 5-10% IgG > IgM
GBS with ophthalmoplegia GQ1b, GT1a 90-100% IgG > IgM
GQ1b/GD1a complex <5 % IgG > IgM
Motor axonal form of GBS GM1/GD1b complex 5-10 % IgG > IgM
MFS
Bickerstaff encephalitis
CANOMAD
GQ1b, GT1a 95-100%
60-70%
100%
IgG > IgM
IgM
MMN GM1 50% IgM
MGUS polyneuropathy GM1 < 5% IgM > IgG
MAG 50% IgM
SGPG, SGLPG 50% IgM
Chronic ataxic neuropathy GD1b, GD2, GD3, GT1b, 
GQ1b
unknown IgM
Chronic sensory neuropathy Sulfatide 0.7-25% IgM > IgG
Abbreviations: GBS, Guillain-Barré syndrome, CIDP, chronic inflammatory demyelinating polyneuropathy, MMN, 
multifocal motor neuropathy, MGUS, IgM monoclonal gammopathy of unknown significance, MFS, Miller Fisher 
syndrome, CANOMAD, Chronic Ataxic Neuropathy, Ophthalmoplegia, IgM paraproteinemia, cold Agglutinin and 
Disialosyl antibodies. 
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therapy. When patients with an IgM MGUS polyneuropathy suddenly deteriorate, when the 
IgM paraprotein further increases or when anti-MAG antibody titers suddenly increase it is 
important to consult the hematologist and again search for any possible malignancy (130). 
The pathogenicity of anti-MAG antibodies is suggested by several observations. IgM 
deposits in peripheral nerve sections of patients with a chronic and distal sensorimotor form 
of polyneuropathy have been demonstrated that co-localize with antibodies to MAG (131). 
Moreover, passive immunization experiments with anti-MAG IgM lead to prominent widening 
of myelin lamellae in chickens, which was a typical finding in human biopsies of patients with 
these antibodies (132). Recently, cats immunized with MAG developed clinical symptoms 
resembling those of anti-MAG neuropathy patients (133). It is suggested that bacterial antigens 
may recruit somatically mutated autoreactive B cells, causing the monoclonal gammopathy 
and subsequent polyneuropathy (134). More research is needed to establish the pathogenicity 
of anti-MAG antibodies and to confirm whether preceding infections lead to development of 
anti-MAG related neuropathies. 
Antibodies to glycosphingolipids
This group can be subdivided into patients with antibodies to GM1, disialylated gangliosides 
and sporadic forms of glycosphingolipids.
A high prevalence of IgM anti-GM1 antibodies is particularly found in multifocal motor 
neuropathy (MMN). This chronic progressive neuropathy exclusively involves motor nerves 
and has a patchy asymmetrical and distal distribution. In electrophysiological examination 
the presence of conductance block is suggestive and mandatory for diagnosis. IVIg therapy 
stabilizes progression and is currently the only proven effective therapy (135). Some patients 
with an IgM MGUS polyneuropathy may also have IgM antibodies to GM1 (136). 
Antibodies to disialylated gangliosides such as GD1b, GD3, GT1b and GQ1b are 
particularly found in patients with sensory symptoms, ataxia and in patients with acute 
ophthalmoplegia. These symptoms and antibodies may be found in the rare chronic 
ataxic neuropathy ophthalmoplegia IgM paraprotein cold agglutinins and disialyl-
antibodies syndrome (CANOMAD). The syndrome may have a relapsing remitting course 
and is associated with a lymphoproliferative disorder producing an IgM-κ or IgM-λ 
gammopathy (137). Case reports suggest that IVIg therapy may be beneficial.
Antibodies that are less frequently observed include anti-sulfatide antibodies and anti-
GM2 antibodies. The clinical spectrum of anti-sulfatide antibodies include sensory axonal 
forms of neuropathies that typically present with pain (138). Anti-GM2 antibodies may be 
found in subgroups of GBS patients or chronic motor forms of polyneuropathy.
Variation in assay techniques for anti-neural antibodies
Despite the significant interest in anti-neural antibodies the past twenty years, inconsistencies 
in the techniques used for detection of these antibodies may have resulted in discrepancies of 
reported frequencies in diseases. Western blotting and ELISA techniques are usually used to 
detect antibodies to MAG and gangliosides. Standardization of the ELISA assay was proposed 
by the European Inflammatory Neuropathy Cause and Treatment group (INCAT) (139). 
The diagnostic value of this INCAT ELISA, however, requires validation in a large group 
of neuropathy patients and controls. Comparative studies of ELISA and western blotting for 
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anti-MAG serology have led to the recommendation by the EFNS/PNS taskforce to consider 
positive western blotting as definite proof and positive ELISAs as suggestive proof. However, 
golden standards are lacking and newer ELISAs have been developed that should be clinically 
validated. 
SCOPE AND OuTLINE OF THESIS
The working hypothesis in the following studies is that host-pathogen interactions trigger 
the induction of an aberrant immune response to peripheral nerves that will lead to the 
development of GBS. Previous studies identified several host-related factors associated with 
GBS, including demographic features, genetic polymorphisms in immune response genes 
and presence of serum antibodies to gangliosides. Other studies found pathogen-related 
factors involved in the pathogenesis of GBS, including distinct types of antecedent infection, 
such as Campylobacter jejuni, and of molecular mimicry with gangliosides. The mechanisms 
by which these host and pathogen factors interact to induce GBS and the clinical relevance 
of these factors are unknown. More specifically the studies in this thesis investigated the 
following topics:
-  demography of antecedent infections in relation to GBS
-  effect of C. jejuni genotype and LOS structure on antibody specificity and GBS phenotype 
-  CD1 gene polymorphisms and the susceptibility to develop GBS 
- modulation of dendritic cells and B-cell activation by C. jejuni lipo-oligosaccharides 
(LOS) 
-  validation of diagnostic methods to detect serum antibodies to peripheral nerve antigens 
In Chapter 2 the epidemiology of C. jejuni infections was compared in patients with GBS 
versus uncomplicated gastroenteritis to identify demographic features that may predispose to 
GBS. Additionally, serum and cerebrospinal fluid samples from GBS patients were screened 
for recent infections with CMV. 
Chapter 3 describes the effect of the pathogen antigenic structure on the antibody 
specificity and clinical phenotype in GBS. First, the genotype of 26 GBS related C. jejuni 
isolates was defined to determine the relation with the molecular structure of the LOS, 
specificity of the cross-reactive antibodies and clinical deficits in GBS. Second, experimental 
support was provided for the hypothesis that serum antibodies to combinations of gangliosides 
or complexes in GBS are also induced by molecular mimicry of C. jejuni LOS. 
Chapter 4 focuses on the role of host cellular activation and antigen presentation by 
pathogens in the development of GBS. We hypothesized that DCs are activated by C. jejuni 
and orchestrate the aberrant immune response leading to GBS. DCs may present C. jejuni 
LOS by CD1, which is a glycolipid antigen-presenting molecule abundantly present on DCs 
and genetically polymorphic. First, variation in CD1 genes was determined in GBS patients 
and healthy controls to assess if these polymorphisms are a susceptibility factor in developing 
GBS. Second, the activation of human DCs to C. jejuni LOS and subsequent proliferation of 
B-cells was defined. These experiments showed that the sialylation of C. jejuni LOS modulates 
the immune activation and may predispose to GBS. 
Chapter 5 describes the clinical validation of current techniques to detect serum 
antibodies to the ganglioside GM1 and to MAG in the diagnosis of patients with immune-
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mediated neuropathies. An illustrative case is reported in which anti-GQ1b antibodies helped 
to distinguish the cause of a relapsing ophthalmoplegia and ataxia.
In Chapter 6 the observations from the studies in chapters 2-5 are summarized and 
discussed in relation to current literature. In addition, recommendations for future research 
are proposed that succeed the observations described in this thesis.
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To the editor - Steininger et al. (1) reported the presence of cytomegalovirus (CMV) 
DNA in cerebrospinal fluid (CSF) of patients with Guillain-Barré syndrome (GBS). In the 
understanding of the pathogenesis of GBS as a post-infectious disorder, this observation may 
have important consequences. In their study, CMV DNA was demonstrated by a polymerase 
chain reaction (PCR) assay in CSF of 13 (31%) and serum of 14 (33%) of 42 GBS patients. 
These observations would indicate that CMV is a predominant preceding infection in GBS 
and that serological studies, in which usually less than 15% of patients are considered to be 
CMV positive, underestimates the frequency of this infection (2). In addition, serology studies 
may be biased to certain types of CMV as suggested by Steininger et al. (1). This would 
also have implications for further delineating GBS patients in pathogenic subgroups, since 
some reports indicate that patients with positive CMV serology are thought to be younger of 
age with a clinical variant of severe involvement of motor, sensory and cranial nerves and 
a prolonged progressive active phase and have cross-reactive antibodies to the ganglioside 
GM2 (3,4). The presence of CMV in CSF may also indicate that endogenous reactivation of 
CMV infection within the central nervous system compartment occurs and that perhaps these 
patients may profit from antiviral therapy (1). The interesting finding of Steiniger et al. (1) and 
the possible consequences for pathogenic research prompted us to investigate the presence of 
CMV DNA by PCR in our own collection of CSF samples of GBS patients.
We have collected acute phase, pre-treatment CSF samples from 170 (43%) of 397 GBS 
patients participating in the multicenter Dutch GBS trials (5,6). These patients did not differ 
clinically from the remaining patients. All patients fulfilled the diagnostic criteria for GBS, 
were in their acute phase of disease (less than 2 weeks between first signs of weakness and 
randomization) and were unable to walk independently (6). The patients we studied were 
comparable to those studied by Steininger et al. (1) with regard to age, frequency of positive 
CMV IgM serology (2), (estimated) time-interval to lumbar puncture and CSF protein 
level (Table). Serological evidence of a recent CMV infection was detected in 22 (14 %) of
159 patients (Table). In contrast, we could detect CMV DNA in CSF from only a single GBS 
patient. This patient also had serum CMV-specific IgM antibodies.
The discrepancy with the results of Steininger et al. (1) are remarkable since a method 
with similar assay characteristics (as determined by quality control proficiency testing) was 
used by the two reference laboratories. Random errors in our study are less likely considering 
the large number of included patients. Patient selection cannot be excluded although both 
study groups were similar with respect to relevant clinical characteristics and frequency of 
positive CMV IgM serology. Steininger et al. (1) only tested patients for CMV DNA in CSF 
and serum when CMV-specific IgG or IgM antibodies was present, which was a selection of 
42 out of 65 identified GBS patients. Our patients may have been more severely affected, as 
indicated by the larger proportion of ventilated patients in our group and the inclusion criteria 
requiring that patients were unable to walk independently. Furthermore, the time interval 
between onset of GBS and lumbar puncture were defined slightly different. However, the 
CSF protein content and the observed time intervals were not significantly different between 
the groups, indicating that the CSF was obtained at about the same time in the acute phase of 
the disease. Steininger et al. (1) reported that in none of the five patients with positive CMV 
IgM serology CMV DNA was present in CSF. Of all their sera tested positive for CMV DNA, 
only 2 (15%) had CMV-specific IgM antibodies. Furthermore, in only 3 (7%) of their patients
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CMV DNA could be detected in both CSF and serum. The lack of demonstrable CMV 
DNA in our patients, invokes the question whether there are geographical differences in the 
incidence of CMV related GBS. More data from other laboratories are required to clarify the 
role of intrathecal CMV in the pathogenesis of GBS and especially to suggest the beneficial 
use of antiviral therapy.
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chain reaction (PCR) results in two groups of Guillain-Barré syndrome (GBS) patients. 
Present study Steiniger et al. (1)
Number of patients 170 42
Age, mean (SD), years 50 (19.5) 47 (22.7)
CSF protein, mean (g/l) 1.48 1.72
Ventilation required no. (%) of patients 50 (29) 4 (10%)
Interval between onset of GBS and lumbar puncture, geomatric 
mean, days
CMV DNA present in CSF
CMV DNA absent in CSF
2
4.4
3.3
6.0
Positive CMV IgM serological test result (serum), no. positive/
total tested (%)
22 / 159 (14)a 5 / 42 (12) 
Positive CMV PCR (CSF), no. positive/total tested (%) 1 / 170 (<1) 13 (31)
NOTE  SD, standard deviation; CSF, cerebrospinal fluid
aSerological results were partially published previously (2).
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ABSTRACT
BACKGROuND: Campylobacter jejuni infections are the predominant cause of bacterial 
gastroenteritis in the industrialised world. The most perilous complication of C. jejuni 
gastroenteritis is the Guillain-Barré syndrome (GBS), an immune mediated neuropathy 
that occurs in about 1 in 1,000 to 5,000 persons infected. Serological evidence for a recent 
C. jejuni is found in nearly 40% of GBS patients, although C. jejuni isolation is often negative 
because of the delay between infection and onset of weakness. Risk factors for developing 
GBS after a C. jejuni infection are unknown. 
AIM OF STuDy: The aim of this study was to compare the epidemiology of C. jejuni-related 
gastroenteritis and culture- and serology proven C. jejuni-related GBS to identify new risk 
factors for development of GBS after C. jejuni-related gastroenteritis. 
PATIENTS: Demographic, clinical and serological data were available from 406 GBS 
patients that participated in clinical trials during 1986 and 2005. In addition, demographic 
data were available from 16,621 culture proven C. jejuni–related gastroenteritis patients 
from the Dutch Laboratory Surveillance between 2002-2007 and 1,107 sera from the general 
population collected between 1999 and 2001. 
RESuLTS: A recent C. jejuni infection was demonstrated by culture in 24 of 369 (7%) GBS 
patients and by serology in 128 of 369 (35%) patients. GBS patients with a positive serology 
and culture differed on the same clinical characteristics to the serology negative group such 
as preceding diarrhoea, clinical course and presence of anti-ganglioside antibodies. However, 
serologically proven C. jejuni-related GBS patients were slightly older, had less frequently 
diarrhoea, a pure motor GBS or anti-ganglioside antibodies compared to culture proven 
C. jejuni-related GBS. C. jejuni-related GBS tended to be less frequent during spring and 
more frequent during winter in GBS patients whereas C. jejuni gastroenteritis peaked during 
summer months. GBS patients of 61-70 years had the highest relative rate of preceding 
C. jejuni infection.
CONCLuSION: The relative risk of developing GBS following C. jejuni infection is 
increased in older patients and during the Northern hemisphere winter season, which may be 
related to increased susceptibility of older people for circulating infections during winter or 
other environmental factors.
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INTRODuCTION
Campylobacter jejuni is the worlds’ most common cause of bacterial gastroenteritis and is 
associated with the post-infectious development of the Guillain-Barré syndrome (GBS), 
a severe inflammatory neuropathy characterized by progressive muscle weakness (1,2). 
The frequency of antecedent infection caused by C. jejuni in GBS ranges between 20 to 
40%, and is considered the predominant infection preceding GBS (3). C. jejuni infections 
are associated with a specific subgroup of GBS characterized by pure motor involvement, 
severe weakness and a poor prognosis (4). Approximately one in 1,000 to 5,000 patients with 
C. jejuni infections develop GBS, but the risk factors that determine the onset of GBS after a 
C. jejuni infection are unknown (5-7). 
The seasonality of C. jejuni–related gastroenteritis depends on regional differences (8-12). 
Higher temperatures and daily hours of sunlight increase the chance to become infected by 
C. jejuni in temperate regions of the world (13-16). In general, males are more often infected 
by C. jejuni, except for the 20-to-29-year-old age group in which females are (17,18). Directly 
comparing the seasonality and demography of C. jejuni-related gastroenteritis and GBS in 
well described patients may lead to identification of new risk factors for development of 
GBS.
For epidemiological studies of C. jejuni-related GBS a reliable method to identify 
C. jejuni-related GBS patients is required. The disadvantage of demonstrating antecedent 
C. jejuni infection in GBS patients by selective culturing techniques is the poor sensitivity 
due to the interval between neurological symptoms and gastrointestinal infection and possible 
intermediate treatment with antibiotics. Recently, a capture ELISA assay was validated 
specifically for patients with GBS and reactive arthritis (19). It is unknown whether clinical 
differences exist between culture and serology proven C. jejuni-related GBS. Comparing the 
clinical characteristics between these groups is relevant in order to study the epidemiology of 
C. jejuni-related GBS because serology can be easily performed in a large number of patients. 
In contrast, prospectively collecting culture-proven C. jejuni-related GBS cases is extremely 
time-consuming for obtaining a sufficient number of patients. 
In this study the demography and seasonality of C. jejuni-related gastroenteritis and GBS 
were compared to identify risk factors that increase the chance of developing GBS after a 
C. jejuni infection. C. jejuni infections were defined by both serological and culture studies. 
In addition, we assessed the patient characteristics related to a positive culture or serology for 
C. jejuni infection. 
MATERIALS AND METHODS
Patients and C. jejuni isolates
Demographic, clinical and serological data were available from 406 GBS patients collected 
in previous prospective clinical trials and surveys conducted in The Netherlands between 
1986 and 2005 (20-22). Because paediatricians did not participate in these trials and survey 
studies but do primarily see children with GBS in The Netherlands, 37 patients younger 
than 21 years were left out of analysis in order to minimize selection bias. This resulted in 
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369 GBS patients available for analysis. Demographic and seasonal data were also available 
from 16,621 culture-proven C. jejuni–gastroenteritis patients that are part of Dutch national 
surveillance studies (11,23). In addition, serum from 1,107 healthy individuals with known 
date of sampling between 1999 and 2001 was available (11,24).
In total our laboratory has obtained 24 C. jejuni isolates from GBS patients or patients 
with the Miller-Fisher syndrome (MFS), a clinical variant of GBS with opthalmoplegia, ataxia 
and areflexia. These strains were isolated between 1991 and 2005. C. jejuni was not isolated 
from GBS patients between 1986 and 1991 as C. jejuni cultures were only performed on 
routine basis starting from 1991. Eighteen patients had GBS, 4 patients MFS and two patients 
an overlapping form of GBS with opthalmoplegia. From 19/24 of these patients serum was 
available obtained during onset of disease. Fourteen of the 24 patients had participated in one 
of the Dutch clinical trials or survey studies. The remaining C. jejuni isolates were obtained 
from 10 patients seen by neurologists in various hospitals in The Netherlands. Diagnosis 
in these patients was retrospectively confirmed from patient records according to standard 
diagnostic criteria (25). Demographic and clinical data were available from these patients.
Disease severity was defined by the GBS disability score (F-score), ranging from 0 (no 
symptoms) to 6 (dead), and the Medical Research Counsil (MRC) sumscore, ranging from 0 
(tetraplegia) to 60 (normal) at nadir (26,27). Time to nadir was expressed as the number of 
days before reaching the highest disability score or lowest MRC sumscore during follow-up. 
C. jejuni ELISA
Serological screening for most common antecedent infections and anti-ganglioside antibodies 
was performed using standard procedures (28). Serology for recent C. jejuni infection was 
performed by an IgM and IgA capture ELISA and indirect ELISA for IgG and was recently 
validated for use in GBS (19). Our criteria for a recent infection with C. jejuni were the 
presence of either elevated IgA or elevated IgM in serum. The cut-off values used for 
determining positivity were determined in a previous study (19). In this previous study, we 
found that an IgA ratio of >0.6 and/or IgM ratio >1.0 cut-off value, yielded a 93% specificity 
level and sensitivity levels of 82% in uncomplicated culture proven C. jejuni-enteritis patients 
and 96% in culture proven Campylobacter-related GBS cases (19).
Statistical analysis
The relative rate per month concerned the fraction of all GBS cases found in that month divided 
by the fraction of all gastroenteritis cases found in that month. 95% confidence intervals of the 
relative rates were determined using a bootstrap method (29) that involved sampling both GBS 
and gastroenteritis datasets by resampling with replacement 10,000 times and recalculation of 
the monthly relative rates after each round. The 95% confidence interval of a month concerns 
the interval between the 2.5th and 97.5th percentile of the 10,000 calculated relative rates for 
that month. For comparison of groups Chi-square tests were used. For comparison of groups 
for age and MRC-sumscores the non-parametric Kruskal-Wallis test was used. For calculating 
confidence intervals and tests a P-value of 0.05 was used.
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RESuLTS
Frequency and clinical correlates of Campylobacter infection in GBS 
Using the revised criteria for ELISA, 152/369 (41%) of GBS patients had evidence for a 
recent C. jejuni infection. All culture positive cases tested (n=24, 7%) were also positive in 
serology (Table I). 
To ensure that our results using data based on ELISA results were valid, we investigated 
whether the clinical characteristics of C. jejuni serology-positive GBS patients, differed 
from C. jejuni culture-positive GBS patients (Table I). Although GBS patients from whom 
C. jejuni was isolated in stool cultures were younger (p<0.01), more frequently had antibodies 
against anti-GD1a (p<0.03) or anti-GQ1b (p<0.003) or a pure motor variant (p<0.04) than 
serology positive patients, the clinical characteristics of both were similar to C. jejuni-related 
GBS cases described in earlier studies (30-32). Moreover, the serology positive patients had 
lower MRC sumscores at nadir (p<0.002) than the culture positive group. In addition, patients 
with positive C. jejuni serology more often had diarrhoea and less often upper-respiratory 
tract infections, lower MRC sum-scores at nadir and more frequently had anti-ganglioside 
antibodies than serology negative GBS patients (Table I). In consideration of these differences 
it was decided to further study the culture- and serology positive group in combination.
Age distribution of C. jejuni-related gastroenteritis and GBS patients 
In older age categories of the total GBS cohort, the number of GBS patients was generally 
higher than in the younger age categories (Figure 1A). Above the age of 70, these numbers 
decreased which reflects the distribution of age in the general population. The number of 
GBS patients peaked within the 61-70-age category. The fraction of C. jejuni-related patients 
(50%) was higher in this group compared to other age categories. Within the C. jejuni-related 
GBS cases, 26% of patients were also between 61-70 years of age. 
In contrast, uncomplicated C. jejuni-related gastroenteritis occurrence generally declined 
with age and the fraction of patients with uncomplicated C. jejuni-related gastroenteritis 
between 21-30 years was highest (23%) compared to the other age groups (3-19%, 
Figure 1B). The odds-ratio (OR) for the 21-30-age group to develop GBS after a C. jejuni 
infection was 0.64 (95% CI 0.39-1.04, p<0.07) whereas the OR was 3.83 (95% CI 2.69-5.58, 
p <0.0001) for the age group of 61-70 years (Figure 1C). 
Seasonality of C. jejuni-related gastroenteritis and GBS patients 
GBS occurred throughout the year in the Netherlands, with a slight preponderance in the winter 
months. As in other countries in non-tropical regions such as the Netherlands, uncomplicated 
C. jejuni-related gastroenteritis cases peak in summer (8,11). Surprisingly, besides August 
the highest numbers of C. jejuni-related GBS cases were found in November, December and 
January (Figure 2). The percentage of C. jejuni-related cases of GBS varied from 13% in 
November (OR 1.89 compared to C. jejuni-related gastroenteritis, p<0.007) to 4% in May 
(OR 0.58 compared to C. jejuni-related gastroenteritis, not significant). This pattern was also 
reflected in the fraction of C. jejuni-related GBS cases per month and height of IgA, IgM and 
IgG serum reactivity to C. jejuni in ELISA (Figure 2B and 3A). No seasonal fluctuation of 
antibody reactivity to C. jejuni in ELISA was observed in healthy controls (N=1,107, Figure 3B). 
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Table I. Demographic and clinical characteristics of patients with culture proven C. jejuni infection and 
serological evidence of C. jejuni infection.
C. jejuni    Culture +
          N=24
   Serology +
     (culture -)
          N=128
    Serology –
       (culture-)
           N=217   p-valuea      p-valueb
Demography
Sex (Male:Female ratio) 3,8 : 1 1,4 : 1 1,3 : 1 0.03 -
Mean age (y) 45 54 53 0.03* -
Season 
- Winter 7 (29) 40 (32) 69 (32) - -
- Spring 1 (4) 20 (16) 50 (23) 0.03 0.098
- Summer 11 (46) 25 (20) 43 (20) 0.004 -
- Autumn 5 (21) 42 (33) 55 (25) - 0.08
Symptoms of preceding infections
Diarrhea 16 (73) 43 (37) 24 (13) <0.0001 <0.0001
Upper respiratory tract 1 (5) 27 (24) 87 (47) <0.0001 <0.0001
Serology for other recent infections
CMV 0 (0) 11 (9) 30 (16) - -
EBV 0 (0) 11 (9) 28 (15) - -
Mycoplasma pneumoniae 0 (0) 9 (8) 5 (3) - 0.04
Clinical features 
Cranial nerve deficits 11 (55) 46 (39) 73 (38) - -
Pure motor 13 (62) 44 (38) 60 (32) 0.007 -
Mechanical ventilation 5 (25) 38 (36) 45 (25) - 0.06
F-score (median, 95%CI))
- At entry 4 (2.8-3.8) 4 (3.8-4.0) 4 (3.8-3.9) - -
- At nadir 4 (3.1-4.4) 4 (4.2-4.5) 4 (4.1-4.3) - 0.05
MRC-sum score (median, 
95%CI)
- at entry 
52 (39-58) 34 (28-36) 42 (36-42) - 0.06*
- at nadir 52 (32-58) 22 (17-26) 38 (31-37) 0.049* <0.0001*
Prognosis 
- Improvement 1 point in 
 F-score during 1st four weeks 
 3 (25) 56 (48) 118 (62) - 0.02
- F-score at 6 months 
 (median, 95%CI)
1 (0.8-2.1) 1 (1.5-2.1) 1 (1.1-1.5) - 0.003
- F<3 at 6 months 12 (80) 81 (71) 162 (88) - <0.0001
Anti-ganglioside serology 
GM1 6 (33) 39 (33) 23 (12) 0.01 <0.0001
GD1a 5 (29) 8 (7) 9 (5) <0.0001 -
GQ1b 10 (59) 9 (8) 10 (5) <0.0001 -
GM1 and/or GD1a and/or   GQ1b 15 (89) 48 (41) 36 (19) <0.0001 <0.0001
In columns the number of patients from available data are shown for each row characteristic with percentages in 
brackets, for F-scores and MRC sumscores median values with 95% confidence intervals (95% CI) are shown. 
a Compared between culture positive only and serology and culture negative, b compared between serology positive 
and culture negative and serology and culture negative., F-score: GBS disability score, MRC sumscore: Medical 
Research Counsil sumscore, - : p > 0.1, * Kruskall-Wallis test.
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Figure 1. 
(A) Age related incidence of GBS patients and C. jejuni-related cases. The incidence of GBS cases 20 years and 
older is standardized to 1 and per age category is expressed relative to this overall incidence. This was done as the 
real number of Dutch GBS cases in the study period is an unknown multiple of the cases collected. The fraction 
of all GBS cases collected per age category however can be assumed to be representative for that age category 
and hence can be compared to the fraction of the Dutch population at risk for that age. Dotted lines represent 95% 
confidence intervals after bootstrap analysis. (B) Age distribution in C. jejuni-related GBS and gastroenteritis patients. 
The fraction of each age decade from the total C. jejuni-related GBS cohort (n=152) or C. jejuni gastroenteritis 
cohort (n=16,621) is shown after bootstrap analysis. (C) Relative rate of C. jejuni-related GBS versus gastroenteritis 
in relation to age. The ratio of fractions from C. jejuni-related GBS and gastroenteritis was calculated for bootstrap 
adjusted fractions for each age decade.
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DISCuSSION
This study shows that the demography and seasonality of patients that develop GBS after 
C. jejuni infection differs from patients experiencing an uncomplicated C. jejuni-related 
gastroenteritis. C. jejuni-related GBS occurred more frequently during the winter months. 
In addition, C. jejuni-related GBS was more often observed in older patients, especially 
between 61 and 70 years. The relationship of GBS with age and season is the inverse of that 
of uncomplicated gastroenteritis due to C. jejuni. This observation suggests that a C. jejuni 
infection in the Netherlands is more frequently followed by GBS during the winter months 
and at older age. 
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Figure 2. 
(A) Seasonal distribution of C. jejuni-related GBS and gastroenteritis. The fraction of each month from the total 
C. jejuni-related GBS cohort (n=152) or C. jejuni gastroenteritis cohort (n=16,621) is shown. (B) Relative rate of 
C. jejuni-related GBS and gastroenteritis in relation to season. The ratio of fractions from C. jejuni-related GBS and 
gastroenteritis was calculated for bootstrap adjusted fractions for each month.
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The frequency of occurrence of C. jejuni-related gastroenteritis generally declined with 
age whereas an opposite pattern was found in C. jejuni-related GBS. A slightly different 
pattern has been reported in a Japanese epidemiological study of C. jejuni isolates from GBS 
patients, in which C. jejuni-related-GBS occurred most frequently in patients younger than 
30 with a second peak in the 50 to 59 age category (33). A recent nationwide study in England 
showed that only among those below 36 years of age, numbers of weekly GBS hospitalizations 
were associated with an increase in weekly C. jejuni reports 4 to 5 weeks earlier (34). 
This observed association does however not provide a direct link between individual GBS 
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Figure 3.
(A) Seasonal fluctuation of serum reactivity (IgM, IgG and IgA) to C. jejuni in GBS patients (n=294) between 1986 
and 2005. IgM, IgA and IgG ratio was determined in a C. jejuni specific capture ELISA recently validated for GBS. 
(B) Seasonal fluctuation of serum reactivity (IgM, IgG and IgA) to C. jejuni in healthy individuals (n=1,107) between 
1999 and 2001.
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patients and C. jejuni positive cultures. In the present study, patients under the age of 18 years 
did not routinely participate in the clinical trials or survey studies and therefore we cannot 
directly compare the age group below 36 years of age. The results of this study suggest that, 
at least in The Netherlands, older individuals are at increased risk for developing GBS after 
a C. jejuni infection. Although it has been reported that elderly patients may be more prone 
to infections with rare C. jejuni serotypes, it is unknown whether these serotypes are more 
common in GBS as is the case for reported serotypes such as HS:41, HS:4 and HS:19 (35). 
Alternatively, sensitization to common C. jejuni strains may determine this increased risk. 
The immunological background and the involved host- and pathogen-related factors that 
explain the age distribution of GBS in relation to C. jejuni need to be studied further. 
The results of this study emphasize that seasonality of GBS may not always follow the 
seasonality of GBS-related infections. During winter months, the fraction of GBS patients 
with preceding C. jejuni infection was higher compared to the other seasons whereas in 
patients with C. jejuni-related gastroenteritis a striking opposite pattern was found. Endemic 
forms of C. jejuni-related GBS have been reported in China and Curaçao in which a rise in 
C. jejuni infections correlated with GBS incidence but seemed not related to season (30,36,37). 
In Japan, seasonality of C. jejuni is less pronounced as one study showed no clear seasonality 
of C. jejuni-related GBS whereas others reported a higher incidence of C. jejuni-related GBS 
during spring (33,38). Preponderance of GBS incidence in the winter months was observed 
in France but could not be attributed to serologically proven C. jejuni infections (39). 
Seasonal fluctuations of C. jejuni laboratory reports in the general population are however 
common. Increases of incidence between June and August have been published in both 
European countries as well as New Zealand at the opposite hemisphere (16,40,41). A direct 
comparison of the seasonality of C. jejuni-related gastroenteritis and GBS was not reported 
previous. Given the inverse seasonal pattern of C. jejuni-related gastroenteritis and GBS 
observed in this study, this indicates that C. jejuni infections that occur during winter in The 
Netherlands are more likely to cause post-infectious sequelae such as GBS. Interestingly, 
4 (3%) patients had symptoms of both diarrhoea and an upper respiratory tract infection, 
which all developed GBS during winter months (November n=1, February n=3). In Japan, 
16 of 107 (15%) GBS and MFS patients with positive C. jejuni culture also had both diarrhoea 
and symptoms of upper respiratory tract infection (33). This may suggest that at least in a 
proportion of GBS patients, multiple infections in a double hit fashion could play a role.
Limitations related to the comparisons made in this study are associated with the 
recruitment of patients and determination C. jejuni infections. By using bootstrap analysis 
as resampling method a comparison could be made that takes into account the difference in 
number of patients within the C. jejuni-related gastroenteritis and GBS cohort. The ELISA 
used in this study is a specifically validated method to demonstrate C. jejuni infections in GBS 
patients (19). However, it should be recognized that patients might have a different clinical 
phenotype when ELISA demonstrates the infection and culture confirmation is not available. 
This confounding by selection can not be completely excluded although similar differences 
between patients without evidence of C. jejuni infection (culture- and serology negative) and 
patients with culture or serology proven C. jejuni infection were observed. To further exclude 
the possibility that the observed patterns are due to inadequate interpretation of ELISA test 
values, we performed the analyses with more stringent cut-off values, resulting in the same 
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seasonal and age-related patterns (not shown). Non-specific seasonal variability of the ELISA 
was neither likely given the absence of seasonal fluctuation of serum reactivity in healthy 
individuals (Figure 3B). We encourage new developments in techniques for sensitive and 
reproducible testing of antecedent infections that may have already been cleared from the host 
such as in GBS patients (42,43). 
In conclusion, C. jejuni-related GBS is more likely to occur in older individuals and during 
the European winter period. Given the fact that only a very small proportion of patients with 
C. jejuni-related gastroenteritis will develop GBS, these results suggest that both environmental 
and host-related risk factors may determine the outcome of C. jejuni infections.
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ABSTRACT 
 
Molecular mimicry between lipooligosaccharides (LOS) of Campylobacter jejuni and 
gangliosides in peripheral nerves plays a crucial role in the pathogenesis of C. jejuni-related 
Guillain-Barré syndrome (GBS). We have analyzed the LOS outer core structures of 26 C. jejuni 
strains associated with GBS and its variant the Miller Fisher syndrome (MFS) by capillary-
electrophoresis coupled with electrospray ionization mass spectrometry (CE-ESI-MS). 
Sixteen out of 22 (73%) GBS-associated and all 4 (100%) MFS-associated strains expressed 
LOS with ganglioside mimics. GM1a was the most prevalent ganglioside mimic in GBS-
associated strains (10/22, 45%) and in 8 of these strains GM1a was found in combination 
with GD1a mimics. All 7 strains isolated from patients with ophthalmoplegia (GBS or MFS) 
expressed disialylated (GD3 or GD1c) mimics. Three out of 22 GBS-associated strains (14%) 
did not express sialylated ganglioside mimics because their LOS locus lacked the genes 
necessary for sialylation. Three other strains (14%) did not express ganglioside mimicks 
because of frame-shift mutations in either the cstII sialyltransferase gene or in the cgtB 
galactosyltransferase gene. It is not possible to determine if these mutations were already 
present during the C. jejuni infection. This is the first report in which mass spectrometry 
combined with DNA sequence data was used to infer the LOS outer core structures of a 
large number of neuropathy-associated C. jejuni strains. We conclude that molecular mimicry 
between gangliosides and C. jejuni LOS is the presumable pathogenic mechanism in most 
cases of C. jejuni-related GBS. However, our findings suggest that in some cases other 
mechanisms may play a role. Further examination of the disease etiology in these patients is 
mandatory.
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INTRODuCTION
Gastro-enteritis caused by Campylobacter jejuni is the most common infection preceding 
the Guillain-Barré syndrome (GBS), an acute immune-mediated neuropathy (1,2). Molecular 
mimicry between lipooligosaccharides (LOS) in the C. jejuni cell wall and gangliosides 
in peripheral nerves plays a crucial role in the pathogenesis of GBS (3). Gangliosides are 
membrane glycolipids that are highly enriched in the nervous system. They are composed 
of a highly variable oligosaccharide core containing one or more sialic acid molecules 
and a ceramide tail inserted in the cell membrane. Acute phase sera of most patients with 
C. jejuni-associated GBS contain high titers of antibodies to various gangliosides that cross-
react with C. jejuni LOS (4,5). The specificity of these anti-ganglioside antibodies relates to 
specific antecedent infections and different clinical presentations of GBS. For example, anti-
GM1 antibodies have been associated with a preceding Campylobacter infection and with a 
severe, pure motor form of GBS (6). The Miller Fisher syndrome (MFS), a variant of GBS 
with oculomotor weakness and ataxia, is strongly associated with the presence of anti-GQ1b 
antibodies (7).
Since the first report in 1993, several studies have demonstrated ganglioside-like 
structures in the LOS outer core of C. jejuni strains isolated from GBS and MFS patients (8). 
Mass spectrometry (MS) and NMR analysis of individual strains has revealed the presence of 
GM1a, GD3, GD1a and GT1a mimics in GBS-associated strains and of GD3 mimics in MFS-
associated strains (9-13). Serological studies on larger collections of isolates have confirmed 
and extended these findings (5,14). However, serological assays are not suitable to determine 
the exact chemical structure of the LOS outer core. 
Detailed knowledge of the biosynthesis and structures of LOS outer cores in neuropathy-
associated C. jejuni isolates may help to further elucidate the role of microbial factors in 
the pathogenesis of GBS, especially since C. jejuni displays considerable structural variation 
in its LOS outer core. Several genetic mechanisms responsible for this variation have been 
described (15). First, there is extensive variation in the gene content of the LOS biosynthesis 
gene locus (“LOS locus”). In addition, variation in homopolymeric tracts, single base deletions, 
insertions and mutations can lead to gene inactivations or glycosyltransferases with different 
acceptor specificities, resulting in the expression of different LOS structures. Previously, we 
analyzed the LOS locus of a collection of Dutch neuropathy-associated and control enteritis 
C. jejuni isolates (16). We found that the class A LOS locus was associated with GBS and 
the expression of GM1-like structures, whereas the class B LOS locus was associated with 
MFS and the expression of GQ1b-like structures. The presence of GM1-like and GQ1b-like 
structures was determined with serological assays and the exact LOS structures were not 
known. The development of new MS methods combined with serotyping and preliminary 
genetic knowledge to predict LOS structures allows quick screening of many strains (17). 
In the current study, we used this method to infer the LOS outer core structures of 26 GBS- 
and MFS-associated C. jejuni strains. Furthermore, we analyzed the genetic mechanisms 
responsible for the observed variation in these structures and we related the different LOS 
structures to clinical symptoms in the corresponding patients.
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MATERIALS AND METHODS
C. jejuni strains 
Twenty-two GBS-associated and 4 MFS-associated C. jejuni isolates were isolated from 
patients from The Netherlands, Belgium and the Netherlands Antilles between 1991 and 2000 
(Table 1). GB13 and GB14, and GB26 and GB27, were cultured from the diarrheal stools of 
family members of two GBS patients (18). In both families, there was an outbreak of C. jejuni 
enteritis whereas only one family member developed GBS. From both GBS patients, we were 
unable to culture C. jejuni, despite the serological evidence that the GBS patients had also 
been infected with C. jejuni. These paired isolates were found to be highly related by various 
genotyping methods (19, 20), suggesting that family members had been infected with the 
Table 1. C. jejuni strains and patient characteristics.
Strain HS serotypea Origin Patient GenBank Accession Nob
GB1 1 The Netherlands GBS EF066651
GB2 UT The Netherlands GBS DQ813306
GB3 19 The Netherlands GBS DQ906040
GB4 37 The Netherlands GBS AY943308
GB5 4, 64 The Netherlands GBS AY854153
MF6 4, 64 The Netherlands MFS AY422196
MF7 35 The Netherlands MFS DQ140270
MF8 23, 36 The Netherlands MFS DQ102714
GB11 2 The Netherlands GBS AY422197
GB13 2 The Netherlands enteritis, family GBS EF101695 
GB14 2 The Netherlands enteritis, family GBS EF101696 
GB15 5, 34 The Netherlands GBS AY423554
GB16 13, 66 Belgium GBS (with ophthal moplegia) EF07670
GB17 4, 13, 64 The Netherlands GBS EF094857
GB18 19 The Netherlands GBS DQ868320
GB19 4, 50 The Netherlands GBS (with ophthal moplegia) DQ357237
MF20 2 The Netherlands MFS EF064287
GB21 13, 65 The Netherlands GBS EF076704
GB22 13, 64 Netherlands Antilles GBS EF091821
GB23 4, 13, 43 The Netherlands GBS EF107518
GB24 31 The Netherlands GBS AY573819
GB25 2 The Netherlands GBS (with ophthal moplegia) EF064288
GB26 1, 44 The Netherlands enteritis, family GBS DQ351737
GB27 1, 44 The Netherlands enteritis, family GBS EF095404
GB28 19, 38 Netherlands Antilles GBS DQ906041
GB31 13, 50 Netherlands Antilles GBS DQ518908
a HS = heat stable (Penner serotyping system). 
b GenBank accession numbers are given for the partial DNA sequences within the LOS locus.
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same C. jejuni strain. The degree of sub-culturing was kept to a minimum, but 6 to 8 passages 
were necessary for isolation, storage, transport and preparing cells for mass spectrometry 
analysis.
 
Determination of the LOS locus class by PCR 
The LOS locus class was determined as described previously (16). To distinguish between 
class D and class F, an additional primer set for the detection of orf17d (specific for class D) 
was included (21).
Mass spectrometry analysis 
Confluent overnight growths from one agar plate (Mueller-Hinton medium) were treated 
as described by Szymanski et al. except that we used proteinase K at 60 mg/mL, RNase 
A at 200 mg/mL and DNase I at 100 mg/mL (17). The O-deacylated LOS samples were 
analyzed by capillary-electrophoresis coupled with electrospray ionization mass spectrometry 
(CE-ESI-MS) as described by St. Michael et al. (22). All CE-ESI-MS and CE-ESI-MS/MS 
were performed using a crystal Model 310 capillary electrophoresis instrument (ATI Unicam, 
Boston, MA, USA) coupled to an API 3000 mass spectrometer (Applied Biosystems/MDS 
Sciex, Concord, Canada) via a microIon-spray interface.
DNA sequencing
Genomic DNA was isolated using a DNeasy Tissue kit (Qiagen). Long PCR products were 
generated using an Advantage 2 PCR kit (Clontech Laboratories). The PCR products were 
sequenced using custom-made primers that were used previously to sequence the LOS locus 
in multiple strains (15). DNA sequencing was performed using an Applied Biosystems model 
373 automated DNA sequencer (Montreal, Canada) and the manufacturer’s cycle sequencing 
kit. See supplementary Table XXVII for additional details.
Cloning and expression of the cst-II gene from C. jejuni GB26 
The GB26 cst-II gene was amplified using Pwo polymerase (Roche Diagnostics, Laval, Canada) 
and the following primers: CJ-131 (5’ CTTAGGAGGTCATATGAAAAA AGTTATTATTGC-
TGGAAATG 3’, 41 mer, NdeI site in italics) and CJ-764 (5’ TTTAGGGTCGA CT-
CAAAGAT TAAA A TT T T T TGAG 3’, 34 mer, SalI site in italics). These two primers 
amplified the region encoding amino acids 1 to 260 of cst-II from C. jejuni GB26. The PCR 
product was digested with NdeI and SalI and cloned in pCWori+(-lacZ) (23) giving construct 
CST-125. E. coli AD202 containing construct CST-125 was grown in 2 YT medium containing 
150 µg/mL ampicillin. The culture was incubated at 37oC until A600 = 0.35, induced with 1 mM 
IPTG, and then incubated 7 h at 37oC. The cells were broken using an Avestin C5 Emulsiflex 
cell disruptor (Avestin, Ottawa, Canada). α-2,3- and α-2,8-sialyltransferase activities were 
assayed as described previously (15).
Statistical analysis. 
Differences in frequencies between groups were analyzed with the Fisher’s exact test using 
InStat version 3.0 (Graphpad Software, San Diego, CA, USA). Differences were considered 
significant at P < 0.05 after two-sided testing.
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RESuLTS
Determination of the LOS outer core structures 
We used CE-ESI-MS on O-deacylated C. jejuni LOS to propose LOS outer core structures 
for the 26 GBS- and MFS-associated isolates (Figures 1 and 2, Table 2, supplementary Tables 
I to XXVI). The CE-ESI-MS procedure did not provide linkage information but provided 
information about the sugar composition of the LOS outer core. The glycosyltransferase 
variants present in the LOS locus of each strain (Table 3) were used to help interpret the data 
obtained by CE-ESI-MS (see supplementary appendixes A and B). For several strains, we 
could only determine sugar composition of the LOS outer core and no structure. In classes 
A and B strains, the presence of a two-domain Cj1135 (glucosyltransferase) suggests that both 
heptoses are substituted with glucose while the presence of a one-domain Cj1135 suggests 
that only HepI is substituted with glucose (24). The extension of the outer core from HepII 
Figure. 1. Mass spectrometry analysis of O-deacylated LOS from repesentative C. jejuni strains with sialylated 
LOS outer cores. 
Panels A and B: C. jejuni GB11, Panels C and D: C. jejuni GB16, Panels E and F: C. jejuni MF8. Panels A, C and 
E show extracted mass spectra from CE-MS. Panels B, D and F show MS/MS of a representative peak from each 
CE-MS spectrum.
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is proposed for the strains that have an active Cj1136 variant while the two strains (MF7 
and MF8) that have an inactive Cj1136 variant due to frame-shift mutations (see GenBank 
DQ140270 and DQ102714) are proposed to have an outer core extended from the glucose 
substituted to HepII. Based on our previous observations with strains whose LOS outer core 
structures were completely determined (24), we propose that the inner galactose is substituted 
with a sialic acid in the strains that have no glucose on HepII and that have CgtA and CgtB 
variants that are specific for a sialylated acceptor. We propose that the inner galactose is 
not substituted with sialic acid in the case of classes A and B strains that have a glucose on 
HepII, an active Cj1136 variant and CgtA/CgtB variants that are specific for non-sialylated 
accceptors.
Fifteen different outer core structures were identified among the 26 strains that were 
analyzed and 14 strains expressed a mixture of at least 2 different outer core structures. It was 
not possible to quantify the proportions of the different outer core structures because their 
different sialic acid contents result in different ionization efficiencies, which then have an 
impact on observed peak intensities. Several strains harboring the same LOS locus expressed 
different LOS structures. Within the class A strains, 5 different (mixtures of) LOS structures 
Figure 2. Mass spectrometry analysis of O-deacylated LOS from repesentative C. jejuni strains with non-
sialylated LOS outer cores. 
Panels A and B: C. jejuni GB15, Panels C and D: C. jejuni GB4, Panels E and F: C. jejuni GB24. Panels A, C and 
E show show extracted mass spectra from CE-MS. Panels B, D and F show MS/MS of a representative peak from 
each CE-MS spectrum.
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were detected. Clearly, knowledge of the LOS locus class is not sufficient to predict the 
LOS structure. It is also necessary to sequence the key glycosyltransferases to determine the 
variants involved and whether they encode complete or truncated products. 
Expression of ganglioside mimics in the LOS 
Sixteen of 22 (73%) GBS-associated isolates and all 4 (100%) MFS-associated isolates 
expressed LOS with ganglioside mimics including GM1a, GM1b, GM2, GD1a, GD1c, GD2 
and GD3. Ganglioside mimics were only detected in strains with a class A, B or C LOS locus 
(presence of ganglioside mimics in class A/B/C vs. other classes: 20/23 vs. 0/3, P<0.01). In 
GBS-associated strains, GM1a was the most prevalent ganglioside mimic, present in 10 out 
of 22 strains (45%). Interestingly, in all 8 GBS strains with a class A LOS locus and GM1a 
mimicry (36% of all GBS strains), the GM1a mimic was present as part of a GM1a/GD1a 
mixture (presence of GM1a/GD1a in class A vs. non-A: 8/13 vs. 0/13, P<0.01). All 7 strains 
isolated from patients with MFS or GBS with ophthalmoplegia expressed structures with 
a terminal di-NeuAc-Gal (GD3 and GD1c), versus only 1/19 other GBS-associated strains 
(5%, P<0.01). These mimics were predominantly found in strains with a class B LOS locus 
(presence of GD1c or GD3 in class B vs. non-B: 6/7 vs. 2/19, P<0.01). Both class A strains 
with a GD1c mimic were isolated from GBS patients with ophthalmoplegia.
LOS outer core structures without ganglioside mimics 
Ganglioside mimics could not be detected in the LOS of 6 out of 22 GBS-associated isolates 
(27%): GB1, GB4, GB5, GB15, GB24 and GB27 (Table 2). These strains were further analyzed 
to explain the absence of ganglioside mimics. The class C LOS locus of strain GB1 contains 
all genes necessary to synthesize sialylated LOS. However, we found a 5-base deletion in the 
cst-III gene of GB1 (GenBank accession number EF066651), resulting in a truncated Cst-III 
(219 aa instead of 294 aa). This will prevent the transfer of sialic acid and subsequent addition 
of the terminal GalNAc to the LOS backbone. Strain GB5 also contains a LOS locus (class 
B) that is essentially capable of directing the synthesis of sialylated LOS, but single base 
deletions in the cgtB and cst-II genes result in the expression of a truncated LOS outer core 
without sialic acid (25). Although GB26 and GB27, isolated from two family members of a 
GBS patient, were indistinguishable by various pheno- and genotyping methods (16,20), mass 
spectrometry revealed that only GB26 expresses sialylated LOS. We detected a poly-G tract in 
the cst-II gene that leads to a frame shift and premature translation stop in GB27 (10-G tract) 
and mostly a complete translation product in GB26 (9-G tract).
We sequenced the entire LOS biosynthesis locus of GB4, GB15 and GB24 and found 
that all three strains lack the genes necessary for sialylation of the LOS (GenBank accession 
numbers AY943308, AY423554 and AY573819, respectively). These three LOS loci do not 
contain either the sialyltransferase gene (cst-II or cst-III) or the genes (neuA, neuB and neuC) 
necessary for the synthesis of sialic acid and its activated donor, CMP-NeuAc. GB15 has a 
class F LOS locus (24), whereas both GB4 and GB24 contained novel LOS loci (classes P and 
K, respectively, Parker et al., manuscript in preparation). The exact LOS outer core structures 
of strains GB4 and GB24 could not be deduced from the mass spectrometry data, but the 
former structure is related to the LOS outer core of strain ATCC 43431 (HS:3 type strain), 
which does not contain a ganglioside mimic (26). The mass spectrometry profile suggests 
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that the LOS outer core of GB15 is composed of 4 hexoses and 1 HexNAc. It is possible that 
the LOS outer core of GB15 mimics a human glycolipid of the globo- or isoglobo- series. 
However, none of the LOS outer cores of GB4, GB15 and GB24 contains sialic acid, as 
shown by the absence of the diagnostic ion (m/z 290) in CE-MS/MS spectra of O-deacylated 
LOS samples from theses strains (Figure 2). This was further confirmed by precursor ion scan 
experiments, in which no glycoforms were detected with a precursor ion at m/z 290 (data not 
shown).
Cst-II variants and LOS structure
Polymorphism in the cst-II gene determines the extent of sialylation of the LOS (15). 
Table 3. Variants of the glycosyltransferases involved in the synthesis of the LOS outer core structures in 
C. jejuni strains with class A or B LOS locus.a
Strain LOS class Cj1135 Cj1136 CgtAI CgtAII CgtB Cst-II b
GB2 A One-domain on Mono-sialyl.c N/A d Mono-sialyl. Mono-
GB3 A One-domain on Mono-sialyl. N/A Mono-sialyl. Mono-
GB5 B Two-domain on e Non-sialyl.f Mono/di-sialyl.g off h off
MF6 B Two-domain on Non-sialyl. Mono/di-sialyl. Non-sialyl. Bi-
MF7 B Two-domain off off Mono/di-sialyl. off Bi-
MF8 B Two-domain off off Mono/di-sialyl. Mono-sialyl. Mono-
GB11 A One-domain on Mono-sialyl. N/A Mono-sialyl. Mono-
GB16 A Two-domain on Non-sialyl. N/A Non-sialyl. Bi-
GB17 B Two-domain on Non-sialyl. Mono/di-sialyl. Non-sialyl. Bi-
GB18 A One-domain on Mono-sialyl. N/A Mono-sialyl. Mono-
GB19 A Two-domain on Non-sialyl. N/A Non-sialyl. Bi-
MF20 B Two-domain on Non-sialyl. Mono/di-sialyl. Non-sialyl. Bi-
GB21 A One-domain on Mono-sialyl. N/A Mono-sialyl. Mono-
GB22 A One-domain on Mono-sialyl. N/A Mono-sialyl. Mono-
GB23 A One-domain on Mono-sialyl. N/A off Mono-
GB25 B Two-domain on Non-sialyl. Mono/di-sialyl. Non-sialyl. Bi-
GB26 A Two-domain on Non-sialyl. N/A Non-sialyl. Mono-
GB27 A Two-domain on Non-sialyl. N/A Non-sialyl. off
GB28 A One-domain on Mono-sialyl. N/A Mono-sialyl. Mono-
GB31 A One-domain on Mono-sialyl. N/A Mono-sialyl. Mono-
a Assignment of the glycosyltransferase variants is based on amino acid sequence comparisons with variants of 
known specificities (15,24).
b Cst-II variants: mono-: monofunctional, Cst-II has α-2,3-sialyltransferase activity, bi-: bifunctional, Cst-II has 
both α-2,3-sialyltransferase and α-2,8-sialyltransferase activity.
c Mono-sialyl.: the glycosyltransferase is specific for mono-sialylated acceptor.
d N/A: Not applicable.
e on: indicates that a gene has no frame-shift mutation.
f Non-sialyl.: the glycosyltransferase is specific for non-sialylated acceptor.
g Mono/di-sialyl.: the glycosyltransferase can use a mono- or a di-sialylated acceptor.
h off: indicates that a gene is inactive because of a frame-shift mutation.
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Therefore, we determined the correlation between Cst-II variants and LOS outer core structure. 
We have previously shown that amino acid residues 51 and 53 affect the level of activity and 
specificity of Cst-II (15). Most of the variants with Asn51 express disialylated LOS outer cores 
(bifunctional Cst-II; α-2,3- and α-2,8-sialyltransferase activity) while most of the variants 
with Thr51 express LOS outer cores with only α-2,3-linked sialic acids (monofunctional 
Cst-II; only α-2,3-sialyltransferase activity). Cst-III, the Cst-II homologue present in class 
C strains, is always monofunctional and was therefore not analyzed in this study. We detected 
8 different variants among the 20 classes A and B neuropathy-associated strains (Figure 3), 5 of 
which had Asn51. Seven out of 10 strains (70%) with an Asn51 variant expressed disialylated 
LOS, as opposed to 1 out of 10 strains (10%) with a Thr51 variant (P=0.02). However, the 
correlation between Cst-II variants and LOS structure was not perfect. MF8 has the Thr51 
variant and expresses a mixture of mono- and di-sialylated LOS outer cores, while GB26 
has Asn51 and expresses only mono-sialylated LOS outer core. The LOS loci of MF8 and 
HS:36 are identical except for a difference in the length of the G-tract in cgtA (15). Although 
speculative, it is possible that a cgtA mostly in an “off status” enables Cst-II with very low 
α-2,8-sialyltransferase activity to add a second sialic acid, since the lack of GalNAc addition 
preserves the acceptor for Cst-II. We cloned and expressed Cst-II from GB26 and found that 
it has only α-2,3-sialyltransferase activity (using in vitro assays, supplementary Figure 1) 
although it has Asn51. Cst-II from GB26 has the sequence that diverges most from the other 
Cst-II sequences (Figure 3) and it is possible that one (or several) amino acid substitution(s) 
has(ve) inactivated the α-2,8-sialyltransferase activity. We observed that the Asn51 variant 
was present in 6/7 class B strains (86%), whereas Thr51 was the most prevalent variant in 
class A strains (9/13, 69%, P=0.06). Likewise, the Asn51 variant was present in 6/7 (86%) of 
MFS-associated strains and strains associated with GBS and ophthalmoplegia, whereas the 
Thr51 variant was primarily found in the other GBS-associated strains (9/13, 69%, P=0.06).
DISCuSSION
Ganglioside mimicry is considered to be a crucial factor in the pathogenesis of C. jejuni-
associated GBS (3). Detailed knowledge of the bacterial components mimicking human 
structures, the genetic mechanisms responsible for the observed variation in these structures 
and their relation to cross-reactive auto-antibodies and clinical features may provide a better 
understanding of the role of molecular mimicry in post-infectious neuropathy. For the first 
time, MS combined with DNA sequence data was used to determine the LOS outer core 
structures of a large number of neuropathy-associated C. jejuni strains. Our data confirm that 
ganglioside mimicry is the most likely pathogenic mechanism underlying the majority of 
C. jejuni-associated GBS cases, but that in some GBS patients mimicry towards microbial 
structures other than ganglioside-like LOS or other mechanisms may lead to the neurological 
damage.
Various ganglioside mimics were found in the LOS of neuropathy-associated strains. 
GM1a was the most prevalent ganglioside mimic in GBS strains and it was predominantly 
present in combination with GD1a mimics (36% of all GBS strains). Although GM1a mimics 
were found in both class A and class C strains, the GM1a/GD1a mixture was only present in 
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strains with a class A LOS locus, which has previously been associated with GBS (16,27). 
Because the prevalence of a class A LOS locus in enteritis-associated strains is 14-17% (16, 
27), it is expected that a maximum of 14-17% of these strains have the GM1a/GD1a mixture. 
The high prevalence of a GM1a/GD1a mixture in GBS-associated strains suggests that a 
cluster or complex of these two ganglioside mimics may be the target antigens in a subgroup 
of GBS, rather than single ganglioside mimics. This finding is consistent with the results 
of Koga et al., but in contrast with those of Nachamkin et al., who found that expression 
of GD1a and not GM1 was associated with GBS (14, 27). Furthermore, our results are in 
agreement with recent observations that ganglioside complexes are important target antigens 
in GBS as well as in MFS (28, 29). 
MFS and GBS with ophthalmoplegia (GBS/MFS overlap) have been associated with the 
presence of anti-GQ1b antibodies and with the presence of GQ1b-like LOS as determined 
with serological assays (5, 7). This association may be explained by the enrichment of GQ1b 
in the nerves that innervate the oculomotor muscles (30). Up to now, MS analysis has not 
demonstrated true GQ1b-like structures in C. jejuni LOS. The detection of structures with a 
Figure 3. Alignment of the Cst-II sialyltransferase amino acid sequences from the GBS and MFS C. jejuni 
strains. 
Only variable residues are shown in addition to the consensus sequence. The “*” indicate conserved residues, the “:” 
indicate strongly similar residues and the “.” weakly similar residues. The amino acids that were shown to influence 
the activity and specificity of Cst-II are underlined (residues 51-53).
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terminal di-NeuAc-Gal in 7 out of 8 (87%) strains associated with ophthalmoplegia suggests 
that in these patients, pathogenic antibodies are raised against the disialylated, GD3- or GD1c-
like LOS and cross-react with GQ1b in the human nerves.
There are several possible explanations for the observation that 6 GBS-associated strains 
did not express ganglioside mimics in their LOS. We have previously demonstrated that a 
GBS patient had been co-infected with two C. jejuni strains while only one strain could be 
linked to GBS (25). In such cases, it is possible that a co-infecting strain, possibly a strain 
without ganglioside mimics, is isolated from the stool sample and wrongfully regarded as 
“GBS-associated” strain. This may also have occurred in patients described here related to 
strains that lacked ganglioside mimics. However, it is also possible that the expression of 
ganglioside mimics vanished during the infection or culture procedures due to mechanisms 
such as phase variation or single base mutations or deletions. Strain GB1 did not express 
ganglioside mimics due to a frame-shift mutation in the cst-III gene. It is possible that GBS 
was induced by a ganglioside-mimicking GB1 strain and that this mutation occurred later 
in the course of the infection or during laboratory processing. This hypothesis is concordant 
with the presence of antibodies against both GM1 and asialo-GM1 in the patient serum (5). 
The same scenario may also apply to strains GB26 and GB27, which had been isolated from 
two family members of a GBS patient who did not develop neurological symptoms. Both 
isolates are genetically highly related, indicating that all family members had probably been 
infected with the same strain. Interestingly, we found that variation in the poly-G tract of 
the cst-II gene was responsible for the lack of ganglioside mimics in the LOS of GB27. In 
this case, GBS may have been triggered by the ganglioside-mimicking variant of the strain 
(GB26) and not by the variant without ganglioside mimics (GB27). Strain GB26 expresses 
an LOS outer core that mimics GM1b which, unfortunately, is not commercially available. 
Consequently we could not determine if the family member who developped GBS had any 
anti-GM1b antibodies.
On the other hand, our findings indicate that sometimes, molecular mimicry with non-
sialylated LOS may be involved in the pathogenesis of GBS. We demonstrated previously that 
the GB5 patient serum contains anti-asialo-GM2 antibodies cross-reactive with GB5 LOS, 
which suggests that GBS was induced by molecular mimicry with C. jejuni LOS without 
ganglioside mimics (25). Other mechanisms, including mimicry with C. jejuni structures other 
than LOS, either sialylated or non-sialylated, or with other microorganisms should also be 
considered in some cases. Strains GB4, GB15 and GB24 do not express ganglioside mimics 
because they do not have the genes that are required for sialylation of the LOS. The acute 
phase patient sera of GB4, GB15 and GB24 did not contain anti-ganglioside antibodies ((5) 
and M. Kuijf, unpublished data), suggesting a pathogenic mechanism other than ganglioside 
mimicry. Further investigations are needed to elucidate the pathogenesis of GBS and the role 
of C. jejuni in these cases. 
Genetic polymorphism of C. jejuni determines the LOS structure and thereby also the 
specificity of the anti-ganglioside antibody response and clinical features of GBS (5,15,16). 
Presence of and polymorphism within the cst-II gene has been associated with the expression 
of ganglioside mimics and with clinical features of GBS (31,32). We found that the Cst-
II Asn51 variant was associated with the expression of disialylated LOS and seemed 
to occur more frequently in class B strains and strains related with clinical symptoms of 
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MFS or GBS with ophthalmoplegia. The Thr51 variant was associated with monosialylated 
LOS and seemed to occur more frequently in class A strains and in GBS-related strains. 
These observations suggest that the previously described associations between a class A LOS 
locus and GBS and class B LOS locus and MFS may be based on the high prevalence of the 
Thr51 variant in the class A LOS locus and the Asn51 variant in the class B LOS locus (16). 
Our findings are concordant with the recent reports of Koga et al. (27,32).
We conclude that the majority of C. jejuni strains isolated from GBS or MFS patients 
express single or multiple ganglioside mimics in their LOS. However, a substantial portion 
of the strains is apparently lacking the antigen that is supposed to give rise to the potentially 
pathogenic anti-ganglioside antibodies. Further examination of the disease etiology in these 
patients is mandatory.
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SuPPLEMENTARy TABLES I TO XXVII
Supplementary Table I. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB1 using a basic structure containing Kdo2 Hep2 Hex5. 
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3060.0 3059.89
GlcN3N-GlcN-2PPEtn 3183.0 3182.94
GlcN3N-GlcN3N-PPEtn 3285.0 3285.27
GlcN3N-GlcN3N-2PPEtn 3408.0 3408.32
Assignments are from a comparison of the observed and calculated mass (Da) based on the proposed structures 
(Table 2). Average mass units were used for calculation of molecular mass values based on proposed compositions 
as follows: Glc/Gal, 162.14; HexNAc, 203.19; Hep, 192.17; Kdo, 220.18; GlcN, 161.16; GlcN3N 160.18; NeuAc, 
291.26; phosphate, 79.98; PEtn, 123.05; phosphoramidate, 78.98; 3-OH C14:0 fatty acid, 226.36.
Supplementary Table II. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB2 using a basic structure containing 
Kdo2 Hep2 Hex3 HexNAc1 NeuAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be 
linked through an α-2,3- linkage.
Lipid A variant t-2,3-NeuAc Observed mass Calculated mass
GlcN3N-GlcN - 3108.0 3107.01
GlcN3N-GlcN-PPEtn - 3231.0 3230.06
GlcN3N-GlcN-2PPEtn - 3351.0 3353.11
GlcN3N-GlcN3N-PPEtn - 3456.0 3455.44
GlcN3N-GlcN-PPEtn + 3522.0 3521.32
GlcN3N-GlcN3N-2PPEtn - 3579.0 3578.49
GlcN3N-GlcN-2PPEtn + 3645.0 3644.37
GlcN3N-GlcN3N-PPEtn + 3747.0 3746.70
GlcN3N-GlcN3N-2PPEtn + 3870.0 3869.75
See Supplementary Table I for the average mass units used for calculation.
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Supplementary Table III. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB3 using a basic structure containing 
Kdo2 Hep2 Hex3 HexNAc1 NeuAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be 
linked through an α-2,3- linkage.
Lipid A variant t-2,3-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3231.0 3230.06
GlcN3N-GlcN-2PPEtn - 3351.0 3353.11
GlcN3N-GlcN3N-PPEtn - 3456.0 3455.44
GlcN3N-GlcN-PPEtn + 3519.0 3521.32
GlcN3N-GlcN3N-2PPEtn - 3579.0 3578.49
GlcN3N-GlcN-2PPEtn + 3645.0 3644.37
GlcN3N-GlcN3N-PPEtn + 3744.0 3746.70
GlcN3N-GlcN3N-2PPEtn + 3870.0 3869.75
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table IV. Assignment of the variants for the lipid A backbone and variable hexose (Hex) of the 
O-deacylated LOS from C. jejuni GB4 using a basic structure containing Kdo2 Hep2 Hex3 HexNAc3 QuiNAc1 
phosphoramidate1.
Lipid A variant Hex Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3327.6 3326.16
GlcN3N-GlcN-2PPEtn - 3450.9 3449.21
GlcN3N-GlcN-PPEtn + 3489.7 3488.30
GlcN3N-GlcN3N-PPEtn - 3553.3 3551.54
GlcN3N-GlcN-2PPEtn + 3613.3 3611.35
GlcN3N-GlcN3N-2PPEtn - 3676.2 3674.59
GlcN3N-GlcN3N-PPEtn + 3715.1 3713.68
GlcN3N-GlcN3N-2PPEtn + 3838.3 3836.73
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table V. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB5 using a basic structure containing Kdo2 Hep2 Hex3 HexNAc1.
Lipid A variant Observed mass Calculated mass
GlcN-GlcN-PPEtn 2713.5 2713.42
GlcN3N-GlcN 2815.5 2815.75
GlcN3N-GlcN-PPEtn 2938.3 2938.80
GlcN3N-GlcN-2PPEtn 3061.8 3061.85
GlcN3N-GlcN3N-PPEtn 3166.3 3164.18
GlcN3N-GlcN3N-2PPEtn 3286.3 3287.23
See Supplementary Table I for the average mass units used for calculation.
77
Structural characterization of C. jejuni LOS
Supplementary Table VI. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB11 using a basic structure containing 
Kdo2 Hep2 Hex3 HexNAc1 NeuAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be 
linked through an α-2,3- linkage.
Lipid A variant t-2,3-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3230.4 3230.06
GlcN3N-GlcN-2PPEtn - 3354.1 3353.11
GlcN3N-GlcN3N-PPEtn - 3456.8 3455.44
GlcN3N-GlcN-PPEtn + 3522.7 3521.32
GlcN3N-GlcN3N-2PPEtn - 3580.0 3578.49
GlcN3N-GlcN-2PPEtn + 3645.9 3644.37
GlcN3N-GlcN3N-PPEtn + 3748.2 3746.70
GlcN3N-GlcN3N-2PPEtn + 3871.1 3869.75
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table VII. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB13 using a basic structure containing Kdo2 Hep2 Hex6 HexNAc1 NeuAc1. 
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3717.0 3716.48
GlcN3N-GlcN-2PPEtn 3840.0 3839.53
GlcN3N-GlcN3N-PPEtn 3942.0 3941.86
GlcN3N-GlcN3N-2PPEtn 4065.0 4064.91
See Supplemetary Table I for the average mass units used for calculation.
Supplementary Table VIII. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB14 using a basic structure containing Kdo2 Hep2 Hex6 HexNAc1 NeuAc1. 
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3717.0 3716.48
GlcN3N-GlcN-2PPEtn 3840.0 3839.53
GlcN3N-GlcN3N-PPEtn 3942.0 3941.86
GlcN3N-GlcN3N-2PPEtn 4065.0 4064.91
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table IX. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB15 using a basic structure containing Kdo2 Hep2 Hex5 HexNAc1.
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3141.0 3140.03
GlcN3N-GlcN-2PPEtn 3261.0 3263.08
GlcN3N-GlcN3N-PPEtn 3365.0 3365.41
GlcN3N-GlcN3N-2PPEtn 3488.5 3488.46
See Supplementary Table I for the average mass units used for calculation.
Chapter 3.1
78
Supplementary Table X. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB16 using a basic structure containing Kdo2 Hep2 Hex4 HexNAc1 NeuAc2.
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3684.0 3683.46
GlcN3N-GlcN-2PPEtn 3805.5 3806.51
GlcN3N-GlcN3N-PPEtn 3908.5 3908.84
GlcN3N-GlcN3N-2PPEtn 4032.0 4031.89
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XI. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acids (NeuAc) of the O-deacylated LOS from C. jejuni GB17 using a basic structure containing 
Kdo2 Hep2 Hex4 HexNAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be linked 
through an α-2,3- linkage while terminal sialic acid (t-2,8-NeuAc) is presumed to be linked through an α-2,8- 
linkage.
Lipid A variant t-2,3 NeuAc t-2,8 NeuAc Observed mass Calculated mass
GlcN3N-GlcN3N-PPEtn - - 3327.0 3326.32
GlcN3N-GlcN-PPEtn + - 3393.0 3392.20
GlcN3N-GlcN-2PPEtn + - 3513.0 3515.25
GlcN3N-GlcN3N-PPEtn + - 3618.0 3617.58
GlcN3N-GlcN-PPEtn + + 3684.0 3683.46
GlcN3N-GlcN-2PPEtn + + 3807.0 3806.51
GlcN3N-GlcN3N-PPEtn + + 3909.0 3908.84
GlcN3N-GlcN3N-2PPEtn + + 4032.0 4031.89
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XII. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB18 using a basic structure containing 
Kdo2 Hep2 Hex3 HexNAc1 NeuAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be 
linked through an α-2,3- linkage.
Lipid A variant t-2,3-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3231.0 3230.06
GlcN3N-GlcN-2PPEtn - 3351.0 3353.11
GlcN3N-GlcN3N-PPEtn - 3456.0 3455.44
GlcN3N-GlcN-PPEtn + 3519.0 3521.32
GlcN3N-GlcN3N-2PPEtn - 3579.0 3578.49
GlcN3N-GlcN-2PPEtn + 3645.0 3644.37
GlcN3N-GlcN3N-PPEtn + 3747.0 3746.70
GlcN3N-GlcN3N-2PPEtn + 3870.0 3869.75
See Supplementary Table I for the average mass units used for calculation.
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Supplementary Table XIII. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB19 using a basic structure containing Kdo2 Hep2 Hex4 HexNAc1 NeuAc2.
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3684.0 3683.46
GlcN3N-GlcN-2PPEtn 3807.0 3806.51
GlcN3N-GlcN3N-PPEtn 3909.0 3908.84
GlcN3N-GlcN3N-2PPEtn 4032.0 4031.89
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XIV. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB21 using a basic structure containing 
Kdo2 Hep2 Hex3 HexNAc1 NeuAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be 
linked through an α-2,3- linkage.
Lipid A variant t-2,3 NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3231.0 3230.06
GlcN3N-GlcN-2PPEtn - 3351.0 3353.11
GlcN3N-GlcN-PPEtn + 3519.0 3521.32
GlcN3N-GlcN-2PPEtn + 3645.0 3644.37
GlcN3N-GlcN3N-PPEtn + 3744.0 3746.70
GlcN3N-GlcN3N-2PPEtn + 3870.0 3869.75
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XV. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB22 using a basic structure containing 
Kdo2 Hep2 Hex3 HexNAc1 NeuAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be 
linked through an α-2,3- linkage.
Lipid A variant t-2,3-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-2PPEtn - 3351.0 3353.11
GlcN3N-GlcN-PPEtn + 3519.0 3521.32
GlcN3N-GlcN-2PPEtn + 3645.0 3644.37
GlcN3N-GlcN3N-PPEtn + 3747.0 3746.70
GlcN3N-GlcN3N-2PPEtn + 3870.0 3869.75
See Supplementary Table I for the average mass units used for calculation.
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Supplementary Table XVI. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB23 using a basic structure containing Kdo2 Hep2 Hex2 HexNAc1 NeuAc1. 
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3066.0 3067.92
GlcN3N-GlcN-2PPEtn 3189.0 3190.97
GlcN3N-GlcN3N-PPEtn 3291.0 3293.30
GlcN3N-GlcN3N-2PPEtn 3414.0 3416.35
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XVII. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB24 using a basic structure containing Kdo2 Hep2 Hex6 HexNAc1 P2.
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3582.8 3585.18
GlcN3N-GlcN-2PPEtn 3705.8 3708.23
GlcN3N-GlcN3N-PPEtn 3808.2 3810.56
GlcN3N-GlcN3N-2PPEtn 3931.6 3933.61
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XVIII. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acids (NeuAc) of the O-deacylated LOS from C. jejuni GB25 using a basic structure containing 
Kdo2 Hep2 Hex4 HexNAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be linked 
through an α-2,3- linkage while the terminal sialic acid (t-2,8-NeuAc) is presumed to be linked through an 
α-2,8- linkage.
Lipid A variant t-2,3-NeuAc t-2,8-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-2PPEtn - - 3225.0 3223.99
GlcN3N-GlcN3N-PPEtn - - 3327.0 3326.32
GlcN3N-GlcN-PPEtn + - 3393.0 3392.20
GlcN3N-GlcN3N-2PPEtn - - 3447.0 3449.37
GlcN3N-GlcN-2PPEtn + - 3513.0 3515.25
GlcN3N-GlcN3N-PPEtn + - 3618.0 3617.58
GlcN3N-GlcN-PPEtn + + 3681.0 3683.46
GlcN3N-GlcN3N-2PPEtn + - 3741.0 3740.63
GlcN3N-GlcN-2PPEtn + + 3807.0 3806.51
GlcN3N-GlcN3N-PPEtn + + 3909.0 3908.84
GlcN3N-GlcN3N-2PPEtn + + 4032.0 4031.89
See Supplementary Table I for the average mass units used for calculation.
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Supplementary Table XIX. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB26 using a basic structure containing 
Kdo2 Hep2 Hex4 HexNAc1. 
Lipid A variant t-2,3-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3099.0 3100.94
GlcN3N-GlcN-2PPEtn - 3222.0 3223.99
GlcN3N-GlcN3N-PPEtn - 3327.0 3326.32
GlcN3N-GlcN-PPEtn + 3393.0 3392.20
GlcN3N-GlcN3N-2PPEtn - 3447.0 3449.37
GlcN3N-GlcN-2PPEtn + 3513.0 3515.25
GlcN3N-GlcN3N-PPEtn + 3618.0 3617.58
GlcN3N-GlcN3N-2PPEtn + 3741.0 3740.63
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XX. Assignment of the variants for the lipid A backbone of the O-deacylated LOS from 
C. jejuni GB27 using a basic structure containing Kdo2 Hep2 Hex4 HexNAc1.
Lipid A variant Observed mass Calculated mass
GlcN3N-GlcN-PPEtn 3099.0 3100.94
GlcN3N-GlcN-2PPEtn 3222.0 3223.99
GlcN3N-GlcN3N-PPEtn 3324.0 3326.32
GlcN3N-GlcN3N-2PPEtn 3447.0 3449.37
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XXI. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB28 using a basic structure containing 
Kdo2 Hep2 Hex3 HexNAc1 NeuAc1. The sialic acid (t-2,3-NeuAc) linked to terminal Gal is presumed to be linked 
through an α-2,3- linkage.
Lipid A variant t-2,3-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3231.0 3230.06
GlcN3N-GlcN-2PPEtn - 3351.0 3353.11
GlcN3N-GlcN3N-PPEtn - 3453.0 3455.44
GlcN3N-GlcN-PPEtn + 3519.0 3521.32
GlcN3N-GlcN3N-2PPEtn - 3579.0 3578.49
GlcN3N-GlcN-2PPEtn + 3645.0 3644.37
GlcN3N-GlcN3N-PPEtn + 3747.0 3746.70
GlcN3N-GlcN3N-2PPEtn + 3870.0 3869.75
See Supplementary Table I for the average mass units used for calculation.
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Supplementary Table XXII. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (t-2,3-NeuAc) of the O-deacylated LOS from C. jejuni GB31 using a basic structure containing 
Kdo2 Hep2 Hex3 HexNAc1 NeuAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be 
linked through an α-2,3- linkage.
Lipid A variant t-2,3-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3228.0 3230.06
GlcN3N-GlcN-2PPEtn - 3351.0 3353.11
GlcN3N-GlcN3N-PPEtn - 3456.0 3455.44
GlcN3N-GlcN-PPEtn + 3522.0 3521.32
GlcN3N-GlcN3N-2PPEtn - 3579.0 3578.49
GlcN3N-GlcN-2PPEtn + 3645.0 3644.37
GlcN3N-GlcN3N-PPEtn + 3747.0 3746.70
GlcN3N-GlcN3N-2PPEtn + 3870.0 3869.75
See Table I for the average mass units used for calculation.
Supplementary Table XXIII. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acid (NeuAc) of the O-deacylated LOS from C. jejuni MF6 using a basic structure containing 
Kdo2 Hep2 Hex4 HexNAc1 NeuAc1. The terminal sialic acid (t-2,8-NeuAc) is presumed to be linked through an 
α-2,8- linkage.
Lipid A variant t-2,8-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - 3390.0 3392.20
GlcN3N-GlcN-2PPEtn - 3513.0 3515.25
GlcN3N-GlcN3N-PPEtn - 3618.0 3617.58
GlcN3N-GlcN-PPEtn + 3684.0 3683.46
GlcN3N-GlcN-2PPEtn + 3807.0 3806.51
GlcN3N-GlcN3N-PPEtn + 3909.0 3908.84
GlcN3N-GlcN3N-2PPEtn + 4032.0 4031.89
See Supplementary Table I for the average mass units used for calculation.
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Supplementary Table XXIV. Assignment of the variants for the lipid A backbone, variable terminal sialic 
acids (NeuAc) and HexNAc of the O-deacylated LOS from C. jejuni MF7 using a basic structure containing 
Kdo2 Hep2 Hex3  NeuAc1. The terminal sialic acid (t-2,8-NeuAc) is presumed to be linked through an α-2,8- 
linkage.
Lipid A variant t-2,8-NeuAc HexNAc Observed mass Calculated mass
GlcN3N-GlcN-2PPEtn - + 3354.0 3353.11
GlcN3N-GlcN-2PPEtn + - 3441.0 3441.18
GlcN3N-GlcN3N-PPEtn + - 3543.0 3543.51
GlcN3N-GlcN3N-2PPEtn - + 3576.0 3578.49
GlcN3N-GlcN-2PPEtn + + 3645.0 3644.37
GlcN3N-GlcN3N-PPEtn + + 3747.0 3746.70
GlcN3N-GlcN3N-PPEtn 3 - 3834.0 3834.77
GlcN3N-GlcN3N-2PPEtn + + 3870.0 3869.75
GlcN3N-GlcN3N-2PPEtn 3 - 3957.0 3957.82
GlcN3N-GlcN3N-PPEtn 3 + 4038.0 4037.96
See Supplementary Table I for the average mass units used for calculation.
Supplementary Table XXV. Assignment of the variants for the lipid A backbone, variable terminal sialic 
acids (NeuAc) and HexNAc of the O-deacylated LOS from C. jejuni MF8 using a basic structure containing 
Kdo2 Hep2 Hex3 NeuAc1. The terminal sialic acid (t-2,8-NeuAc) is presumed to be linked through an α-2,8- 
linkage.
Lipid A variant t-2,8-NeuAc HexNAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn - - 3027.0 3026.87
GlcN3N-GlcN-2PPEtn - - 3150.0 3149.92
GlcN3N-GlcN-2PPEtn - + 3351.0 3353.11
GlcN3N-GlcN3N-PPEtn + - 3543.0 3543.51
GlcN3N-GlcN3N-2PPEtn - + 3579.0 3578.49
GlcN3N-GlcN3N-2PPEtn + - 3666.0 3666.56
See Supplementary Table I for the average mass units used for calculation.
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Supplementary Table XXVI. Assignment of the variants for the lipid A backbone and variable terminal 
sialic acids (NeuAc) of the O-deacylated LOS from C. jejuni MF20 using a basic structure containing 
Kdo2 Hep2 Hex4 HexNAc1. The sialic acid (t-2,3-NeuAc) linked to the terminal Gal is presumed to be linked 
through an α-2,3- linkage while terminal sialic acid (t-2,8-NeuAc) is presumed to be linked through an α-2,8- 
linkage.
Lipid A variant t-2,3-NeuAc t-2,8-NeuAc Observed mass Calculated mass
GlcN3N-GlcN-PPEtn + - 3392.2 3392.20
GlcN3N-GlcN-2PPEtn + - 3516.3 3515.25
GlcN3N-GlcN3N-PPEtn + - 3618.9 3617.58
GlcN3N-GlcN-PPEtn + + 3684.3 3683.46
GlcN3N-GlcN3N-2PPEtn + - 3742.1 3740.63
GlcN3N-GlcN-2PPEtn + + 3807.1 3806.51
GlcN3N-GlcN3N-PPEtn + + 3910.3 3908.84
GlcN3N-GlcN3N-2PPEtn + + 4033.1 4031.89
See Supplementary Table I for the average mass units used for calculation.
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Supplementary Table XXVII. Information about the DNA sequencing of the lipooligosaccharide loci from 
GBS- and MFS-associated strains.
Strain GenBank Accession 
number
Contig size (bp) Double-Strand coverage (%)
GB1     EF066651       1,906 98.3
GB2     DQ813306       6,047 86.1
GB3     DQ906040       6,047 99.4
GB4     AY943308     15,092 96.9
GB5     AY854153     12,403 93.0
MF6     AY422196     12,370 85.8
MF7     DQ140270     12,354 89.3
MF8     DQ102714     12,359 92.3
GB11     AY422197     24,425 98.0
GB13     EF101695       1,906 99.0
GB14     EF101696       1,906 96.3
GB15     AY423554       7,633 87.5
GB16     EF076703       6,036 93.7
GB17     EF094857       7,930 86.0
GB18     DQ868320       6,047 99.4
GB19     DQ357237     11,413 73.1
MF20     EF064287       9,357 96.3
GB21     EF076704       6,047 98.0
GB22     EF091821       6,047 97.8
GB23     EF107518       6,045 83.3
GB24     AY573819       9,295 98.3
GB25     EF064288       9,357 91.5
GB26     DQ351737     11,427 85.3
GB27     EF095404          880   1.2 a
GB28     DQ906041       6,047 99.1
GB31     DQ518908     11,419 96.9
a Only the phase-variable cstII gene was sequenced in GB27. The heterogeneous G-tract prevented sequencing on 
both strands but the sequence was confirmed by multiple same strand sequencing reactions. 
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1             2         3 1            2         3 
Gal-Glc-
NeuAc-Gal-Glc-
NeuAc-Gal-Glc-
NeuAc-NeuAc-Gal-Glc-NeuAc-NeuAc-Gal-Glc-
TLC origin TLC origin 
Supplementary Figure 1. Demonstration that Cst-II from C. jejuni GB26 is mono-functional. 
The α-2,3-sialyltransferase activity was assayed using Galβ-1,4-Glc-FCHASE as acceptor (Panel A). The α-2,8-
sialyltransferase activity was assayed using Neu5Acα-2-3-Galβ-1,4-Glc-FCHASE as acceptor (Panel B). Purified 
recombinant MalE-Cst-II from GB26 was incubated with either Galβ-1,4-Glc-FCHASE (Panel A, lane 3) or 
Neu5Acα-2-3-Galβ-1,4-Glc-FCHASE (Panel B, lane 3) and a 2-fold excess of CMP-NeuAc. Product is observed 
only with Galβ-1,4-Glc-FCHASE (lane 3) as acceptor. Lane 1 from panel A shows where Gal-Glc-FCHASE migrates 
and lane 1 from panel B shows where Neu5Acα-2-3-Galβ-1,4-Glc-FCHASE migrates. Lanes 2 show an example of 
a Cst-II that is bifunctional (Cst-II(Ile53Ser) from C. jejuni OH4384).
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Appendix A: Key to LOS outer core structures 
from Class A: 
The glycosyltransferase variants for each C. jejuni 
strain are indicated in Table 3 
Step 1: Glucosyltransferase variant 
Two-domain Cj1135 
Basic inner core: 
   HepII-HepI  
       |         | 
    Glc   Glc 
One-domain Cj1135 
Basic inner core 
   HepII-HepI  
                 | 
               Glc 
Step 2: Cj1136 variant is always observed as 
complete product in class A strains studied in this 
work 
Case 1: Gal extension from HepII with two glucose 
units on inner core 
       Gal-HepII-HepI  
          |         | 
                    Glc   Glc 
Case 2: Gal extension from HepII with one glucose 
unit on inner core 
      Gal- HepII-HepI  
      | 
    Glc 
Step 3: Addition of NeuAc to the inner Gal by Cst-II 
when there is no Glc on HepII. 
Case 1: No NeuAc on inner Gal 
       Gal-HepII-HepI  
          |         | 
        Glc   Glc 
Case 2: NeuAc on inner Gal 
      Gal- HepII-HepI  
         |               | 
  NeuAc              Glc 
Step 4: Specificity of CgtA and CgtB 
Case1: CgtA and CgtB use non-sialylated acceptors
        Gal-GalNAc-Gal-HepII-HepI  
        |                   | 
      Glc              Glc 
Case 2: CgtA and CgtB use sialylated acceptors 
       Gal-GalNAc-Gal- HepII-HepI  
                   |             | 
 NeuAc            Glc 
Step 5: Mono- or bi-functional Cst-II 
Case1.1: Mono-functional Cst-II
        Gal-GalNAc-Gal-HepII-HepI  
           |       |         | 
   NeuAc     Glc   Glc 
Case 1.2: Mono-functional Cst-II 
       Gal-GalNAc-Gal- HepII-HepI  
          |                   |                  | 
   NeuAc NeuAc         Glc 
Case 2.1: Bi-functional Cst-II
        Gal-GalNAc-Gal-HepII-HepI  
           |       |     | 
   NeuAc   Glc  Glc 
           | 
   NeuAc 
Case 1.2: Bi-functional Cst-II 
       Gal-GalNAc-Gal- HepII-HepI  
          |                  |                  | 
   NeuAc            NeuAc          Glc 
          | 
   NeuAc 
Appendix B: Key to LOS outer core structures 
from Class B: 
The glycosyltransferase variants for each C. jejuni 
strain are indicated in Table 3 
Step 1: Glucosyltransferase variant 
All class B strains have a two-domain Cj1135: 
Basic inner core: 
   HepII-HepI  
       |         | 
    Glc     Glc 
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Step 2: 
Case 1: Cj1136 encodes a full length 
galactosyltransferase which results in a Gal extension 
from HepII with two glucose units on inner core: 
       Gal-HepII-HepI  
       |         | 
    Glc     Glc 
Case 2: Cj1136 encodes a truncated 
galactosyltransferase which prevent extension from 
HepII. An un-identified gene encodes a 
galactosyltransferase that uses the Glc on HepII as 
acceptor:
   HepII-HepI  
       |         | 
           Gal-Glc    Glc 
Note: equivalent to: 
                 Gal-Glc-HepII-HepI  
   | 
              Glc 
Step 3: Addition (or not) of NeuAc to the inner Gal 
by Cst-II:  
Case 1: No NeuAc added to the Gal extension from 
HepII because of the presence of a Glc on HepII. 
       Gal-HepII-HepI  
       |         | 
    Glc   Glc 
Case 2: Addition of NeuAc on Gal attached to Glc 
                 Gal-Glc-HepII-HepI  
   |                       | 
           NeuAc         Glc 
Step 4: Addition of GalNAc 
Case1: CgtA uses a non-sialylated acceptor
              GalNAc-Gal-HepII-HepI  
                          |         | 
           Glc    Glc 
Case 2: CgtA uses a sialylated acceptor 
        GalNAc-Gal-Glc-HepII-HepI  
            |                        | 
        NeuAc        Glc 
Step 5: Addition of a terminal Gal is observed only in 
the non-sialylated extension 
Case 1: 
       Gal-GalNAc-Gal-HepII-HepI  
              |         | 
            Glc   Glc 
Step 6: Mono- or bi-functional Cst-II 
Case1.1: Mono-functional Cst-II
        Gal-GalNAc-Gal-HepII-HepI  
           |               |         | 
   NeuAc            Glc    Glc 
Case 1.2: Mono-functional Cst-II 
                 Gal-Glc-HepII-HepI  
   |            | 
        NeuAc          Glc 
Case 1.3: Mono-functional Cst-II 
      GalNAc-Gal-Glc-HepII-HepI  
                        |                      | 
      NeuAc      Glc 
Case 2.1: Bi-functional Cst-II
        Gal-GalNAc-Gal-HepII-HepI  
           |                           |         | 
   NeuAc          Glc     Glc 
           | 
   NeuAc 
Case 2.2: Bi-functional Cst-II 
               Gal-Glc-HepII-HepI  
  |            | 
          NeuAc          Glc 
                            | 
                        NeuAc 
Case 2.3: Bi-functional Cst-II 
     GalNAc-Gal-Glc-HepII-HepI  
                       |                     | 
     NeuAc     Glc 
                       | 
                  NeuAc 
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ABSTRACT 
 
The origin of antibodies to ganglioside complexes, as new immunotargets for Guillain-
Barré syndrome (GBS), is unknown. This was investigated in 21 GBS patients from which 
Campylobacter jejuni was isolated. Two of these patients had serum IgG to the GM1/GD1a 
complex and two other patients had IgG to the GQ1b/GD1a complex. These pairs of patients 
were clinically distinct. These antibodies all cross-reacted to lipo-oligosaccharides (LOS) from 
the autologous C. jejuni strain. Previous mass spectrometry studies on these LOS showed the 
presence of oligo-saccharides with a similar structure, further supporting the hypothesis that 
in these patients LOS induced the ganglioside complex antibodies. 
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INTRODuCTION
Molecular mimicry between Campylobacter jejuni lipo-oligosaccharides (LOS) and 
peripheral nerve gangliosides plays a crucial role in the pathogenesis of the Guillain-
Barré syndrome (GBS) (1). C. jejuni is the predominant cause of infection preceding GBS 
and highly associated with the presence of antibodies to a variety of gangliosides (2,3). 
The C. jejuni LOS contains ganglioside-like moieties that dictate the specificity of the cross-
reactive anti-ganglioside antibodies (4). These antibodies can also be induced by immunization 
with C. jejuni LOS in animal models that develop a neuropathy resembling GBS (5). 
Interestingly, the specificity of the anti-ganglioside antibodies is related to distinct clinical 
subgroups of GBS (1). However, not all GBS patients associated with C. jejuni infections 
have antibodies to single gangliosides (3,6). 
Recent studies showed that some GBS patients produce antibodies to mixtures or complexes 
of gangliosides, such as GM1/GD1a and GQ1b/GD1a, rather than to single gangliosides (7,8). 
Conformational epitopes recognized by the antibodies may be present in the Schwann cell 
and neuronal plasma membranes where various gangliosides reside in clusters in functional 
domains (9). Interestingly, C. jejuni isolates from GBS patients also frequently express various 
forms of (truncated) LOS each mimicking a different ganglioside (10). At present however, it 
is unknown whether the conformational epitopes formed by ganglioside complexes are also 
present in the LOS of C. jejuni. 
In this study the origin of the antibodies to ganglioside complex was determined in patients 
with GBS from which C. jejuni was isolated. First, acute phase serum samples from 21 of these 
patients were screened for the presence of IgG antibodies to various ganglioside complexes 
in relation to the neurological deficits. Secondly, we studied the cross-reactivity of these 
antibodies to LOS from autologous C. jejuni isolates in relation to the previously determined 
molecular structure of these LOS. Our study provides strong evidence that conformational 
molecular mimicry is also involved in the induction of ganglioside complex antibodies in 
these patients with C. jejuni-related GBS.
MATERIALS AND METHODS
Patients and bacterial strains 
Twenty-six C. jejuni strains were isolated from 24 GBS patients or infected family members 
with enteritis from The Netherlands, Belgium and the Netherlands Antilles between 1991 
and 2000. The family members were excluded from the serological study. From 21 of the 
remaining patients, pre-treatment serum obtained within two weeks of onset of weakness was 
available for the present study. Fourteen of these patients had GBS without ophthalmoplegia, 
three had GBS with ophthalmoplegia and four had the Miller Fisher syndrome (MFS) variant, 
characterized by the presence of ophthalmoplegia, ataxia and areflexia without evident limb 
paresis. All C. jejuni strains were isolated during the acute phase of disease. From all patients 
informed consent was obtained.
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Determination of ganglioside complex serum reactivity
Serum samples obtained from the 21 C. jejuni-related GBS or MFS patients were diluted 
1:100 and tested in duplicate for IgG reactivity to the gangliosides GM1, GM2, GD1a, GD1b, 
GD3 and GQ1b and to all combinations of two of these gangliosides. The antibody activity 
was determined by enzyme-linked immunosorbent assay (ELISA) according to previously 
described methods (11) and by using 150 pmol/well for each ganglioside. Serum reactivity 
for ganglioside complexes was considered positive when the corrected optical densities (OD) 
(extinctions of ganglioside complex coated wells minus OD of non-coated wells) were 0.2 
higher than the corrected OD for a single ganglioside, in accordance with previously defined 
criteria (7). Positive serum samples were titrated using two-fold serial dilution series starting 
at 1:100. The reciprocal of the highest dilution that resulted in an OD higher than the cut-
off value (OD 0.2) was taken to be the titer (11). Residual antibody activity to ganglioside 
complexes was determined in convalescent serum samples obtained at three to six months 
after onset of disease. 
LOS isolation
The LOS fractions from all C. jejuni strains were isolated by hot phenol-water extraction and 
processed as described before (2). The molecular structure of the C. jejuni LOS core antigen 
was previously determined by electrospray ionization mass spectrometry and summarized in 
Table 1 (10). 
Determination of cross-reactivity 
Cross-reactivity of anti-ganglioside complex antibodies to C. jejuni LOS was determined 
by pre-incubation of serum with LOS from C. jejuni isolated from the autologous patients 
and with LOS from the C. jejuni HS:3 Penner serostrain as a control, according to methods 
previously described (2,12). Cross-reactivity of anti-GM1/GD1a complex antibodies was 
also determined to LOS from three non-autologous C. jejuni strains (GB2, GB21 and GB22) 
containing both GM1 and GD1a mimics and to LOS from NTC 11168 reference strain 
containing a GM1 mimic (10,13). LOS concentrations of 50, 13, 3.0, 0.8 and 0.2 μg/ml were 
incubated with serum (diluted 1:100) for 3 hours at 4ºC. The supernatants were centrifuged 
and tested for residual anti-ganglioside activity. Percentage of inhibition was defined as: 
OD (serum without LOS) – OD (serum with LOS) x 100%.
                        OD (serum without LOS)
RESuLTS 
Antibodies to ganglioside complexes
Sera from four of 21 (19%) patients with C. jejuni-related GBS had IgG antibodies to one or 
more of the gangliosides complexes. Two patients (GB11 and GB17) had IgG antibodies to 
the GM1/GD1a complex and two other patients (GB16 and GB19) had IgG antibodies to the 
GQ1b/GD1a complex (Table 2). The patients GB17 and GB16 also had IgG antibodies to the 
GD1a/GD1b and GD3/GQ1b complexes respectively (Table 2). Convalescent serum samples 
available from the patients GB11, GB16 and GB19 contained no residual antibody activity 
to ganglioside complexes. None of the patients had antibodies to the ganglioside complexes 
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composed of GM1/GM2, GM1/GD1b, GM1/GD3, GM1/GQ1b, GM2/GD1a, GM2/GD1b, 
GM2/GD3, GM2/GQ1b, GD1a/GD3, GD1b/GD3, GD1b/GQ1b. Some of the patients without 
anti-ganglioside complex antibodies have antibodies to single gangliosides as was previously 
published (4).
Characteristics of patients with ganglioside complex antibodies
The patients with ganglioside complex antibodies all had preceding symptoms of an infectious 
disease, serological evidence for a recent C. jejuni infection and serum IgM and IgG antibodies 
to the LOS from the autologous C. jejuni isolate. All patients had a rapidly progressive form 
of GBS without ataxia. Patient GB11 and GB17, with antibodies to the GM1/GD1a complex, 
had a pure motor variant of GBS without cranial nerve involvement (except for a mild facial 
palsy in patient GB11) (Table 2). Patients GB16 and GB19, with antibodies to the GQ1b/
GD1a complex had a severe variant of GBS with ophthalmoplegia (Table 2). Patient GB16 
had to be ventilated and GB19 had an additional bulbar palsy. 
Table 1. Molecular structures and ganglioside mimics of LOS from C. jejuni isolates from GBS patients used 
in the studya.
Strain(s)     LOS structure   Ganglioside mimics
GB2, GB11, GB21, GB22     Gal-GalNAc-Gal-Hep-Hep              GM1
                                |              |
                                                NeuAc   Glc
       Gal-GalNAc-Gal-Hep-Hep              GD1a
           |                    |              |
              NeuAc            NeuAc   Glc
GB17        Gal-GalNAc-Gal-Hep-Hep          none (GA1)
                                                      |       |
                                                    Glc  Glc 
       Gal-GalNAc-Gal-Hep-Hep              GM1b
                                      |                           |      |
           NeuAc                  Glc  Glc 
        Gal-GalNAc-Gal-Hep-Hep              GD1cb
                                        |                            |      |
           NeuAc                   Glc  Glc 
                                      |
           NeuAc
GB16, GB19      Gal-GalNAc-Gal-Hep-Hep             GD1cb
                   |                            |     |
              NeuAc                   Glc Glc
                 |
             NeuAc
a Structures were previously published (10).
b GD1c structurally similar to GD3. 
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Cross-reactivity of ganglioside complex antibodies
The cross-reactivity of the ganglioside complex antibodies to C. jejuni LOS was studied by 
inhibition ELISA. Up to 90-100% of serum reactivity to the ganglioside complexes in the 
four patients was inhibited by 50 μg/ml LOS from the autologous C. jejuni isolate (Figure 1). 
This inhibition was dose dependent whereas no inhibition of serum reactivity was found 
using LOS from the control C. jejuni HS:3 Penner serostrain which lacks ganglioside mimics 
(Figure 1). 
Anti-GM1/GD1a complex antibodies from patient GB11 were also inhibited by pre-
incubation with LOS containing GM1 and GD1a mimics from three non-autologous 
C. jejuni strains isolated from patients without these antibodies (Figure 2). This activity was 
also inhibited by 50 μg/ml of LOS from the GB17 C. jejuni strain, but not by LOS from the 
C. jejuni NTC 11168 reference strain containing a GM1 mimic but not the GD1a mimic (data 
not shown). 
Table 2. Serology and clinical features of GBS patients with ganglioside complex antibodies.
Patients GB11 GB17 GB16 GB19
Clinical characteristics
Age, years 50 64 53 29
Sex Male Male Male Male
Days to nadira 13 14 2 2
Ophthalmoplegia  -  - + +
Sensory involvement  -  -  - +
Motor involvementb 46 39 6 34
GBS disability scorec
  At nadir 4 3 5 4
  At 26 weeks 1 3 0 NA
Serum IgG antibody titers
GM1 800 100 0 0
GD1a 0 0 12800 100
GD1b 3200 0 0 0
GD3 0 100 3200 0
GQ1b 0 0 102400 12800
GM1/GD1a 12800 12800 0 0
GD1a/GD1b 0 12800 0 0
GD1a/GQ1b 0 100 409600 25600
GD3/GQ1b 0 0 25600 0
a Number of days between onset and most severe weakness (nadir). 
b Severity of weakness expressed as MRC-sum scores: sum of scores according to the Medical Research Council 
grading system of 6 bilateral muscle groups (deltoid, biceps, triceps, iliopsoas, quadriceps and tibialis anterior 
muscles) ranging from 60 (normal strength) to 0 (tetraparalytic).
c GBS disability score: 0 = no symptoms, 1 = minor signs or symptoms, 2 = able to 10 m without support but incapable 
of manual work, 3 = able to walk 10 m with walking aid, appliance or support, 4 = bed- or chair-bound, 5 = requiring 
assisted ventilation, 6 = dead. 
NA = not available.
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DISCuSSION
In this study we demonstrated that serum ganglioside complex antibodies cross-reacted with 
LOS from autologous C. jejuni isolates, strongly indicating that these antibodies were induced 
by C. jejuni LOS. Structural analysis had previously identified ganglioside-like moieties in the 
LOS from these autologous strains (10). The C. jejuni strain from one patient with anti-GM1/
GD1a antibodies (GB11) expresses an heterogeneous LOS mimicking the expected GM1 and 
GD1a. The C. jejuni strain from the other patient with anti-GM1/GD1a antibodies (GB17) 
expresses a slightly different but also heterogeneous LOS that mimics asialo-GM1, GM1b and 
GD1c. These mimics share the terminal Gal-GalNAc- and NeuAc-Gal-GalNAc-moieties with 
GM1 and GD1a respectively. The serum anti-GM1/GD1a complex antibodies from patient 
GB11 also cross-reacted to this LOS suggesting the recognition of a similar epitope. The anti-
GM1/GD1a complex antibodies from patient GB11 did not cross-react to LOS from HS:3 
Penner serostrain lacking ganglioside-mimics and the NTC 11168 reference strain expressing 
a GM1 mimic only, illustrating the specificity of this recognition. Surprisingly, the two strains 
isolated from the patients with anti-GQ1b/GD1a antibodies (GB16 and GB19) both express 
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Figure 1. Cross-reactivity of ganglioside complex antibodies.
Antibodies to ganglioside complexes cross-react with LOS from the autologous C. jejuni strains (filled circles) but 
not with LOS from the control HS:3 Penner serostrain lacking ganglioside mimicry (open triangles). (A) Inhibition 
of IgG anti-GM1/GD1a complex reactivity in serum from patient GB11 by pre-incubation with LOS from the 
autologous C. jejuni GB11 strain (GM1/GD1a mimic, Table 1) and from Penner serostrain HS:3. (B) Inhibition of 
anti-GM1/GD1a complex reactivity in serum from patient GB17 by pre-incubation with LOS from the autologous 
GB17 strain (GM1b/GD1c mimic) and from Penner serostrain HS:3. (C) Inhibition of anti-GD1a/GQ1b complex 
reactivity in serum from patient GB16 by pre-incubation with LOS from the autologous GB16 strain (GD1c mimic) 
and from Penner serostrain HS:3. (D) Inhibition of anti-GD1a/GQ1b complex reactivity in serum from patient GB19 
by pre-incubation with LOS from the autologous GB19 strain (GD1c mimic) and from Penner serostrain HS:3. 
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a homogeneous LOS with only a GD1c mimic. This mimic however, shares the terminal 
NeuAc-NeuAc-Gal-GalNAc epitope with GQ1b and the NeuAc-Gal-GalNAc with GD1a. 
Both patients had additional high titers of anti-GQ1b antibodies, although the titer was lower 
than the anti-GQ1b/GD1a antibodies. We can not exclude the possibility that the detected 
antibody activity to GQ1b is caused by antibodies to GQ1b/GD1a complexes, since the GQ1b 
used in these studies may be contaminated with other gangliosides. 
Previous results showed that infection with C. jejuni expressing ganglioside-like LOS 
does not always lead to production of anti-ganglioside antibodies and GBS (10). In the present 
study we demonstrated that this restriction also applies for ganglioside complex mimics in 
LOS. Ganglioside complex antibodies were absent in some GBS patients that were infected 
with C. jejuni strains containing both GM1 and GD1a mimics in LOS. Interestingly, the GM1/
GD1a complex antibodies from patient GB11 cross-reacted to at least three of these isolates 
(Figure 2). This illustrates the important role of host-factors in addition to molecular mimicry 
in the production of cross-reactive antibodies.
Several findings in the current study support the hypothesis that the cross-reactive antibodies 
to ganglioside complexes in these patients contributed to the development of GBS. First, the 
specificity of the antibodies to ganglioside complexes in these patients was associated with a 
specific clinical phenotype: the two patients with anti-GM1/GD1a antibodies both had a pure 
motor variant without severe cranial nerve involvement, while the two patients with anti-
GQ1b/GD1a antibodies both had a severe GBS with ophthalmoplegia. Serum reactivity to the 
NeuAc-Gal-GalNAc-moiety of the GQ1b/GD1a complex antibodies may have contributed to 
the severe limp paresis and may explain why these patients did not develop ophthalmoplegia 
only. Secondly, this dichotomy in antibody specificity and clinical symptoms corresponded to 
the molecular structure of the LOS from the C. jejuni isolates from these patients. Thirdly, the 
titer of the serum antibodies to ganglioside complexes declined with clinical recovery of the 
patients. Studies in bioassays are required to further address the presumed neurotoxic effects 
of these antibodies.  
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Figure 2. Cross-reactivity of IgG GM1/GD1a complex antibodies to non-autologous C. jejuni strains containing 
GM1/GD1a mimics.
Inhibition of IgG anti-GM1/GD1a complex reactivity in serum from patient GB11 by pre-incubation with LOS from 
C. jejuni strains GB2 (open circles), GB21 (asterisks) and GB22 (filled squares) isolated from GBS patients without 
ganglioside complex antibodies.
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Our study illustrates both the relevance and the intricacy of molecular mimicry in the 
induction of antibodies to ganglioside complexes in patients with C. jejuni-related GBS. In three 
cases the carbohydrate structures in the bacterial LOS were similar, but not identical to those 
in the associated ganglioside complexes. Furthermore, we found that in 11 of 17 ganglioside 
complex seronegative patients a heterogeneous C. jejuni LOS, as determined previously by 
mass spectrometry, is present as well (10). The configuration of the oligosaccharide moieties is 
highly influenced by the micro-environment, and depends on the epitope density and proximity 
of other oligosaccharides and possibly on the nature of the lipid carrier (9,14). Apparently, 
these different oligosaccharide moieties in the LOS and the ganglioside complexes form 
similar conformational epitopes, since both structures were recognized by the same serum 
antibodies. Immunizations with protein ‘mimotopes’ to induce antibodies to Haemophilus 
influenzae LOS also show that structural identity is not required to produce cross-reactive 
antibodies (15). Alternatively, the carbohydrate composition of LOS may also have changed 
due to genetic alterations in the LOS biosynthesis locus after the initial infection. However, 
the observed cross-reactivity of ganglioside complex antibodies and the similarity between 
the ganglioside mimics present in LOS clearly indicates that conformational epitopes can be 
formed by ganglioside-like complexes in C. jejuni LOS.
Our findings illustrate the importance of demonstrating antibody cross-reactivity in 
addition to defining molecular structures. The conformation of the oligosaccharide moieties 
in C. jejuni LOS and the recognition of these complex moieties by the adaptive immune 
system can not be predicted by the biochemical structure only. This may partly explain why 
C. jejuni strains expressing ganglioside-like structures have also been isolated in patients with 
uncomplicated enteritis, without the production of anti-ganglioside antibodies and subsequent 
development of GBS.
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ABSTRACT
Immune responses to microbial glycolipids that cross-react to neural epitopes may trigger 
the Guillain-Barré syndrome (GBS). CD1 molecules are involved in antigen presentation 
of glycolipids and variation in CD1 genes was recently reported to confer susceptibility to 
develop GBS. This hypothesis was tested by comparing single nucleotide polymorphisms 
(SNPs) of CD1A and CD1E in 312 well defined GBS patients and 212 healthy controls. SNPs 
in CD1A and CD1E were not associated with GBS susceptibility, specific clinical subgroups, 
anti-ganglioside antibodies, antecedent infections and prognosis. Based on this study, CD1 
polymorphisms are not a susceptibility or disease modifying factor in GBS.
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INTRODuCTION
Guillain-Barré syndrome (GBS) is an immune mediated polyneuropathy that rarely follows 
common types of infections. Campylobacter jejuni is the predominant antecedent infection 
in GBS but only one in an estimated 1,000 to 5,000 persons with this type of infection will 
develop GBS (1). A crucial step in the pathogenesis of C. jejuni-related GBS is the production 
of cross-reactive antibodies to nerve gangliosides. These antibodies are induced by ganglioside 
mimicking C. jejuni lipo-oligosaccharide (LOS) and have shown to damage peripheral 
nerves (2). Antigen presentation of these bacterial glycolipids by dendritic cells or other 
antigen presenting cells may determine whether this aberrant immune response will occur or 
not.
Single nucleotide polymorphisms (SNPs) in the genes coding for antigen presenting 
molecules may influence the susceptibility to develop GBS. Extensive studies showed 
no general or consistent association between the human leucocyte antigen (HLA) class II 
haplotypes and GBS (3). HLA class II molecules yet present peptides whereas CD1 molecules 
are involved in antigen presentation and processing of glycolipids. In humans, five types of 
CD1 molecules exist, of which CD1a, CD1b, CD1c and CD1d are expressed at the cellular 
surface. The CD1e is an intermediate form that accumulates intracellular in late endosomal 
compartments and co-localizes with CD1b that in turn is transported to the cell membrane (4).
CD1b is expressed on dendritic cells and is involved in activation of GM1-specific T-cells 
upon infection with C. jejuni LOS (5). Variation occurs in exon 2 of all CD1 genes, but only 
result in amino acid substitutions in CD1a and CD1e (6). In CD1A, the two alleles result in 
the replacement of threonine by isoleucine (1) and the replacement of cysteine by tryptophan 
(2). Both variants are expressed at the cell surface (7). In CD1E, the replacement of glutamine 
by arginine occurs in the region flanking the lipid binding groove. The effects of these SNPs 
on antigen presentation of lipids are however unknown. Interestingly, a recent report indicated 
that genotype variants in exon 2 of CD1A and CD1E genes are susceptibility factors for 
developing GBS, although this study was based on a relatively small cohort of 65 patients (8).
In the present study, a detailed described cohort of 312 GBS patients and 212 healthy 
controls was used to determine if these CD1 SNPs are related to the development of GBS.
Furthermore, we assessed the relationship between these SNPs and subgroups of GBS patients 
defined by preceding infections, serum antibodies and clinical characteristics.
PATIENTS AND METHODS
Patients and controls
DNA was obtained from 312 Dutch patients (median age 47 years, range 7-82 years, male-
female ratio =1.1) fulfilling the diagnostic criteria for GBS (9). Detailed clinical and serological 
data were available in a subgroup. This group consisted of 213 patients who participated in 
one of the Dutch GBS trials or survey studies (10-13). Disease severity was defined by the 
GBS disability score, ranging from 0 (no symptoms) to 6 (dead), and the MRC sumscore, 
ranging from 0 (tetraplegia) to 60 (normal) at nadir (3). Clinical outcome was evaluated as 
the number of days required for patients to be able to walk independently (i.e. reaching GBS 
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disability score of 2) with a follow-up time of 6 months. Time to nadir was expressed as 
the number of days before reaching the highest disability score or lowest MRC sumscore. 
Serological screening for most common antecedent infections and antiganglioside antibodies 
was performed using standard procedures (3). Dutch healthy blood bank donors were used 
as controls (N=212, median age 35 years, range 19-60 years, male/female ratio=0.66). 
The study was approved by the Medical Ethical Committee of Erasmus MC. All patients and 
controls gave their written informed consent (14).
Genotyping
Genotyping was performed using the LightCycler® technique (Roche Diagnostics, 
Mannheim, Germany) (3). The set of primers and hybridization probes were designed by 
TibMolBiol and are listed in table 1 (Berlin, Germany). Sequence-verified control donors 
were used in every experiment as internal control. The PCR-reaction and the final melting 
curve were performed in LightCycler capillaries (Roche Diagnostics) with a final volume of 
20 μl, containing 10 ng genomic DNA, 0.5 μM of each primer, 0.15 μM of each hybridization 
probe, 1x LightCycler DNA Master Hybridization Probes (Roche Molecular Biochemicals, 
Mannheim, Germany) and 2 mM MgCl2. Sealed capillaries were centrifuged and placed in 
the rotor of the LightCycler instrument (Roche Diagnostics). The PCR thermocycling profile 
included 10 min at 95°C, followed by 45 cycles of 95°C for 0.1 sec, 60°C for 15 sec and 72°C 
for 20 sec. Next, the melting curve profile was performed, which included 1 cycle of 95°C 
for 2 min, 55°C for 1 min, 45°C for 30 sec, 40°C for 3 min after which the temperature was 
slowly increased (0.1°C/sec) to 85°C under continuous detection of the emitted light. Finally, 
the cooling down was performed at 40°C for 30 sec. Data were analysed using the melting 
curve program. In each experiment we used sequenced DNA from confirmed control donors 
for each genotype.
Statistical analyses
Verification of Hardy-Weinberg equilibrium, genotype and allele frequencies was compared 
using two-sided Chi-square or Fisher’s exact test. An expectation-maximization algorithm 
was used to test for linkage disequilibrium and to compare estimated haplotype distributions. 
SNP associations for clinical outcome were studied by Kaplan-Meier analysis using logrank 
tests. Correction for type I errors was performed by Bonferroni adjustment. P-values < 0.05 
were considered to be statistically significant.
Table 1. used primer sets and hybridazation probes.
Gene Primers (5’ → 3’) Hybridization probes (5’ → 3’)
CD1A CCGCACTCTGGCACCTTTCT (forward)
TTGCTGAAGTTTCCACTGGACC (reverse)
CTCATACCTGGGACAGCAATTCCAGCACC-fluorescein
LC Red705-TCGTTTTCCTGTGCCCCTGG
CD1E TGGGCACCATCCGCTTTC (forward)
CATGCAGGCCCTTTTGTGT (reverse)
TCCATAGTTTTATCCAGATAGTGCAAGCT-fluorescein
LC Red640-CTGCTGGTCAATTTCAGCTTGA
ATGTAAGTTC
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RESuLTS
All SNPs tested were in Hardy-Weinberg equilibrium and in linkage disequilibrium. 
No differences were found between the frequencies of the various alleles, genotypes and 
haplotypes in GBS patients and controls (Table 2). In GBS patients there was no significant 
association between the SNPs and sex, age, symptoms of preceding infection (diarrhea 
or upper-respiratory tract infection), serology (for recent infections with C. jejuni, 
Mycoplasma pneumoniae, CMV and EBV), disease severity at nadir, presence of sensory 
or cranial nerve deficits, mechanical ventilation and serum IgM/IgG antibodies to GM1 or 
GD1a. Clinical outcome of GBS patients, after 6 months of onset and during follow-up, was 
not associated with specific CD1A and CD1E SNPs in Kaplan-Meier analysis.
A subgroup analysis was performed in patients with anti-GM1 antibodies (n=46). 
There was an association with the CG variant of the CD1A genotype and the GG variant of 
the CD1E genotype and good clinical outcome (logrank respectively p=0.04 and p=0.03) but 
after correction for multiple testing this was not significant. No associations were found for 
clinical deficits and disease severity in relation to CD1A and CD1E SNPs within patients 
having antiganglioside antibodies and/or C. jejuni infections.
Table 2. CD1A and CD1E polymorphisms in GBS patients and controls.
SNP GBS patients 
(n=312)
Healthy controls 
(n=212) 
% %
CD1A
G-allele 
C-allele 
CD1E
A-allele 
G-allele
CD1A (genotype)
GG
GC
CC
CD1E (genotype)
AA
AG
GG
CD1 haplotype (CD1E / CD1A)
AC
AG
GC
GG
6.3
93.7
64.6
35.4
0
12.5
87.5
41.2
46.9
11.9
64.5
0
29.2
6.3
6.4
93.6
66.5
33.5
0
12.7
87.3
44.3
44.3
11.3
66.5
0
27.1
6.4
Allele-, genotype and haplotype distributions were compared between GBS patients and healthy controls using two-
sided Pearson chi-square tests. No significant associations were found for SNPs in exon 2 of CD1A and CD1E.
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DISCuSSION
In our study, no difference was found in the frequency of CD1A and CD1E SNPs between 
the group of GBS patients and the group of healthy controls, indicating that these gene
polymorphisms do not influence the general susceptibility to develop GBS. In addition, 
there was no genetic association with clinical outcome, clinical characteristics or serological 
subgroups of GBS, including antecedent C. jejuni infections and anti-ganglioside antibodies.
These results give no support to the hypothesis that CD1A and CD1E influence the risk
of getting GBS as raised in a previous study that was based on results in a much smaller 
cohort of GBS patients (8). It is unlikely that this discrepancy is caused by differences in 
patient populations, since the subgroup analysis in the current study showed no association 
with specific subgroups of patients. Population stratification can not be excluded although 
both groups had a similar ethnic background and showed a similar distribution of CD1 gene 
polymorphism frequencies. Differences may partly be explained by the methods of statistical 
analysis (15,16). In the current study, two-sided tests were used because we were unable 
to predict a priori whether a certain CD1 gene polymorphism was related to an increased 
or decreased susceptibility to develop GBS. Most likely, the sample size of the studies 
has influenced the findings. Studies based on smaller number of patients may have more 
frequent chance associations. Although the current study population was almost five-times
larger, even 524 patients and controls is a relatively small number for candidate gene 
association studies. Confirmation in more extensive studies is required that fulfill the criteria 
put forward by the NCI-NHGRI working group (17). Given the relative rarity of GBS, this 
can only be accomplished by substantial international collaboration. 
CD1 molecules are key players in immune responses to glycolipids and may be involved 
in the pathogenesis of GBS, especially in patients with antecedent C. jejuni infections and 
crossreactive anti-ganglioside antibodies. CD1b binds to GM1 on antigen presenting cells and 
may induce GM1-specific T-cell activation independent from CD1e (5,8). SNPs in the CD1B, 
CD1C and CD1D genes were not determined in the current study since these are either very 
rare and/or silent (6). Sequencing of the nucleotides that encode amino-acids directly involved 
in binding antigens in the CD1 groove may possibly reveal unknown mutations. Recently, a 
naturally occurring mutation in CD1E has been reported that influences antigen presentation 
via CD1b (18). The absence of association with CD1 gene polymorphisms does not exclude 
the possibility that CD1 molecules play an important role in the pathogenesis of GBS. 
Further research is needed to determine whether CD1 molecules or pathways downstream of 
CD1 are involved in the process of antigen presentation of glycolipids in GBS.
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ABSTRACT
In Guillain-Barré syndrome (GBS), ganglioside mimicry of Campylobacter jejuni lipo-
oligosaccharide (LOS) drives the production of cross-reactive antibodies to peripheral 
nerve gangliosides. The mechanism for this aberrant humoral immune response to C. 
jejuni in GBS is unknown. Here we address whether human dendritic cell (DC) activation 
and subsequent B-cell proliferation is modulated by sialic acid residues in GBS associated 
C. jejuni LOS. Highly purified sialylated LOS of C. jejuni isolates from GBS patients induced 
human DC maturation and secretion of inflammatory cytokines that was mediated by TLR4. 
The extent of TLR4 signaling and DC activation was higher with LOS from wild type 
isolates than with non-sialylated LOS of the corresponding sialyltransferase gene knockout 
(cst-II mutant) strains, indicating that sialylation boosts the DC response to 
C. jejuni LOS. Supernatants of LOS-activated DCs induced B-cell proliferation after cross-
linking of surface immunoglobulins in absence of T-cells. Lower B-cell proliferation indices 
were found with DC supernatants after stimulation with cst-II mutant or neuraminidase 
desialylated LOS. In serum from C. jejuni-related GBS patients (n=27), antibody activity 
to sialylated LOS was significantly higher compared to C. jejuni enteritis patients 
without GBS (n=20) or healthy controls (n=30). This study shows that sialylation of 
C. jejuni LOS enhances human DC activation and subsequent B-cell proliferation, which may 
explain the development of cross-reactive anti-ganglioside antibodies found in GBS patients 
following C. jejuni infection. 
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INTRODuCTION
The Guillain-Barré syndrome (GBS) is a post-infectious neuropathy characterized by 
rapidly progressive muscle weakness. In its most severe form, patients have a paralysis 
of all cranial, limb and respiratory muscles for which they need mechanical ventilation 
for months. Various types of infection may precede GBS, but Campylobacter jejuni is the 
predominant cause, especially in patients with extensive weakness (1,2). Patients with 
C. jejuni-related GBS frequently have serum antibodies to human peripheral nerve gangliosides, 
which induce multiple neurotoxic effects after passive transfer to mice (3,4). C. jejuni triggers 
the production of anti-ganglioside antibodies in these patients by molecular mimicry. More 
specifically, some C. jejuni strains express lipo-oligosaccharides (LOS) with similar sialic 
acid (N-acetyl-neuraminic acid) carbohydrate moieties as present in gangliosides (5,6), 
resulting in the production of cross-reactive antibodies (7). Rabbits sensitized with GM1-like 
C. jejuni LOS produce cross-reactive anti-ganglioside antibodies and develop a neuropathy 
and flaccid paresis similar to patients (8). The variation in ganglioside mimicry is controlled 
by the sialyltransferase cst-II gene, which is associated with C. jejuni from GBS patients 
(9, 10). LOS sialylation is therefore a key factor in the development of GBS after C. jejuni 
infection. 
In cases with uncomplicated C. jejuni gastroenteritis not leading to GBS, however, the 
antibody response to LOS is usually very low or even undetectable (6). The mechanism 
responsible for the induction of a high antibody response to LOS in GBS is unknown. We 
hypothesize that the immunogenicity of LOS during C. jejuni infection, which is required to 
induce the high titer cross-reactive antibodies to gangliosides in GBS, also depends on the 
sialylation of the LOS. Sialylated LOS is more frequently found in C. jejuni isolates from 
GBS patients than in isolates from enteritis controls, and sialic acids are known to modulate 
the immune response in other types of infection (6,11). This process may be controlled by 
dendritic cells (DCs), which constitute one of the first lines of mucosal immune defense and 
are pivotal in bridging innate and adaptive immunity (12). In the present study, the maturation 
and cytokine production of human DCs in response to sialylated LOS from three GBS-
related C. jejuni isolates was compared to the DC response to non-sialylated LOS from the 
corresponding cst-II mutant strains. In addition, the proliferation of human tonsillar B-cells in 
response to soluble factors from these activated DCs was determined. Our study shows that 
the sialylation of C. jejuni LOS modulates the DC activation which subsequently contributes 
to stronger proliferation of naïve mucosal B-cells.
RESuLTS
High antibody titers to sialylated C. jejuni LOS in serum from GBS patients
To demonstrate that the production of antibodies to sialylated LOS is related to the development 
of GBS, acute phase serum samples were tested from GBS patients with a preceding C. jejuni 
infection (n=27), enteritis controls with a C. jejuni infection but no GBS (n=20) and healthy 
controls without a recent C. jejuni infection (n=30). The LOS for this serological study was 
purified from the GB11 wild-type (WT) strain, a C. jejuni isolated from a patient with GBS, 
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which is highly sialylated and mimics the gangliosides GM1 and GD1a (Table 1). High titers 
of IgM and IgG antibodies to the LOS from the GB11 WT were found exclusively in the 
serum from patients with GBS (Figure 1A). Based on the extinctions for anti-LOS antibodies 
found in the healthy control group, cut-off values for positivity were defined (Figure 1A). 
In the group of GBS patients, 18 (67%) were positive for anti-LOS IgG and 13 (48%) for anti-
LOS IgM. These results show that only in GBS patients the C. jejuni infections had resulted 
in significant antibody responses to sialylated LOS. 
Next, we determined whether these antibodies in the serum from GBS patients are 
directed to the sialic acid residues in C. jejuni LOS by performing adsorption studies with 
the non-sialylated LOS from the corresponding cst-II knockout mutant strain. Cst-II is a 
sialyltransferase that is essential for the synthesis of α(2-3)- and α(2-8)-linked sialic acids 
to galactose in the outer core of LOS from C. jejuni (10). The GB11 cst-II knockout mutant 
strain expresses a truncated LOS outer core without sialic acids and lacks ganglioside mimicry 
(Table 1) (5,10). IgG antibody activity to GB11 WT LOS in serum from GBS patients was 
inhibited much more efficiently when pre-incubated with LOS from the same strain (median 
96% inhibition), than with LOS from the GB11 cst-II mutant strain (median 37% inhibition) 
(p=0.002) (Figure 1B). These results confirm that the high antibody activity to C. jejuni LOS 
in patients with GBS is caused by an immune response mainly directed to the sialylated 
moieties in LOS. 
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Figure 1. High serum reactivity to C. jejuni LOS in GBS patients due to sialylation of LOS. 
(A) Serum antibody activity to sialylated LOS from GB11 WT, a C. jejuni isolate from a GBS patient, was 
significantly higher in acute phase serum from C. jejuni related GBS patients than in acute phase serum from C. jejuni 
enteritis patients without GBS or healthy controls. (B) Absorption of IgG antibody activity, expressed as percentage 
of inhibition, to LOS from GB11 WT in serum samples from GBS patients by pre-incubation with 100 μg/ml LOS 
was significantly lower with LOS from the GB11 cst-II mutant strain, indicating that the antibodies recognize the 
sialic acids in LOS from GB11 WT. 
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C. jejuni LOS induces DC activation through TLR4
To further explore the human immune response to C. jejuni LOS, DC derived from 
peripheral blood monocytes from healthy blood donors were cultured in the presence of 
heat-inactivated C. jejuni whole bacteria. The three C. jejuni WT strains isolated from GBS 
patients were cultured with DC in multiplicities of infection (MOI) ranging from 1:2 to 
1:100. MOIs of 1:2 already induced upregulation of the DC surface-expressed co-stimulatory 
molecules CD80, CD86, CD40 and HLA-DR, indicating cellular activation (Figure 2A). 
In agreement with these observations, highly purified LOS from these C. jejuni WT strains also 
induced a dose-dependent up-regulation of CD80 on these DCs from a starting concentration 
of 0.1 ng/ml (Figure 2B). Activation of DCs was also reflected by secretion of inflammatory 
cytokines in the supernatant (Figure 3A). After stimulation of DCs with C. jejuni LOS there 
was a dose-dependent increase in supernatant levels of IL-6, IL-8, IL-10, IL12p40 and TNF-α 
(Figure 4B). 
Table 1. Carbohydrate outer core structure of LOS from C. jejuni strains isolated from GBS patients used in 
the current studya.
a Molecular structures were determined by mass spectrometry and previously published (7). 
b GD1c is structurally similar to GD3. Neu5Ac: N-acetylneuraminic acid, Gal: galactose, GalNAc: N-acetyl 
galactosamine, Hep: heptose, WT: wildtype, cst-II: sialyltransferase knockout mutant. 
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.  ohydrate outer core structure of LOS from C. jejuni strains isolated from 
GBS patients used in the current studya.
Strain(s)      LOS structure   Ganglioside mimic 
GB2-, GB11 WT       Gal-GalNAc-Gal-Hep-Hep        GM1 
                                 |              | 
                                        Neu5Ac   Glc 
         Gal-GalNAc-Gal-Hep-Hep        GD1a 
            |                     |             | 
                  Neu5Ac          Neu5Ac  Glc 
GB19 WT             Gal-GalNAc-Gal-Hep-Hep        GD1cb 
                    |                            |       | 
                Neu5Ac                  Glc  Glc 
                    | 
                Neu5Ac 
GB2-, GB11-cst-II mutant           Gal-GalNAc-Gal-Hep-Hep         none 
                                               | 
                                                       Glc 
                 GalNAc-Gal-Hep-Hep            none
                                               | 
                                                       Glc 
                    Gal-Hep-Hep            none 
                                               | 
                                                       Glc 
GB19-cst-II mutant        Gal-GalNAc-Gal-Hep-Hep          none
                                               |       | 
                                             Glc  Glc 
                     
                 
a Molecular structures were determined by mass spectrometry and previously published (7).  
b GD1c is structurally similar to GD3. Neu5Ac: N-acetylneuraminic acid, Gal: galactose, 
GalNAc: N-acetyl galactosamine, Hep: heptose, WT: wildtype, cst-II: sialyltransferase 
knockout mutant.
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DC activation by microbial patterns is mediated through toll-like receptors (TLRs) 
expressed at the cell-surface or intra-cellular (13). Interactions between microbial antigens 
and TLR4 lead to downstream activation of NF-κB that regulates the transcription of pro-
inflammatory cytokines such as TNF-α, IL-8 and IL-12p40 (14). TLR4 is a member of the 
pattern-recognition receptor family (PRR) and binds to endotoxin or lipid A present in LPS 
from gram-negative bacteria. The C. jejuni LOS is devoid of the repetitive oligosaccharides 
present in the O-specific chain of LPS but it does contain the evolutionary conserved lipid A 
structure. Therefore, it is presumed that LOS may also induce DC activation through TLR4. 
To test this, DC were cultured with a neutralizing mouse anti-human TLR4 mAb during LOS 
stimulation. Neutralization of TLR4 inhibited C. jejuni LOS induced secretion of IL-12p40 
by DCs (Figure 3B). In addition, DC activation and secretion of IL-6, IL-8, IL-10, and TNF-α 
were also attenuated by the anti-TLR4 mAb. In sum, human DC activation occurs at low 
concentrations of C. jejuni LOS and is partly mediated through TLR4 leading to induction of 
cytokine secretion.
Figure 2. Human DCs are dose-dependent activated by C. jejuni whole bacteria and C. jejuni LOS.
(A) Immature DCs (105 cells/well) were incubated for 18 h with either heat-inactivated C. jejuni GB11 WT whole 
bacteria at a MOI of 1:10 (top panel) or 100 ng/ml of purified LOS from the same strain (lower panel). Cells were 
stained with mAbs to the co-stimulatory molecules CD86, CD80, CD40 as well as to HLA-DR to determine DC 
activation. Histogram represents unstimulated DCs (void histogram) and DCs stimulated with C. jejuni whole bacteria 
or LOS (filled histogram). Representative results of one of 15 experiments. (B) DCs were stimulated with increasing 
concentrations of LOS from C. jejuni GB19 WT. Upregulation of CD80-FITC indicating DC activation was observed 
at 0.1 ng/ml and increased further at higher concentrations of LOS. Void histogram represents unstimulated cells and 
grey histograms LOS stimulated cells. Representative results of one of 15 experiments.
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C. jejuni LOS carbohydrate moiety modulates DC activation
To assess whether the carbohydrate moiety of C. jejuni LOS influences the DC response, 
LOS from the three WT strains and corresponding cst-II mutant strains were compared for 
their ability to induce DC activation and secretion of cytokines. The expression of surface co-
stimulatory molecules on DCs was higher after incubation with sialylated LOS from the GB11 
WT strain as compared to non-sialylated LOS from the GB11 cst-II mutant strain (Figure 4A). 
A similar higher expression of these markers on DCs was found after stimulation with LOS 
from GB2 and GB19 WT compared to LOS from the GB2 and GB19 mutant strains. In 
addition, the secretion of pro- and anti-inflammatory cytokines was significantly higher when 
DCs were stimulated with LOS from WT strains compared to their cst-II mutant strains 
(Figure 4B). An approximately 10-fold higher concentration of LOS from the GB11 cst-II 
mutant compared to the GB11 WT was needed to obtain similar levels of induced cytokine 
secretion. The cst-II mutants of two other GBS-associated tested C. jejuni isolates showed 
similar results (Figure 4B, last panel). These data indicate that the carbohydrate moiety of 
C. jejuni LOS indeed modulates the human DC activation and cytokine secretion. 
Sialylation of C. jejuni LOS modulates DC response 
The observations presented above showed that the carbohydrate structure of LOS 
modulates the DC response and suggest that the sialylation of LOS mediated this effect. 
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Figure 3. DCs secrete inflammatory cytokines partially through TLR4 upon stimulation with C. jejuni LOS. 
(A) DCs stimulated with 100 ng/ml LOS from C. jejuni GB11 WT or medium as control were harvested after 
overnight incubation. Mean cytokine levels (10 experiments) in DC supernatants ± standard errors. (B) DCs were 
stimulated with LOS from C. jejuni GB11 WT (control) and incubated concomitantly with a neutralizing mouse anti-
humanTLR4 mAb or an isotype control mAb.
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To further determine the modulating effects of sialylation, LOS from the C. jejuni GB19 
WT was incubated with neuraminidase from Arthrobacter ureafaciens, cleaving off the 
α(2-8)-linked- and terminal α(2-3)-linked sialic acid residues. The desialylation of LOS from 
the GB19 WT by this neuraminidase treatment (GB19 WT NA) was confirmed by showing 
that the binding of a mAb to GD3 was lost, while instead the LOS gained reactivity to a 
serum with antibodies to asialo-GM1 (Supplemental figure S1). This LOS was subsequently 
incubated overnight with DCs and compared with LOS from GB19 WT and cst-II mutant 
strains. The DC activation and TNF-α secretion after incubation with LOS from the GB19 
WT NA was lower than after incubation with LOS from the GB19 WT, and just as low as 
after incubation with LOS from the GB19 cst-II mutant (Figure 5A-B). The secreted levels of 
IL-6, IL-8, IL-10 and IL-12p40 were also lower, similar to the levels seen after stimulation 
with LOS from the cst-II mutant. These data demonstrate that the DC activation is enhanced 
by sialylation of the LOS from C. jejuni. 
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Figure 4. Sialylation of C. jejuni LOS increases DC activation and cytokine secretion. 
(A) DCs were stimulated with 1 ng/ml LOS from C. jejuni GB11 WT (filled purple histogram), GB11 cst-II mutant 
strain (dark gray overlay histogram) or not stimulated (light gray overlay histogram). After overnight incubation 
DCs were harvested and surface expression of CD80 and CD86 was determined by flowcytometry. (B) DCs were 
incubated overnight with a concentration range of 0.1 to 100 ng/ml of LOS from GB11 WT (filled data points) 
and GB11 cst-II mutant strains (void data points). Cytokine levels in supernatant were determined by ELISA. 
Filled data points represent GB11. In the last panel, 1 ng/ml of LOS from GB2 WT and GB19 WT (black bars) were 
also compared with their corresponding cst-II mutant strains (void bars). Wilcoxon-signed rank tests were used for 
statistical comparisons, * P<0.05; ** P<0.005.
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Sialylation of C. jejuni modulates DC response 
To assess whether the enhanced cell activation by sialylated LOS was specifically due to 
differences in TLR4 signaling, a TLR4 transfected cell line (HEK293/TLR4) was used that 
secretes IL-8 in response to TLR-4 ligation (14). Non-sialylated LOS from both the GB19 cst-
II mutant and the GB19 WT NA induced significant lower IL-8 levels compared to LOS from 
the GB19 WT (Figure 5C). These data suggest that the sialylation of C. jejuni LOS modulates 
activation of DCs through differences in LOS/TLR4 signaling.
Sialylation of C. jejuni LOS influences proliferation of naïve B-cells through DC-derived 
soluble factors
Supernatants from DCs stimulated with microbial products are known to enhance B-cell 
responses (15). In light of the previous observations, we hypothesized that the DC activation 
by C. jejuni may also affect B-cell responses. A proliferation assay was designed in which 
human tonsillar B-cells were cultured in the presence of DC-derived supernatant. These 
mucosal B-cells were stimulated with low concentrations of goat-anti-human-IgM to cross-
link B-cell receptors (BcRs), mimicking antigen-recognition as a first signal for B-cell 
activation. Stimulation of B-cells with C. jejuni LOS alone up to concentrations of 10 μg/ml 
had no effect, consistent with the absence or low TLR4 expression in human non-activated 
B-cells (16). Next, B-cells were cultured in the presence of supernatant from DCs previously 
stimulated with C. jejuni LOS, which resulted in an enhancement of B-cell proliferation 
(Figure 6A). Because centroblasts previously activated in vivo may proliferate without 
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Figure 5. Neuraminidase treatment of C. jejuni LOS attenuates DC activation. 
LOS from C. jejuni GB19 WT was incubated at 37 ºC for 3 h with 0.8 U/ml of neuraminidase (NA). After inactivation 
of neuraminidase, this desialylated LOS (GB19 WT NA) was incubated overnight with immature DCs or HEK/
TLR4 cells (105 cells/ml). The effects were compared with those observed after incubation with LOS from GB19 WT 
and GB19 WT cst-II mutant strains. TNF-α and IL-10 levels in DC cell media (A and B) and IL-8 levels (pg/ml) in 
HEK/TLR4 cell media (C), as a measure for TLR4 signaling, were determined by ELISA. TNF-α and IL-10 levels 
represent pooled data from 5 separate experiments, error bars represent standard errors. TLR4 signaling are mean 
results from 2 experiments. Ns: not significantly different.
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further exogenous stimulation, flowcytometric sorting of naïve IgD+CD27− and IgD−CD27+ 
centroblasts cells was performed. Comparison of the two subsets derived from CD43− cells 
showed that the naïve B-cell population (CD43−IgD+CD27−) proliferated in the presence of 
DC supernatant (Figure 6A). The extent of B-cell proliferation correlated with the cytokine 
response and activation of DCs by LOS (Figure 6B), and increased dose-dependently with the 
LOS concentrations (Figure 6C). Supernatants from DC cultures stimulated with desialylated 
LOS from GB19 WT NA and GB19 cst-II mutant were less effective in enhancing B-cell 
proliferation (Figure 6C). These results demonstrate that C. jejuni LOS influence mucosal 
B-cells proliferation through DC activation, even without cell-cell interactions between DCs 
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Figure 6. B-cell proliferation is modulated by LOS sialylation, DC-derived solubles and correlates with 
cytokine levels.
(A) Human tonsils were depleted of CD43+ cells by magnetic labeling. The cells were further sorted by flowcytometry 
into IgD+CD27− and IgD−CD27+ fractions. B-cells (4*106 cells/ml) were cultured on plates coated with polyclonal 
anti-IgM in the presence or absence of 1:1 supernatant from DCs. Supernatant used to stimulate B-cells was used 
from various experiments in which DCs were either unstimulated or stimulated with C. jejuni LOS in different 
concentrations. After 48 h co-culture, proliferation was determined by (3H)-thymidine incorporation. (B) DCs were 
stimulated with LOS from different C. jejuni strains (GB2, GB11, GB19 WT and cst-II mutants) at concentrations 
ranging from 0.1 to 100 ng/ml. DC supernatant was used to stimulate B-cells. B-cell proliferation was assessed 
by 3H-thymdine incorporation. Linear regression lines with 95% confidence intervals (dotted) are shown. 
Spearmann correlations were significant at p<0.0001 for TNF-α and IL-6 and at p=0.002 for IL-12p40. Results are 
from one out of three representative experiments. (C) DCs were stimulated with sialylated LOS from GB19 WT 
or with non-sialylated LOS from GB19 cst-II mutant strains or from GB19 WT treated with neuraminidase (GB19 
WT NA). A range of LOS concentrations was used to demonstrate a dose dependent effect. Supernatant from DCs 
stimulated with GB19 WT LOS induced higher B-cell proliferation compared to GB19 cst-II mutant strain and GB19 
WT NA LOS. Representative results from one of two experiments. 
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and B-cells. Sialylated LOS from C. jejuni enhances this proliferation of B-cells through 
activation of DCs. 
Contributing factors for DC-induced B-cell proliferation 
In order to determine which DC-derived soluble factor(s) enhances B-cell proliferation, 
inhibition studies were performed for candidate molecules. Heating the supernatant up to 80 °C 
abrogated its stimulatory effect. This confirmed our previous observation that the thermo 
stable LOS does not interact directly with B-cells. The observed thermo-instability suggests 
that temperature sensitive molecules such as proteins may be involved. In addition, freeze 
thawing had mild attenuating effects. Next, the role of candidate cytokines known to influence 
B-cells was investigated. Supplementing culture media with neutralizing antibodies to IL-6 
and IL-12 did not inhibit or abrogate the effect (Supplemental figure S2). These results imply 
that the enhanced B-cell proliferation orchestrated by C. jejuni stimulated DCs is likely 
induced by heat instable factors and do not seem to be the result of common B-cell stimuli, 
such as IL-6 and IL-12 (15,17). 
DISCuSSION
The current study demonstrates that the sialylation of C. jejuni LOS enhances human DC 
activation via TLR4 signaling and that supernatants from activated DCs induce proliferation 
of mucosal B-cells. C. jejuni strains isolated from GBS patients more frequently express 
sialylated LOS than C. jejuni strains from patients with uncomplicated gastro-enteritis (6). 
The sialylated outer core of C. jejuni LOS determines the specificity of the cross-reactive 
antibodies to gangliosides and thereby the site of nerve damage and clinical phenotype in 
GBS. The current study shows complementary that sialic acids in C. jejuni LOS boost DC 
activation and stimulate the subsequent B-cell response. This enhancement may explain the 
high antibody activity to sialylated LOS in serum from patients who develop GBS after a 
C. jejuni infection. Breaking of the natural tolerance to host gangliosides may result in a 
cross-reactive antibody response to peripheral nerves and subsequent neuropathy.  
C. jejuni infections are usually resolved before an adaptive immune response is mounted 
(18), indicating a key role of the innate immune response in clearing the infection. C. jejuni 
strains expressing sialylated LOS have been found to invade intestinal epithelial cells 
significantly better as compared to strains with non-sialylated LOS (19). DCs reside directly 
under the epithelial cell layer are therefore well positioned to interact with both invasive but 
also with non-invasive pathogens (20). Previous studies showed that C. jejuni are readily 
internalized by DCs and induce cell maturation and cytokine production (21). In agreement 
with these findings in DCs, the current study demonstrates that LOS from GBS-related 
C. jejuni strains induced an up-regulation of co-stimulatory cell surface markers, including 
CD40, CD80, CD86 and HLA-DR, and secretion of inflammatory cytokines, including IL-1β, 
IL-6, IL-8, IL-10, IL-12p40, and TNF-α. Interestingly, high levels of these cytokines are also 
found in serum from patients in the acute stage of GBS (22,23). 
For most bacteria, surface sialic acids provide protection from host innate defenses by 
mimicry of host glycoconjugates found on cell surfaces and in mucus. In Neisseria meningitidis, 
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sialylation of LOS results in a reduced phagocytosis by DCs without influencing cytokine 
secretion (24). In contrast, sialylation of N. meningitidis LOS resulted in enhanced siglec-
dependent macrophage-mediated phagocytosis (25). In addition, Haemophilus influenzae 
mutant strains expressing non-sialylated LOS induce an attenuated response in an in vivo 
model of otitis media in chinchillas (11). Sialic acids, therefore, do not always function as 
anti-recognition molecules and may in fact also sterically impede microbial-host interactions 
(26). The present study clearly shows that removal of sialic acids in LOS of C. jejuni by 
neuraminidase treatment or site-directed mutagenesis of the sialyltransferase cst-II results in 
attenuated DC activation and subsequent B-cell proliferation. This could explain the usually 
low antibody response to non-sialylated LOS after uncomplicated C. jejuni gastro-enteritis. 
TLR4 engages LOS via lipid A, which leads to secretion of several inflammatory 
cytokines through activation of NF-κB transcription (14). Previous studies demonstrated NF-
κB transcription in human DCs upon stimulation with C. jejuni LOS (21). Accordingly, the 
observed secretion of IL-12p40 and other cytokines induced by GBS-associated C. jejuni 
LOS in the current study was reduced when binding to TLR4 was prevented. HEK/TLR4 
cells stimulated with C. jejuni LOS secreted high levels of IL-8, further indicating that cellular 
activation is mediated by direct interaction of C. jejuni LOS with TLR4. Interestingly, IL-8 
production by HEK/TLR4 cells was significantly reduced after stimulation with non-sialylated 
LOS from GB19 WT after neuraminidase treatment or the corresponding cst-II mutant strain. 
This finding suggests that sialic acids in C. jejuni LOS enhance the TLR4 signaling. Besides, 
gangliosides alter the expression of TLR4 in microglia and astrocytes and transcription of 
inflammatory cytokines after exposure to gangliosides (27). Sialic acids in glycoconjugates 
may directly interact with TLR4 or other adjacent receptors forming functional units or 
influence the conformation of LOS in such way that lipid A more efficiently binds to TLR4. 
Human DCs also express sialic acid binding Ig-like lectins (siglecs) that bind to C. jejuni 
(28), which may play a critical role in the efficiency of TLR4 signaling after stimulation with 
C. jejuni with sialylated LOS.
Activation of B-cells is required to produce a cross-reactive antibody response to 
gangliosides and is an essential step in the pathogenesis of C. jejuni -related GBS. The relatively 
low affinity of the anti-ganglioside antibodies and the absence of sustained serum titers in GBS 
(3), may be compatible with a T-cell independent immune response. Recently, a mechanism 
was described in which activated DCs provide direct B-cell help in absence of T-cells (15, 
17,29-31). Our observation that C. jejuni LOS-activated DCs induce proliferation of human 
tonsillary B-cells via soluble factors, in which sialylation of LOS further enhances this effect, 
suggests a comparable mechanism for the antibody response to infections with C. jejuni. 
Co-incubation with blocking monoclonal antibodies to IL-6 or IL-12, or a combination of 
both, did not inhibit this B-cell proliferation. In a previous study in which DCs were stimulated 
with E. coli LPS, neutralizing monoclonal antibodies to IL-6 and IL-12 abolished a similar 
effect on B-cells (15). However, in this study T-cell help was also added to DC supernatant. 
DCs can directly induce T-cell independent proliferation and class-switching in B-cells via 
expression of B-cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) and 
skew adaptive immune responses by TLR-dependent mechanisms (30,31). Further studies are 
required to demonstrate which soluble factors are responsible for the proliferation of B-cells 
by supernatants from C. jejuni -activated DCs and whether B-cells show gene rearrangements 
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and maturate into antibody producing plasma cells in this particular context. 
In conclusion, our study shows that sialylation of LOS in C. jejuni is a key determinant 
in the extent of human DC activation and subsequent B-cell proliferation. This feature of 
C. jejuni LOS may explain the high titers of serum antibodies to LOS found in patients with 
GBS that cross-react with peripheral nerve gangliosides. 
MATERIALS AND METHODS
Patients and controls
Pre-treatment, acute phase serum samples were obtained from 27 GBS patients who 
participated in a previous clinical trial (32). All these patients fulfilled the diagnostic criteria 
for GBS (33) and had preceding diarrhoea and a positive serological for a recent C. jejuni 
infection (34). As controls, acute phase serum samples from 20 patients with culture proven 
C. jejuni gastro-enteritis without GBS were used, as well as serum samples from 30 healthy 
blood donors. All experiments were performed according to the guidelines of the medical 
ethical committee of the Erasmus MC and all patients had signed informed consent. 
Cell cultures
Peripheral blood mononuclear cells (PBMC) from healthy volunteers were isolated by density 
gradient (Lymphoprep) centrifugation. Monocytes were isolated by positive selection using 
CD14-microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. To obtain 
monocyte-derived DCs, monocytes were cultured in 6-well plates for 6 days in the presence 
of GM-CSF (800 U/ml, Novartis) and IL-4 (400 U/ml, R&D systems). Immature monocyte-
derived DCs were washed, seeded at 1 x 106 cells/ml in 96-wells plates and stimulated with 
either heat-inactivated C. jejuni whole bacteria or purified C. jejuni LOS fractions for 18 h. 
Neutralizing mAb to TLR4 (clone HTA125) and isotype control mIgG2a (both used at 
25 µg/ml) were purchased from eBioscience. Human tonsils were obtained from children that 
underwent routine tonsillectomy at the local Sophia Children’s Hospital. Tonsils were crushed 
in a 100 µm nylon mesh and washed extensively in PBS. After isolation of mononuclear cells 
by density gradient (Lymphoprep), B-cells were isolated by depletion of CD43+ cells with 
CD43-microbeads (Miltenyi Biotec). This procedure yielded a population with typically 15% 
(± 9%) CD5+ cells and < 2% contaminating CD3+ cells (denoted as naïve B-cells). FACS-
sorting using a FACSAria cell sorter was performed to further separate this cell population 
into IgD+CD27− and IgD−CD27+ fractions. B-cells isolated from tonsils were cultured in 
triplicate in a 96-well plate supplemented with or without DC supernatant (1:1) in culture 
medium and Goat anti-Human IgM (Jackson Immunoresearch Laboratories). After 48 h cells 
were supplemented with 0.5 μCi 3H-thymidine per well and harvested with an automated 
harvester after another 18 h. 3H-thymidine incorporation in the newly synthesized DNA from 
proliferating B-cells was measured in a Beta-counter (Wallac MicroBeta®). 
Bacteria and LOS purification
Three C. jejuni strains were isolated from different GBS patients (GB2, GB11 and GB19). 
The carbohydrate structure of the C. jejuni LOS core antigen has been designed previously 
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by mass spectrometry (Table 1) (5, 10). Mutagenesis of the cst-II target gene in GB2, GB11 
and GB19 has been described before (5, 9, 19). The corresponding cst-II mutants express a 
truncated LOS outer core due to the absence of sialic acids and lack ganglioside mimicry 
(Table 1) (5, 10). LOS was purified by an extended protocol described from the original hot-
phenol method (35) as described in the S3 Materials and Methods. It was excluded that non-
specific differences in LOS were compared since similar purity yields in a commercial silver 
staining (Invitrogen) and mass spectrometry of all tested batches were observed (Supplemental 
figures S4 and S5). 
FACS analysis
FACS-analysis was performed on a Becton Dickinson FACscalibur. The following mAbs 
were used: CD86-PE, CD80-FITC, CD40-FITC, HLA-DR-PE, CD11c-Cy5, CD5-FITC, 
CD19-APC, IgD-PE, CD3-FITC, CD27-APC and CD43-PE. All monoclonal antibodies were 
purchased from BD Biosciences-Pharmingen. 
HEK293/TLR4 cells
HEK293/TLR4 cells were grown in T75 flasks and harvested upon confluence, generally after 
6 days of culture. Cells (105 cells/ml) were then plated into 96-well plates at 100 μl/well and 
stimulated with LOS or control medium for 24 h.
Cytokine detection by ELISA 
Cytokines present in DC supernatants, including IL-6, IL-8, IL-10, IL12p40 and TNF-α, was 
determined by a capture ELISA according to the manufacturers’ guidelines (Biosource). 
LOS and ganglioside ELISA
The LOS ELISA was performed as described previously (36). For determining the adsorption 
of IgG anti-LOS activity, LOS was incubated with serum (diluted 1:100) for 3 hours at 4ºC. 
The supernatants were centrifuged and tested for residual anti-LOS activity. Percentage of 
inhibition was defined as: 
OD (serum without LOS) – OD (serum with LOS)  x 100%.
    OD (serum without LOS)
The anti-ganglioside ELISA was performed as previously described (7). 
Statistics
Significant differences in DC activation, cytokine production and B-cell proliferation were 
evaluated by non-parametric Wilcoxon-signed rank tests or Mann-Whitney U tests (GraphPad 
Prism 5 software). A p-value of <0.05 was considered to be significant.
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1
Figure S1. Effective enzymatic desialylation of LOS from C. jejuni GB19 wT. 
LOS from GB19 WT shares with gangliosides GD1c and GD3 a terminal disialyl group (α(2-3)- and α(2-8)-linked 
Neu5Ac. LOS was incubated at 37ºC for 3 h with or without 0.8 U/ml of neuraminidase in sodium-acetate solution 
(pH 5.5). This enzymatic treatment resulted in effective desialylation of LOS, as indicated by loss of binding of an 
anti-GD3 mAb (TBG-3) and appearance of binding with serum from a patient with high titer anti-GA1 reactivity. 
Detection of serum reactivity to gangliosides was performed as described in the Materials and Methods section.
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Figure S3. Neutralization of IL-6 and IL-12 does not affect the enhanced B-cell proliferation. 
DCs were stimulated with various concentrations of LOS from GB11 WT, ranging from 0.1 to 100 ng/ml, after which 
supernatants were used to stimulate human CD43-depleted tonsillar B-cells. Neutralizing mouse mAb to human 
IL-6 (R&D systems, clone 6708, used at 5µg/ml), or to IL-12 (R&D systems clone 24910, used at 20 µg/ml), or 
a combination of both were added to the DC supernatants before incubation with the B-cells. The resulting B-cell 
proliferation, indicated by (3H)-thymidine incorporation, did not differ from the situation when DC supernatant and 
an isotype IgG1 control mouse mAb (R&D systems clone 11711, used at 25 µg/ml) or when DC supernatant only was 
added to the B-cells. These results show that neutralization of IL-6 and IL-12 in the DC supernatant did not influence 
B-cell proliferation. 
                    




	
	






	
	
	
	


 



 

127
Sialylation of C. jejuni modulates DC response 
S3 Supplemental Material and Methods
Before LOS purification, 100 blood agar plates were inoculated with one of the six strains and cells were harvested 
in the log-phase. Next, bacteria were lyophilized and extracted three times with 90% hot-phenol (65ºC). The water 
phases were collected and combined. After dialysis with 3.5 kDa membranes, water phases were lyophilized again. 
LOS yield was determined and the material was treated at 37ºC with DNase (200 μg/ml, Sigma-Aldrich) and RNase 
(50 μg/ml, Sigma-Aldrich) subsequently followed by proteïnase K (1mg/ml, Sigma-Aldrich) treatment at 65ºC. 
After dialysis and lyophilisation, LOS yield was measured using a high precision balance.
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1
Supplemental figure 4 
Purification of LOS from C. jejuni strains used in the study yields similar clean products. 
LOS from C. jejuni isolates of GBS patients and corresponding cst-II mutant strains was purified by 
hot-phenol extraction and subsequent RNase and DNase treatments. No impurities were detected in a 
sensitive silver staining of SDS-PAGE gels loaded with large amounts of each LOS fraction (4 g). 
LOS from the cst-II mutant strains is truncated and has a different degree of ionization and net charge 
and migrates faster in the gel than LOS from the WT strains. 
Figure S4. Purification of LOS from C. jejuni strains used in the study yields similar clean products.
LOS from C. jejuni isolates of GBS patients and corresponding cst-II mutant strains was purified by hot-phenol 
extraction and subsequent RNase and DNase treatme ts. No impurities wer  detected in a sensitive silver staining 
of SDS-PAGE gels loaded with large amounts of each LOS fraction (4 μg). LOS from the cst-II mutant strains is 
truncated and has a different degree of ionization and net charge and migrates faster in the gel than LOS from the 
WT strains. 
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Figure S5.
LOS from(A)  WT and cst-II do not contain significant amounts of contaminating peptides. Fourier Transform Mass 
spectrometry was performed in negative charge ionization mode. Peptide specific masses were not observed. 
Results in lower mass range (500 – 1000 Da) are visualized.
Results in higher mass range (1000 – 2500 Da).(B) 
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SuMMARy
Serum antibodies to the ganglioside GQ1b are associated with immune-mediated 
ophthalmoplegia and ataxia in patients with Miller Fisher syndrome (MFS) and Guillain-
Barré syndrome. A patient with two clinically similar episodes of progressive bulbar signs, 
ophthalmoplegia and ataxia is reported here. During both episodes the patient required artificial 
ventilation. Serum anti-GQ1b antibodies were detected during the first episode compatible with 
MFS, but were absent during the second. Neuroradiological investigations during the second 
episode showed brain stem ischaemia and obstruction of the left posterior inferior cerebral 
artery. These findings illustrate that anti-GQ1b serology is a reliable and robust method that 
helped to distinguish between different causes of relapsing dysarthria and ataxia. 
BACKGROuND
The clinical triad of ophthalmoplegia, ataxia and areflexia with a monophasic disease course 
is the classical description of Miller-Fisher syndrome (MFS) (1). However, patients with MFS 
often show only part of the triad, occasionally have other cranial nerve palsies or progress into 
the closely-related Guillain-Barré syndrome (GBS) if significant weakness of neck, shoulder 
and arm musculature is observed (1,2). In addition, relapses in MFS and GBS occur in up to 
2% to 5% of patients, introducing a further diagnostic problem (3,4). When patients present 
with additional symptoms such as diplegia facialis, bulbar dysarthria or limb weakness, other 
causes should be considered in the diagnostic work-up. The presence of serum IgG and 
IgM antibodies to the ganglioside GQ1b may help to confirm or reject the diagnosis MFS, 
particularly when a patient with MFS has a recurrence of symptoms. We report a patient with 
relapsing dysarthria and ataxia in whom determination of serum anti-GQ1b antibodies helped 
to make the correct diagnosis. During the first episode the patient had MFS, but during the 
second episode the symptoms were caused by brain stem infarction. 
CASE PRESENTATION
A vital 80-year-old man with a history of claudicatio intermittens developed double vision 
and unsteadiness of gait 1 week after a mild upper respiratory tract infection. Within 2 days he 
noticed difficulties with speech and swallowing. Neurological examination revealed a bilateral 
external ophthalmoparesis with normal light reactions, diplegia facialis and bulbar dysarthria 
with paresis of the pharyngeal muscles. Additionally, he had a symmetrical mild weakness 
of deltoid and biceps muscles, sensory ataxia, almost absent vibration sense and areflexia 
with normal plantar reflexes. The patient was unable to stand or walk unaided. The clinical 
symptoms were compatible with a diagnosis of MFS. 
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INVESTIGATIONS
This diagnosis was supported by the presence of an elevated cerebral spinal fluid protein 
content (0.77 g/litre, normal reference <0.58 g/litre) without pleiocytosis and a high serum 
antibody reactivity to GQ1b (IgG titre 3200 and IgM titre 1600). Cerebral CT scanning 
showed a small silent brain infarct in the left corona radiata. 
TREATMENT
Immediately after admission the patient deteriorated and developed a paralysis of pharyngeal 
muscles followed by respiratory failure, for which he required mechanical ventilation. He was 
treated with a standard dose of intravenous immunoglobulins (0.4 g/kg/day for 5 days) after 
which he gradually improved. 
OuTCOME AND FOLLOw-uP
At 4 weeks after admission the patient had a residual ataxia but was able to walk independently. 
The oculomotor movements also improved, leaving a mild bilateral ophthalmoparesis. 
The patient was discharged to a rehabilitation centre. 
At 5 months later the patient developed a second episode with symptoms that were largely 
similar to the first episode. The patient again complained of progressive speech disturbances, 
double vision and unsteadiness of gait. This time the patient also complained of vertigo and 
nausea. The onset of this episode was possibly acute, although the symptoms fluctuated in 
severity and progressed within several hours. Neurological examination revealed normal 
consciousness and a residual external ophthalmoplegia with progression of impaired abduction 
on the right side without nystagmus. There was slight peripheral facial nerve palsy on the right. 
Bulbar dysarthria had worsened compared with the neurological examination at discharge. 
Visual fields were normal. The patient was unable to walk and showed respiratory distress. 
Tendon reflexes were absent and plantar reflexes were normal. Based on these findings, basilar 
artery thrombosis and recurrent MFS were considered as differential diagnoses. Cerebral CT 
scanning showed no new abnormalities compared to the CT scan of the previous episode. 
CT angiography showed occlusion of the intradural segment of the left vertebral artery 
(V4), compatible with acute thrombosis, and a normal basilar artery. Cerebral MRI showed 
a hypointensive area on T1 and a hyperintensive area on T2 in the left medulla oblongata, 
compatible with recent ischaemia due to occlusion of the left posterior inferior cerebellar 
artery (Figure 1). Moreover, anti-GQ1b serology was negative this time (Figure 2). 
The patient rapidly developed respiratory failure again and required mechanical ventilation. 
He received a tracheostomy and was able to breathe independently after 3 weeks. He was 
discharged to a rehabilitation centre after 7 weeks, where he suddenly died of an unknown 
cause 2 months later. 
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Figure 1. MRI scan of patient during second episode. 
T2-weighted axial MRI shows a hypodense area in left brain stem corresponding to the drainage area of the posterior 
cerebellar inferior artery (A). The ischaemic lesion is also visible in a diffusion weight MRI scan (B).
Figure 2. IgG serum reactivity to GQ1b in time during the first and second episode. 
Serial measurements of serum reactivity to GQ1b in blood samples obtained during the first and second clinical 
episode.
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DISCuSSION
This patient had two episodes within 6 months with almost similar clinical symptoms, but 
with different causes. The first episode was attributed to a MFS and the second to a brain stem 
infarction caused by occlusion of the left posterior inferior cerebellar artery. To our knowledge 
a relationship between MFS and brain stem infarction has not been described in the literature 
before. Moreover, in this patient the difference in pathogenesis was reflected by the high titres 
of serum anti-GQ1b antibodies in the first episode that were absent during the second. 
Anti-GQ1b antibodies are specific for MFS and related syndromes such as GBS with 
ophthalmoplegia, CANOMAD (chronic acquired neuropathy associated with M protein, cold 
agglutinins and disialyl-ganglioside antibodies) and Bickerstaff encephalitis (5). Based on a 
series of patients from Japan, the sensitivity is higher than 95% for MFS and between 60 and 
70% for Bickerstaff encephalitis (6,7). CANOMAD is defined by the presence of serum IgM 
antibodies to gangliosides with disialylated moieties, including GQ1b (5). The specificity of 
anti-GQ1b antibodies for these syndromes is also high (generally more than 90%). The GQ1b-
related syndromes have in common that they are characterised by ophthalmoplegia and ataxia. 
This may suggest that in these patients anti-GQ1b antibodies interfere with normal function of 
the neurological circuits responsible for eye movement and coordination. High concentrations 
of GQ1b have been demonstrated in the extramedullar portion of the oculomotor nerve and 
positive immunostaining with monoclonal antibodies to GQ1b was found in large neurons of 
the dorsal root ganglia (6,8,9). In MFS, the antibodies are induced by preceding infections, 
including Campylobacter jejuni and Haemophilus influenza, which contain ganglioside-
like moieties in lipo-oligosaccharides that induce a crossreactive antibody response (5,10). 
The precise cellular mechanism involved in this aberrant mucosal immune response and 
the breakdown of tolerance to self-antigens, however, is not well understood. In a mouse 
model, anti-GQ1b antibodies induced complement dependent disruption of presynaptic motor 
nerve terminals at the neuromuscular junction (11). These studies provide strong evidence 
that anti-GQ1b antibodies are pathogenic and are related to specific neurological deficits. 
Determination of serum anti-GQ1b antibodies in these patients may have important additional 
diagnostic value. 
In general, serum IgG titres to ganglioside antibodies in GBS disappear after weeks to 
months as was also found in this patient. This unusual titre course may be a reflection of the 
aberrant immune response to infections in MFS. In this report, a standardised technique to 
determine anti-ganglioside antibodies was used. The interassay and intra-assay variation for 
this method has been validated and appears to be relatively robust for glycolipid assays (12,13). 
Anti-GQ1b serology is a reliable technique that can be used to perform serial measurements 
in patients with relapsing symptoms caused by different pathophysiological mechanisms. 
This may have diagnostic value in patients with relapsing symptoms caused by (postinfectious) 
immune-mediated polyneuropathies. 
MFS is usually a monophasic illness but in rare instances recurrences may occur, even 
after long asymptomatic intervals (3). In the patient reported here, the symptoms of the second 
episode resembled the first. However, during the second episode there was possibly a more 
acute onset of symptoms and a fluctuating and progressive course. In addition, the patient also 
complained of vertigo, which is unusual in MFS. The time course and the vertigo is typical 
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of basilar artery occlusion (14). In patients with MFS and relapsing symptoms characteristic 
for MFS with negative anti-GQ1b serology, different causes than a MFS relapse should be 
considered.
LEARNING POINTS
• GQ1b serology is a reliable test to distinguish Miller Fisher syndrome from other  
 causes of acute ophthalmoplegia and dysarthria.
• The classical triad of symptoms in Miller Fisher syndrome is often incomplete or  
 complemented with other signs.
• Brain stem infarctions should enter the differential diagnosis in recurrent Miller 
 Fisher syndrome.
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ABSTRACT
The Inflammatory Neuropathy and Treatment (INCAT) group developed a standardized ELISA 
method for the detection of serum anti-GM1 antibodies. The diagnostic value of anti-GM1 
antibodies determined by this method has not yet been established in large groups of patients. 
We assessed the reproducibility, sources of variation, optimal cut-off values and evaluated the 
diagnostic relevance of the INCAT-ELISA in various groups of patients and controls (N=1232). 
The coefficient of variance was 11.2% for IgM and 3.8% for IgG. High IgG titers were only 
found in Guillain-Barré syndrome (GBS) and other inflammatory polyneuropathies. High 
IgM titers were associated with GBS and multifocal motor neuropathy. Low IgM titers had 
no additional diagnostic value. The INCAT-ELISA is a reliable test with additional diagnostic 
value in specific clinical situations. 
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INTRODuCTION
Determining antibodies to the ganglioside GM1 as a diagnostic marker for immune mediated 
neuropathies remains controversial because they have been reported in a wide spectrum of 
neurological diseases, autoimmune disorders and in healthy controls. The frequency of anti-
GM1 antibodies in these groups of patients and controls also varies considerably between 
reports. These variations could largely be explained by differences in techniques used to 
detect anti-GM1 antibodies (1).
To facilitate the comparison of results from different laboratories a standardized enzyme-
linked immunosorbent assay (ELISA) for measuring serum anti-GM1 antibodies was proposed 
by the Inflammatory Neuropathy and Treatment (INCAT) group (2). The INCAT initiative 
consists of a group of European neurological centers with the aim to develop standardized 
laboratory and clinical protocols to optimize research, diagnosis and treatment of inflammatory 
neuropathies. In a previous study of the INCAT-ELISA protocol, the variation between six 
laboratories was determined. This study showed that 41% of this variation was generated by 
the intra-laboratory variation (2). The sources of variation and the frequency of anti-GM1 
antibodies in large groups of patients and controls using this standardized INCAT method 
have not yet been established. 
In this study, as an intra-laboratory quality control, the reproducibility and sources of 
variation of the INCAT-ELISA were established. In addition, the frequency of anti-GM1 
antibodies in large groups of patients was determined for the first time using this method. 
Based on the INCAT-ELISA, this study also provides the positive and negative predictive 
values for neurological disorders related with anti-GM1 antibodies assessing the diagnostic 
value of these antibodies in clinical practice. 
MATERIALS AND METHODS
Patients
Serum samples were obtained from 1232 patients and controls. These serum samples were 
retrospectively studied for the presence of IgM and IgG anti-GM1 antibodies. The study 
included patients with multifocal motor neuropathy (MMN, N=52), Guillain-Barré syndrome 
(GBS, N=471), chronic inflammatory demyelinating polyneuropathy (CIDP, N=82), 
paraprotein-related polyneuropathy (PP-PNP, N=102), other inflammatory polyneuropathy 
(I-PNP, N=40), non-inflammatory polyneuropathy (N=74), motor neuron disease (MND, 
N=78), multiple sclerosis (MS, N=38), other neurological diseases (OND, N=47), other 
autoimmune diseases associated with autoantibodies (AID, N=138) and healthy controls (HC, 
N=110). 
All GBS serum samples were obtained pre-treatment and within 2 weeks of onset 
of weakness. All MMN serum samples were obtained prior to treatment with intravenous 
immunoglobulins. In the CIDP group the serum samples of 12 patients were obtained in the 
initial phase of disease and prior to any treatment. The GBS patients included in this study 
participated in one of the Dutch Guillain-Barré trials or survey studies and were described 
in detail elsewhere (3-6). Eight GBS patients that did not participate in one of the former 
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studies also fulfilled the diagnostic criteria for GBS (7). In 133 out of 233 GBS patients 
that participated in the Dutch Guillain-Barré trial published by van Koningsveld et al. (6) 
electrodiagnostic examination was performed. Acute motor axonal neuropathy (AMAN) 
syndrome and acute inflammatory demyelinating polyneuropathy (AIDP) were classified 
according to published electrodiagnostic criteria (8). 
The I-PNP group included patients with paraneoplastic polyneuropathy (N=5), 
vasculitic polyneuropathy (N=6), mononeuritis multiplex (N=5), multifocal demyelinating 
polyneuropathy (N=6) and polyneuropathy associated with systemic autoimmune disease 
(N=18). The AID group included patients with myasthenia gravis (N=24), Lambert-Eaton 
myasthenic syndrome (N=3), dermatomyositis (N=1), celiac disease (N=20), systemic lupus 
erythematosus (N=20), Sjögren syndrome (N=30), Wegener granulomatosis (N=20) and 
untreated hyperthyroidism (N=20). 
In the MND group, patients with upper and lower motor neuron involvement (N=26) were 
diagnosed according to El Escorial criteria (9) as amyotrophic lateral sclerosis (ALS) and 
adult patients with lower motor involvement (N=51) were diagnosed as spinal muscle atrophy 
type IV (SMA type IV). One patient in this group had a mild paresis that could be attributed 
to post-poliomyelitis.
Serum samples from most of the patients were obtained from the out-patient clinic of the 
Erasmus MC, Rotterdam, The Netherlands. The local Sanquin Bloodbank South West Region, 
The Netherlands, provided the serum samples obtained from healthy controls. All samples 
were stored at -20°C or -80°C before being tested. 
Enzyme-Linked Immunosorbent Assay (ELISA)
Serum IgM and IgG anti-GM1 ganglioside antibodies were determined, without knowledge 
of diagnosis, by ELISA according to the method previously described (10) and standardized 
by the INCAT group (2). To determine anti-GM1 reactivity we used the mean difference of 
optical densities (d-OD) of two GM1 coated wells and two uncoated wells. To evaluate cut-
off values for positive IgM and IgG anti-GM1 reactivity a receiver-operating characteristic 
(ROC) curve was made. The ROC-curves were based on the available d-OD results of MMN 
patients for IgM and the available d-OD results of GBS patients for IgG because these patient 
subgroups show relative highest and most frequent reactivity for these isotypes in the literature 
and in this study. To determine the ROC-curves the d-OD results of healthy controls was used 
as a control group for both isotypes. Positive serum samples were titrated using two-fold 
serial dilution series starting at 1:100. The reciprocal of the highest dilution that resulted in an 
OD higher than the cut-off value was taken to be the titer. In each experiment a positive and 
negative control sample was included. 
Experiments for analysis of variance factors
Zsample obtained from a GBS patient with high IgM and IgG anti-GM1 reactivity (IgM 
titer 1600, IgG titer 51200). Anti-GM1 reactivity in this serum was confirmed previously 
in thin-layer chromatography (TLC) overlay (10). Two experienced technicians tested 
this positive serum sample on two consecutive days in two plates per day using 12 series 
of two GM1 coated wells and two uncoated wells to determine the d-OD for each isotype. 
To compare the variation of this serum we performed an experiment using 2 plates in which 24 
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GM1 coated wells were incubated for 1 hour with 1 μg/ml of peroxidase-conjugated cholera 
toxin β-subunit (Sigma). In addition, the variation in a serum sample with low anti-GM1 
reactivity and low titer, as well as a serum sample without detectable anti-GM1 reactivity was 
tested. For each serum one plate was used to determine d-OD results (N=24 d-OD results per 
plate).
Statistic analysis
A nested analysis of variance was performed to determine the variances of technicians, days, 
plates and wells within the plates and their relative contribution in the overall intra-laboratory 
assay variance (11). The variation was also expressed as the coefficient of variance (CV) 
defined as the standard deviation (SD) divided by the overall mean. 
Ruling-in and ruling-out gains were defined as the gain of a positive and negative test 
result, respectively, in diagnosing a patient correctly (1). The gain of a test was calculated 
by subtracting the positive predictive value and the negative predictive value by prior 
probabilities. The positive and negative predictive values of the test depend on the prior 
probability. Because the predictive values are related to the sensitivity and specificity these 
values also depend on the test results for specific patient subgroups, including the definition 
of controls. In Figures 4A and 4B the groups of HC, OND, AID and MS (total n=333) were 
used as a control group to determine the sensitivity and specificity.
Statistical analysis was performed using The SAS System for Windows version 8.2 (SAS 
Institute Inc., Cary, USA) and SPSS for Windows release 11.0.1 (SPSS Inc, Chicago, USA).
RESuLTS
Analysis of variance factors in INCAT anti-GM1 ELISA
The results of the experiments to determine the relative contribution of the variation between 
technicians, days, plates and wells within the plates to the overall variation are shown in 
Figure 1. The CV of the overall intra-laboratory assay variance was 11.1% for IgM and 
3.9% for IgG. The largest contributive variance factor for IgM was the variation between 
plates (62% of total variance) and wells within the plates (38% of total variance). For IgG, 
the largest contributive factor was the variation between wells within the plates (77% of 
total variance). There was no additional variance between technicians for IgM and IgG. 
The additional variance between days for IgG was low (15% of total variance) whereas for IgM 
the additional variance was negligible. The variance in days was also analyzed retrospectively 
by comparing the d-OD results of the same positive control serum used in 34 routine diagnostic 
experiments in a period of 4 years. The CV of the retrospective d-OD results was 17.2% for 
IgM and 14.9% for IgG. Two plates were incubated with cholera toxin β-subunit that binds to 
GM1 with high affinity. In these plates the CV’s were 4.5% and 4.0% respectively. 
The variability in test results with the serum with high anti-GM1 reactivity was compared 
with that of a serum without anti-GM1 reactivity and a serum with low anti-GM1 reactivity. 
The variability of a serum without anti-GM1 reactivity (SD IgG: 0.02, IgM: 0.01) was lower 
(Levene test p<0.001) than of a serum with low anti-GM1 reactivity (SD IgG: 0.06, IgM: 
0.05) and a serum with high anti-GM1 reactivity (SD IgG: 0.09, IgM: 0.07). 
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Cut-off values used to determine positive reactivity
To determine the optimal cut-off values for positive anti-GM1 reactivity and to discriminate 
between patients and controls we performed a ROC analysis. We used the d-OD results from 
healthy controls as a negative state variable and for respectively IgM and IgG the d-OD results 
of MMN and GBS patients as a positive state variable (Figure 2). For further analyses we used 
a cut-off value of 0.30 for IgM and 0.20 for IgG. ROC analysis indicated a corresponding 
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Figure 1. Assessment of intra-laboratory variation assay using a single positive serum sample.
Two experienced technicians tested a single positive serum sample positive for IgM and IgG reactivity to GM1 in 
ELISA on two consecutive days using two plates per day with 12 series of 4 wells (2 coated and 2 uncoated wells) 
per plate.
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Figure 2. ROC curves for anti-GM1 reactivity.
ROC-curves for cut-off values of positive anti-GM1 IgM and IgG reactivity, based on the delta of optical densities 
(d-OD). The d-OD´s obtained from MMN and GBS patients were used respectively for IgM and IgG. For both 
isotypes healthy controls were included as a negative state variable.
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specificity of 100% for IgM and a specificity of 100% for IgG with sensitivities of 45% and 
13% respectively. The area under the curve for IgM was 0.89 and for IgG 0.55.
Anti-GM1 antibodies in patient subgroups
A total of 1232 patient serum samples were tested for the presence of IgM and IgG anti-GM1 
antibodies. Of these, 155 (12.6%) were either positive for IgM and / or IgG, 119 (9.7%) for 
IgM only and 69 (5.6%) for IgG only (Table 1). The positive samples were further titrated 
(Figure 3).
IgM anti-GM1 reactivity was demonstrated in nearly all subgroups except for MS and HC. 
IgM titers higher than 200 were observed in patients with MMN (14%), GBS (5%), CIDP 
(1%), PP-PNP (1%), MND (3%) and OND (<1%). The four PP-PNP patients with positive 
IgM anti-GM1 reactivity had paraproteins of different isotypes and light chains. One patient 
had a monoclonal IgM-κ paraprotein, another patient had a monoclonal IgM-λ paraprotein, a 
third patient had both a biclonal IgM-κ paraprotein and a monoclonal IgG-κ paraprotein and a 
fourth patient both a monoclonal IgM-λ paraprotein and a biclonal IgG-λ paraprotein. The IgM 
anti-GM1 positive patients categorized as MND included 2 patients with ALS, 5 patients with 
SMA type IV and one patient with a mild paresis attributed to post-poliomyelitis. The OND 
patient with higher IgM reactivity (titer 400) presented with an oculomotor cranial nerve palsy 
without anti-GQ1b antibodies. IgG anti-GM1 reactivity was highly specific for GBS patients 
(13%). Other patients with positive IgG reactivity included five patients with CIDP (6%), one 
patient with a chronic inflammatory sensory-motor polyneuropathy of unknown cause (1%, 
titer 100), one patient with a slowly progressive distal sensory-motor axonal polyneuropathy 
(1%, titer 100) and a patient with a chronic pure motor neuropathy of unknown cause (1%, 
titer 100). Two IgG positive CIDP patients had an atypical clinical presentation. One of these 
patients had additional symptoms of ataxia; the other had additional proximal demyelination 
and cranial nerve involvement. 
Anti-GM1 reactivity in GBS patients was associated with both diarrhea previous to onset of 
illness (p<0.001) and positive serology for a recent Campylobacter jejuni infection (p<0.001). 
Anti-GM1 antibodies were identified in 3 of 4 (75%) patients with AMAN, 9 of 40 (23%) with 
AIDP and in 17 of 89 (19%) patients who did not fulfill the criteria for AMAN or AIDP. 
Table 1. Frequency of anti-GM1 antibodies in various patient subgroups.
Diagnosis MMN GBS CIDP PP-PNP I-PNP NI-PNP MND MS OND AID HC Total
N 52 471 82 102 40 74 78 38 47 138 110 1232
IgM positive
N 23 64 6 4 5 3 8 0 4 2 0 119
% 44 14 7 4 13 4 10 0 9 1 0 9.7
IgG positive
N 0 61 5 0 1 2 0 0 0 0 0 69
% 0 13 6 0 3 3 0 0 0 0 0 5.6
See figure 3 for used abbreviations. The total number and percentages of positive IgM and IgG anti-GM1 reactive 
sera as well as the total number of tested sera are listed.
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Figure 3. Titers of antibodies in anti-GM1 reactive sera.
(A) IgM anti-GMI antibody titers. (B) IgG anti-GMI antibody titers. Abbreviations used: MMN = multifocal 
motorneuropathy, GBS = Guillain-Barré syndrome, CIDP = chronic demyelinating polyneuropathy, PP-PNP = 
paraprotein-related polyneuropathy, I-PNP = other inflammatory polyneuropathy, NI-PNP = non-inflammatory 
polyneuropathy, MND = motor neuron disease, MS = multiple sclerosis, OND = other neurological disease, AID = 
other autoimmune disease, HC = healthy controls. Only sera with anti-GM1 reactivity are shown in this figure, see 
table 1 for total number of tested sera.
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Predictive value of anti-GM1 antibodies
The sensitivity and the specificity of the assays were calculated based on the frequencies 
of anti-GM1 reactivity in the various patient subgroups and controls. These were used to 
determine the gain of the test shown in Figure 4. 
The gain of a positive test to diagnose a patient correctly based on the test result was 
highest for MMN when the prior probability was between 10% and 40% (Figure 4A, ruling-
in gain). For example, when the prior probability is 20% and a positive test result is obtained 
(gain of test 65%) the chance for a patient having MMN will change to 85% (post-test 
probability). The ruling-out gain of a negative test result was lower. A negative test will help 
to exclude the diagnosis in a presumable MMN patient optimally when the prior probability 
was between 40% and 70% (Figure 4A). The chance for a patient having MMN will change 
from e.g. 60% (prior probability) to 46% (60% -14%) when the test result is negative 
(Figure 4A). To determine the gain of a test result in the total group of inflammatory 
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Figure 4. Ruling-in and ruling-out gains for prior probabilities.
Ruling-in and ruling-out gains plotted, as percentages, against the prior probability for patients with either MMN 
(Figure 4A, n=52) or an inflammatory polyneuropathy (Figure 4B including GBS, CIDP, MMN, PP-PNP and I-PNP 
patients, n=747). The control groups used for figures 4A and 4B included healthy controls, OND, AID and MS 
(n=333). For example, if the hypothetical prior probability for a patient having an inflammatory polyneuropathy is 
30%, after a positive test the post-test probability for a patient having an inflammatory polyneuropathy is 80% (30% 
+ 50%). 
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neuropathies we combined the subgroups MMN, GBS, CIDP, PP-PNP and I-PNP (total 
n=747) (Figure 4B).
When different groups are used to determine the specificity of the test, the gain of a test 
can be used as a measure to distinguish between patient subgroups. The gain of the test in 
distinguishing a MMN patient from a MND patient was relatively low (Figure 4C). When all 
inflammatory neuropathies were to be distinguished from non-inflammatory polyneuropathies 
the gain of the test was also lower (Figure 4D).
DISCuSSION
The INCAT-ELISA demonstrated good intra-laboratory reproducibility. The overall variability 
in our laboratory expressed as CV was 11.1% for IgM and 3.8% for IgG, which is lower than 
the findings in the previous INCAT study (2). In that study the intra-laboratory variance was 
determined less extensively and estimated based on results obtained from various laboratories. 
In a single experiment we determined the relative contribution that may influence the intra-
laboratory variance of technicians, days, plates and wells within plates. This study showed 
that the inter-well variation within plates is the most important factor. The experiment used to 
determine the relative contribution of variance factors can be considered as a quality control 
for individual laboratories. 
The most likely explanation for the relatively high inter-well variation in the INCAT-
ELISA is related to the low titers and low affinity of anti-GM1 antibodies (12-14), that makes 
detection of these antibodies susceptible for small variations in the environment. This is 
especially the case for low titer IgM anti-GM1 antibodies that can be found in healthy donors 
and other controls. This notion is supported by the fact that the IgM variability was more 
than twice the IgG variability. Further experiments showed that cholera toxin, which has a 
high affinity to GM1, gives a CV of 4%. This is theoretically the lowest variation that can be 
obtained using the INCAT protocol. Differences between batches of plates have previously 
been suggested as a variation source (13). Differences in optical densities within separate 
regions of the plates (border versus center of plate) in our study were not significant (data 
not shown). To optimize the detection of antibodies of lower affinity the INCAT protocol 
recommends plates with high binding capacity for glycolipids like GM1, in duplo tests, long 
serum incubations at low temperatures and avoidance of detergents. To further improve the 
inter-laboratory variance individual laboratories should determine the factors that influence 
this variation and cooperate in exchanging control serum samples.
Using the INCAT-ELISA we found high frequencies of IgM anti-GM1 antibodies 
predominantly in MMN and GBS patients. These findings are in accordance with results from 
other studies using similar protocols as the INCAT-ELISA (1,15,16), but differ considerably 
with those of studies using other methods (17). In particular, we found no evidence for high 
titers of IgM or IgG anti-GM1 antibodies in serum from patients with MS or other autoimmune 
diseases. This difference in results from other studies most likely can be attributed to the use 
of different ELISA methods, although differences in patient populations can also play a role. 
This makes it difficult to discuss whether this method is the optimal one to use. To improve 
the comparison of different studies, we recommend the use of standardized methods such as 
proposed by the INCAT. 
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The presence of low titers of IgM anti-GM1 antibodies in control groups may indicate that 
anti-ganglioside antibodies are normal constituents of the human natural antibody repertoire 
(18). These antibodies could also represent a genetic predisposition to produce autoantibodies 
or may be related to polyclonal B-cell proliferation or to an autoimmune response secondary 
to tissue damage. In contrast, a proportion of patients with GBS, CIDP, MMN, PP-PNP and 
I-PNP have high titers of polyclonal or monoclonal IgM or IgG antibodies that may play 
a significant role in the pathogenesis of the immune mediated damage of peripheral nerve 
fibers (19,20). In an attempt to discriminate the disease related antibodies from i.e. naturally 
occurring antibodies we assessed the optimal cut-off value based on a ROC analysis of the 
d-OD’s in samples from healthy controls versus patients with MMN and GBS. This analysis 
showed that these values correspond to an excellent specificity but a low sensitivity. The use 
of a lower cut-off value will increase the sensitivity but also result in an unwanted higher 
false positive fraction. We recommend a lower false positive fraction in favor of a higher 
sensitivity, especially because of the lack of discriminative power of the assay in general. 
The diagnostic value of a laboratory assay in clinical practice also depends on the a 
priori chance of these diseases that determines the positive and negative predictive value. 
To determine the gain of the test, based on a range of a priori chances of diseases and predictive 
values, we assessed the frequency of anti-GM1 antibodies in serum from a large spectrum 
of patients and controls. The presence of anti-GM1 antibodies using the INCAT-ELISA 
showed a significant positive predictive value for MMN and the combined inflammatory 
neuropathies (GBS, CIDP, MMN, PP-PNP and I-PNP) when compared to controls (Figure 
4A and 4B). However, the positive predictive value was lower when comparing clinically 
similar groups of patients, which is a better reflection of the situation in clinical practice. 
A relatively low additional gain of a positive test was found in discriminating MMN 
from motor neuron disease (gain of a positive test 33%, Figure 4C) and in discriminating 
inflammatory polyneuropathy from non-inflammatory polyneuropathy (gain of a positive 
test 32%, Figure 4D). In both situations however, the optimal gain for a positive test was 
obtained when there was still reasonable doubt for the diagnosis (a priori chance 20 to 50%). 
After adjustment for the availability of alternative assays (including electromyography, CSF 
and laboratory examination) to discriminate these disorders, the additional informative value 
of the INCAT-ELISA is presumably lower. A negative test result is therefore not helpful for 
excluding a diagnosis based on the test due to the low frequencies of these antibodies in 
specific disorders.
The application of anti-GM1 antibody assessment in the diagnostic work-up of 
inflammatory neuropathy patients can be informative, especially when there is reasonable 
doubt about the diagnosis and when positive results are obtained. It may be beneficial to 
treat patients with other forms of neuropathy with intravenous immunoglobulins if anti-GM1 
antibodies have been demonstrated. To confirm this additional research is certainly needed. 
The ELISA method as suggested by the INCAT taskforce is a reliable and reproducible test 
that could be used as diagnostic tool in this matter.
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ABSTRACT
Background: Detection of serum antibodies to myelin-associated glycoprotein (MAG) 
by Western blot (WB) is a valuable assay to diagnose a distinct type of demyelinating 
polyneuropathy with IgM monoclonal gammopathy. In this study, the diagnostic accuracy of 
a new and more practical ELISA to detect these antibodies was validated. 
Methods: Routine WB from two independent laboratories and ELISA were used to detect anti-
MAG IgM in serum from 207 neuropathy patients and controls. The sensitivity and specificity 
of these assays were compared and related to the patient clinical and electrophysiological 
characteristics. 
Results: In ELISA, anti-MAG antibodies were found in serum from 49 (72%) of 68 patients 
with demyelinating polyneuropathy and IgM monoclonal gammopathy. However, in this 
subgroup of patients only 30 (44%) and 37 (54%) were positive in the two WBs. All of 
the patients positive in the two WBs were also positive in ELISA. A high correlation was 
found for IgM activity in ELISA to MAG and sulfate-3-glucuronyl paragloboside (SGPG) 
(Spearman’s rho 0.72, p <0.0001), supporting the notion that the shared sulfated glucuronic 
acid moiety of MAG and SGPG is preserved. Most patients positive in anti-MAG ELISA 
had a slowly progressive sensory-motor demyelinating polyneuropathy, even if the WB was 
negative. In control groups, however, four WB negative patients with a non-demyelinating 
monoclonal gammopathy related polyneuropathy were positive in anti-MAG ELISA. The 
remaining samples were negative in ELISA.
Conclusion: ELISA is more sensitive than WB to diagnose anti-MAG related polyneuropathy, 
although a positive serology may be found in other forms of polyneuropathy as well. 
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INTRODuCTION 
Patients with an IgM monoclonal gammopathy may develop a polyneuropathy if the 
monoclonal antibody binds to peripheral nerve antigens. In about half of these patients 
serum antibodies to myelin-associated glycoprotein (MAG) can be detected by Western 
blotting (WB) (1). Most patients with anti-MAG antibodies have a slowly progressive, distal, 
sensory or sensory-motor demyelinating polyneuropathy (2-4). These antibodies recognize 
the HNK-1 carbohydrate epitope on MAG, which is also present on other peripheral nerve 
glycoconjugates, including sulfate-3-glucuronyl paragloboside (SGPG) (5). The majority 
of patients with antibodies to MAG therefore also have serum antibodies to SGPG (3,4,6). 
In clinical practice, assays to detect anti-MAG and anti-SGPG antibodies are valuable diagnostic 
tools to diagnose a distinct subset of patients with chronic demyelinating polyneuropathy and 
IgM monoclonal gammopathy.
Anti-MAG WB serology, however, may be negative in patients who have otherwise the 
typical phenotype of the anti-MAG related polyneuropathy. This may indicate that anti-MAG 
antibodies are present in these patients, but that the sensitivity of the WB is insufficient. 
Recently an ELISA was developed to determine serum anti-MAG antibody reactivity (7). 
In general, ELISA is a highly reproducible and sensitive technique in which the antibody 
reactivity can be more easily quantified. At present it is unknown if ELISA is more sensitive 
than WB to detect anti-MAG antibodies and if testing for anti-SGPG antibodies has additional 
diagnostic value. 
In the current study we used the ELISA to determine the frequency of anti-MAG antibodies 
in patients with various forms of chronic polyneuropathy and monoclonal gammopathy. 
These results were compared with those in anti-MAG WB and anti-SGPG ELISA, and analyzed 
in relation to the clinical and electrophysiological characteristics following the criteria as 
proposed by the Standards for Reporting of Diagnostic Accuracy (STARD) guideline (8). 
METHODS  
Patients  
The study population comprised 154 patients with a chronic polyneuropathy who were recruited 
and diagnosed by neuromuscular specialists at the Departments of Neurology of the University 
Medical Center of Utrecht (UMCU) and the Erasmus MC in Rotterdam, The Netherlands, 
between 1986 and 2005. Medical history, physical examination, electrophysiology, laboratory 
results, including immunoelectrophoresis and immunofixation, were obtained according to a 
predefined diagnostic protocol and eligibility criteria as reported elsewhere (9). 
Of these polyneuropathy patients, 87 had an IgM monoclonal gammopathy and were 
screened for (pre)malignancies. These studies demonstrated non-Hodgkin lymphoma 
in one patient, Waldenström’s disease in two patients and breast cancer in one patient. 
No other causes for the neuropathy were found in the other 83 patients. Disease course was 
distinguished as either ‘moderate progressive’ (deterioration reaching endpoint within one 
year) or ‘slowly progressive’ (deterioration reaching endpoint at more than one year) (10). 
Endpoint was defined as a progression of the neuropathy leading to disability decrease of the 
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Rankin disability score of one point or decrease of sensory function or strength according 
to scales as published previously (11,12). The clinical phenotype was categorized as either 
pure sensory, sensory-motor or pure motor. Sensoric ataxia was defined as disturbance of gait 
or limb movements, which intensified when the eyes were closed (13). Nerve conduction 
and concentric needle examination identified a predominantly demyelinating neuropathy in 
68 (77%) of these patients, according to previously described criteria (14). 
The remaining 67 patients with a chronic polyneuropathy had an IgG monoclonal 
gammopathy (N=26), chronic inflammatory demyelinating polyneuropathy (CIDP, N=30) 
and chronic idiopathic axonal polyneuropathy (CIAP, N=11). For control studies we also 
included 19 patients with an IgM monoclonal gammopathy without polyneuropathy and 
34 healthy blood donors. 
Data collection
Consecutive cases with polyneuropathy associated with a monoclonal gammopathy and 
patients with IgM monoclonal gammopathy without polyneuropathy were previously 
included (N=132) (15). Recruitment of other patient groups was performed in a diagnostic 
Eligible patients 
and controls 
N=207
Anti-MAG ELISA 
N=207
Positive test 
N=53
Negative test 
N=152
Inconclusive test 
N=2
30/53 positive in WB-a 
37/53 positive in WB-b 
Not tested in
WB-a or WB-b 
N=0
0/77 positive in WB-a 
0/29 positive in WB-b 
Not tested in 
WB-a: N=75 
  WB-b: N=133 
Not tested in
WB-a: N=0  
WB-b: N=2 
0/2 positive in WB-a 
Figure 1. Flowchart of study.
Flowchart of initial data collection according to STARD criteria. WB-a and WB-b were used as reference test and 
applied on a selection of sera as depicted. 
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work-up context. These patients were selected randomly and not tested in anti-MAG ELISA 
before. Serum samples were tested in routine diagnostic WBs in two independent laboratories 
(reference standards WB-a and WB-b). All sera positive in anti-MAG or anti-SGPG ELISA 
and all patients with a demyelinating polyneuropathy and IgM monoclonal gammopathy 
(N=74) were retested in WB-b. Data for the ELISA and WB-b were collected prospectively 
and for WB-a retrospectively. The flowchart of this study is presented in Figure 1. 
Standard Protocol Approvals, Registrations, and Patient Consents
Institutional approval from ethical standards committees of the Erasmus MC and the UMCU 
on human experimentation was received for experiments using human subjects (Erasmus MC 
METC 2004-242, UMCU METC 02/321). Participants gave written informed consent. 
Anti-MAG serology
Pre-treatment serum samples from all 207 patients and controls were tested for anti-MAG 
IgM activity using an ELISA (Bühlmann Laboratories AG, Switzerland), according to the 
manufacturing instructions. Briefly, strips of wells pre-coated with human brain derived MAG 
purified by monoclonal antibodies were incubated in duplicate with serum samples diluted in 
incubation buffer at 1:1000 for two hours at 4°C. After washing, wells were incubated with 
anti-human IgM conjugate solution for two hours at 4°C. Next, the wells were rinsed and 
incubated with tetramethylbenzidine substrate solution for 30 minutes at room temperature. 
The reaction was stopped with an acidic stop solution within 30 minutes and the extinctions 
were read at 450 nm using a multiscan reader (Bio-Rad, Hercules, USA). Serum antibody 
activity was determined by using a standard calibration run and expressed as Bühlmann titer-
units (BTU). 
Serum IgM antibodies to SGPG were determined in all patients and in 17 of the 34 healthy 
controls using an ELISA (Bühlmann Laboratories AG, Switzerland). Instructions were the 
same as for the anti-MAG ELISA with a few modifications. Wells were pre-coated with SGPG 
purified from bovine cauda equine, also containing small amounts of lactosaminyl homologue 
(SGLPG), and sera were tested in 1:1000 dilutions. Serum anti-SGPG antibody activity was 
expressed as the mean optical density ratio of the patient sample and the calibration sample. 
The method of WB-a was previously described (4). In short, human brain derived myelin 
protein fraction was separated by polyacrylamide gel electrophoresis in sodium dodecyl 
sulfate (SDS-PAGE) and transferred to nitro-cellulose blots. The blots were incubated with 
1:500 serum dilutions, washed and subsequently incubated with peroxidase-conjugated rabbit 
anti-human IgM antiserum. Positive sera, defined by the presence of a 100 kDa band, were 
titrated by serial two-fold dilutions until negative. The titer was defined as the highest serum 
dilution that showed the anti-MAG band. In WB-b, myelin was isolated from human brain by 
a protocol modified from Norton and Poduslo and loaded in 1 mg/ml in 10% SDS-PAGE (16). 
Gels were run at 200 volts for 3-4 hours and subsequently transferred to nitrocellulose blots. 
Next, patient sera diluted 1:500 were incubated at room temperature and after washing visualized 
by horseradish peroxidase anti-human IgM and stained by enhanced chemiluminescences on 
Kodak x-ray films. 
All studies were performed blinded for clinical data and results in other assays. 
Three individuals blinded for each other’s observations screened WB-b readings. 
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Positivity for WB results was then decided on consensus. WB-b was independently screened 
by three co-workers and final scores were reached by consensus. 
Statistical analysis 
Receiver operating characteristic (ROC) curve analysis was used to determine optimal cut-
off values in the anti-MAG and anti-SGPG ELISA to discriminate between patients with 
typical anti-MAG related polyneuropathy versus the other patients or healthy controls. 
Subgroups of patients defined by the test results in anti-MAG WB and ELISA were compared 
using the Chi-square test or Fishers´ exact test. Spearman correlation coefficients and kappa 
values were used to compare the anti-MAG antibody activity found in ELISA and WB. 
Statistical analysis was performed with SPSS for Windows version 14.0. P-values <0.05 were 
considered to be significant.
RESuLTS
Reproducibility and validation of anti-MAG and anti-SGPG ELISA
ROC curves for serum anti-MAG and anti-SGPG IgM activity were constructed based on 
the 68 cases with demyelinating polyneuropathy and IgM monoclonal gammopathy versus 
the 139 other patients and controls (Figure 2). A high discriminative power for the anti-MAG 
ELISA (area under the curve 0.84) and anti-SGPG ELISA (area under the curve 0.87) was 
found. The ROC analysis established that the optimal diagnostic cut-off value for the anti-
MAG ELISA was 1500 BTU and for the anti-SGPG ELISA was a ratio of 1.0. The coefficient 
of variance was 6.8% for the anti-MAG ELISA and 6.1% for the anti-SGPG ELISA. 
The reproducibility of the anti-MAG ELISA was further determined by testing 64 patients 
Figure 2. Receiver operating characteristic curve for the presence of serum IgM antibodies to MAG and 
SGPG determined by ELISA.
Receiver operating characteristic (ROC) curves are based on patients with demyelinating polyneuropathy associated 
with IgM monoclonal gammopathy patients (N=68) versus controls (N=139). Dotted line (- -) represents the anti-
SGPG results, the solid line (–) the anti-MAG results. 
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with polyneuropathy and IgM monoclonal gammopathy a second time in which 62 (97%) had 
the same test result. In a third measurement the two discordant serum samples were negative 
and were further classified as such (Figure 1). 
Frequency of serum anti-MAG and anti-SGPG IgM antibodies in patients and controls
Using this diagnostic cut-off value for the anti-MAG ELISA , 53 (26%) of the 207 samples 
were positive (Figures 1 and 3). From these, 49 (92%) had demyelinating polyneuropathy 
and IgM monoclonal gammopathy, three (6%) non-demyelinating polyneuropathy and 
IgM monoclonal gammopathy and one (2%) non-demyelinating polyneuropathy and 
IgG monoclonal gammopathy. The sensitivity of the anti-MAG ELISA was 72.1% for 
demyelinating polyneuropathy and IgM monoclonal gammopathy and 100% for the 
subgroup positive in anti-MAG WB. The specificity of the anti-MAG ELISA was defined 
in the combined groups of patients with chronic polyneuropathy, excluding patients with a 
paraprotein without polyneuropathy and healthy controls, to reflect the situation in clinical 
practice. The specificity of the anti-MAG ELISA was 95.3% for identifying a demyelinating 
polyneuropathy and IgM monoclonal gammopathy. 
The test results in ELISA were compared with the results from the two routine diagnostic 
anti-MAG WBs (WB-a and WB-b). In the 68 patients with demyelinating polyneuropathy 
and IgM monoclonal gammopathy, WB-a was positive in 30 (44%) patients, WB-b in 
37 (54%) patients, whereas anti-MAG ELISA was positive in 49 (72%) patients. All patients 
with a positive test result in WB-a or WB-b were also positive in the anti-MAG ELISA. In the 
38 patients from this subgroup that were negative in WB-a, 19 (50%) were positive in anti-
MAG ELISA. From the 31 patients negative in WB-b, 12 (39%) were positive in ELISA. 
The two routine WB-a and WB-b showed only a moderate agreement (kappa 0.62): three 
patients were positive in WB-a only and 10 patients in WB-b only. WB-b showed a weak 
positive band in the patient with a non-demyelinating polyneuropathy and IgG monoclonal 
gammopathy that was positive in anti-MAG ELISA.
Anti-SGPG IgM antibodies were found in 55 (29%) of the 190 serum samples tested 
(Figure 3). From these, 49 (89%) had a demyelinating polyneuropathy and IgM monoclonal 
gammopathy, four (7%) a non-demyelinating polyneuropathy and IgM monoclonal 
gammopathy, one (2%) a non-demyelinating polyneuropathy IgG monoclonal gammopathy 
and one (2%) an IgM monoclonal gammopathy without polyneuropathy. The sensitivity of 
the anti-SGPG ELISA for demyelinating polyneuropathy and IgM monoclonal gammopathy 
was 72.1% (and for the subgroup with a positive anti-MAG WB 100%). The specificity of 
the anti-SGPG ELISA for demyelinating polyneuropathy and IgM monoclonal gammopathy 
defined in all patients with a chronic neuropathy was 94.2%. 
There was a high correlation between the serum IgM activity determined in the anti-MAG 
ELISA and anti-SGPG ELISA (Spearman’s rho 0.72, p < 0.0001) (Figure 4). Comparing the 
positive and negative test results of the anti-MAG ELISA and anti-SGPG ELISA, we found 
a high kappa of 0.92. Four anti-SGPG positive patients were negative in anti-MAG ELISA. 
From these, one patient had a non-demyelinating polyneuropathy and IgM monoclonal 
gammopathy, one patient a IgM monoclonal gammopathy without polyneuropathy and two 
patients a demyelinating polyneuropathy and IgM monoclonal gammopathy (Figure 3). 
Two anti-SGPG negative patients were positive in anti-MAG ELISA and both had a 
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Figure 3. IgM antibodies to MAG and SGPG in serum from patients and controls (N=207). 
Serum from patients and controls was tested in ELISA for the presence of IgM antibody activity to MAG expressed 
as Bühlmann titer units (BTU) and to SGPG expressed as antibody ratios. Abbreviations used: WB-a: Western blot 
performed in laboratory a, WB-b: Western blot performed in independent laboratory b. Dotted lines represent cut-off 
values for positivity.
(A) Anti-MAG IgM activity in ELISA is shown for patients with demyelinating polyneuropathy and IgM monoclonal 
gammopathy (N=68) and compared with activity in two routine diagnostic WBs (WB-a and WB-b), being positive 
(WB+) or negative (WB-). The left panel compares the activity in ELISA with the results in WB-a, the right panel 
with the results in WB-b. 
(B) Identical to (A) but for anti-SGPG IgM activity. 
(C) Anti-MAG IgM activity of control groups including patients with (1) non-demyelinating polyneuropathy and 
IgM monoclonal gammopathy (all negative in WB, N=19), (2) polyneuropathy and IgG monoclonal gammopathy 
polyneuropathy (all negative in WB, N=26), (3) chronic inflammatory demyelinating polyneuropathy (N=30), (4) 
chronic idiopathic axonal polyneuropathy (N=11), (5) monoclonal gammopathy without polyneuropathy (all negative 
in WB, N=19), and (6) healthy controls (N=34). 
(D) Identical to (C) for anti-SGPG IgM activity.
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demyelinating polyneuropathy and IgM monoclonal gammopathy. All sera positive with WB-a 
were positive in anti-SGPG ELISA. There was one patient positive in WB-b but negative in 
anti-SGPG ELISA. This patient had a demyelinating polyneuropathy and IgM monoclonal 
gammopathy and was also positive in anti-MAG ELISA. 
Clinical characteristics of patients with anti-MAG serum antibodies in ELISA
The clinical characteristics of the patients with a demyelinating polyneuropathy and IgM 
monoclonal gammopathy were compared in relation to the test results in anti-MAG ELISA, 
WB-a and WB-b (Table). Slow progression of disease was more frequently found in patients 
with positive anti-MAG serum reactivity in both ELISA and WB-a or WB-b compared to 
those negative in both tests (Table). None of the other patient characteristics was associated 
with the presence of anti-MAG or anti-SGPG antibodies in either ELISA or WB. In addition, 
there were no differences between patients positive in ELISA only (negative in WB-a or 
WB-b) compared to patients positive in WB-a or WB-b. One of the patients that was positive 
in ELISA only was a 64 year-old female with a slowly progressive demyelinating sensory-
motor polyneuropathy. Immunohistological investigation of a sural nerve biopsy in this patient 
showed the presence of IgM deposits at the myelin sheets, a finding frequently seen in patients 
with anti-MAG polyneuropathy.
Four patients from the other chronic neurpathy groupswere also positive in anti-MAG 
ELISA, but negative in WB-a. Three patients had a non-demyelinating polyneuropathy and 
IgM monoclonal gammopathy. One of these patients developed Waldenström’s disease and 
another amyloidosis. The electrophysiological studies performed in these patients did not 
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Figure 4. Correlation between IgM antibody activity to MAG and SGPG in serum from polyneuropathy 
patients and controls (N=190). 
Scatter plot of serum IgM antibody activity to MAG and SGPG in ELISA, which shows that these activities are 
strongly correlated (Spearman’s rho 0.72, p < 0.0001). Dotted lines represent cut-off values for positivity. Solid line 
represents nonlinear regression line. 
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show signs of demyelination. The other patient also had a non-demyelinating polyneuropathy 
but with an IgG monoclonal gammopathy and a non-Hodgkin lymphoma. 
DISCuSSION
The current study showed that in patients with demyelinating polyneuropathy and IgM 
monoclonal gammopathy serum anti-MAG antibodies are more frequently detected by ELISA 
compared to WB. More than 70% of these patients were positive in ELISA while 44 to 54% 
were positive in the two routine diagnostic WBs, a percentage comparable with previous 
reports on WB (2,4). Our study indicates that patients who are positive in ELISA but negative 
in WB, may have a polyneuropathy with the typical anti-MAG phenotype. First, these patients 
had a similar slowly progressive, sensory or sensory-motor demyelinating polyneuropathy 
Table. Characteristics of 68 patients with a demyelinating polyneuropathy and IgM monoclonal gammopathy 
in relation to serum anti-MAG reactivity in wB and ELISA.
WB-a WB-b WB-a or WB-b
WB+ ELISA+ WB− ELISA+ WB+ ELISA+ WB− ELISA+ WB− ELISA−
N=30 N=19 N=37 N=12 N=19
Demography
 Mean age, y (SD) 60 (10) 58 (11) 59 (10) 61 (11) 61 (8)
 Gender (W:M) 7:23 7:12 11:26 3:9 5:14
Slow progression (%) 21 (70) * 8 (42) 24 (65)† 5 (42) 5 (26)
Ataxia (%) 15 (50) 6 (32) 15 (41) 6 (50) 5 (26)
Classification (%)
 Sensory 0 (0) 1 (5) 0 (0) 1 (8) 1 (5)
 Sensory-motor 30 (100) 17 (90) 36 (97) 11 (92) 17 (90)
 Motor 0 (0) 1 (5) 1 (3) 0 (0) 1 (5)
IgM light chain (%)
 Kappa 22 (74) 14 (74) 29 (78) 7 (58) 13 (68)
 Lambda 4 (13) 3 (16) 4 (11) 3 (17) 3 (16)
 Both 4 (13) 2 (11) 4 (11) 2 (25) 3 (16)
Anti-SGPG positive (%) 30 (100) 17 (89) 36 (97) 11 (92) 2 (11)‡
WB: Western blot, WB-a: Western blot performed in laboratory a, WB-b: Western blot performed in independent 
laboratory b, y: year, SD: standard deviation, W: women, M: men. * p=0.003 compared to WB− ELISA−, † p=0.006 
compared to WB− ELISA−, ‡ p<0.0001 compared to WB+ELISA+ and WB−ELISA+ in WB-a and WB-b.
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as seen in the anti-MAG WB positive patients. Secondly, nearly all ELISA positive but WB 
negative patients had additional IgM serum antibodies to SGPG (96%), indicating that the 
antibodies are directed to the shared sulfated glucuronic acid moiety in MAG and SGPG, 
which is typical for patients with anti-MAG polyneuropathy (4,6). Third, a sural nerve 
biopsy from these patients positive in ELISA only showed myelin sheet IgM deposits in 
myelin sheets, a finding frequently seen in anti-MAG polyneuropathy (17-21). Together these 
observations suggest that ELISA is more sensitive than WB for identifying patients with an 
anti-MAG related polyneuropathy. 
At present however, the WB method is considered to be the golden standard technique 
to determine serum anti-MAG antibodies (22). An important advantage of WB compared 
to ELISA is the possibility to verify that the antibodies are directed to the typical 100 kDa 
protein and not to a contaminant in the purified myelin fraction. The ELISA validated in 
the current study, however, uses a highly purified MAG fraction, showing no contaminants 
in silver staining, Coomassie blue staining or immunoblotting (Figure e-1 and Figure e-2). 
Disadvantages of WB compared to ELISA are the difficulties to control the quality of the used 
myelin fractions and to quantify the staining band. This may limit not only the sensitivity to 
detect anti-MAG antibodies, but also the inter-laboratory reproducibility, as illustrated in the 
comparison between WB-a and WB-b in our study. Previous studies comparing ELISA and 
WB also reported the moderate agreement in antibody activity to MAG measured by the two 
techniques (4,6). Detection of serum antibodies may be influenced by differences in ELISA 
and WB to capture MAG and present reactive epitopes. Our finding that all patients positive 
in WB have high anti-MAG antibody activity in ELISA, indicates that ELISA at least can be 
used as a first screening method in the clinical work-up of patients with chronic demyelinating 
polyneuropathy and IgM monoclonal gammopathy. Following the guidelines of the European 
Federation of Neurological Societies and the Peripheral Nerve Society, it may be useful to 
confirm the anti-MAG ELISA positive sera in WB (23). 
The anti-MAG ELISA was also positive in four patients with a non-demyelinating 
polyneuropathy. These patients all had a monoclonal gammopathy (three IgM and one IgG), but 
were negative in anti-MAG WB. The additional positive serology for SGPG in these patients, 
suggests that their serum antibodies recognized the shared sulfated glucuronic acid moiety 
in MAG and SGPG. Previous studies indicate that in exceptional cases patients with axonal 
neuropathy can be positive for anti-MAG antibodies, even in WB (24). Serum antibodies 
from anti-MAG positive patients may bind to peripheral nerve axons, especially if there is 
additional serum reactivity for SGPG (25). This staining pattern may reflect the presence of 
SGPG in human peripheral nerve axons (26). These findings indicate that electrophysiological 
studies are required in the diagnostic work-up and cannot be replaced by anti-MAG serology. 
If the routine testing for anti-MAG antibodies is restricted to patients with a demyelinating 
form of polyneuropathy, this may not influence the specificity of the ELISA in the diagnosis 
of the classical anti-MAG polyneuropathy. 
Disease markers for chronic immune mediated neuropathy are required to classify 
diseases and predict the response to therapy. The presence of serum IgM antibodies to 
MAG defines a distinct type of neuropathy, in which these antibodies are probably involved 
in the pathogenesis of disease (18,27-29). Previous studies using WB indicate that about 
half of the patients with demyelinating polyneuropathy and IgM monoclonal gammopathy 
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have anti-MAG antibodies (2,4). The current study indicates that anti-MAG antibodies are 
found in more than 70% of patients with a typical IgM monoclonal gammopathy related 
demyelinating polyneuropathy. This may indicate that the group of patients with demyelinating 
polyneuropathy and IgM gammopathy is more homogenous than previously thought. 
Patients with a non-demyelinating polyneuropathy or with a demyelinating polyneuropathy 
without detectable IgM gammopathy incidentally may have anti-MAG antibodies (17,24). 
Nerve biopsy studies are needed to determine whether these patients also have the typical anti-
MAG related immunopathology. Detection of anti-MAG antibodies is also relevant because it 
may help to target immunotherapy. It has been shown that IgM anti-MAG neuropathy usually 
responds poorly to most conventional immunomodulatory therapies (30). Recent studies in 
IgM anti-MAG neuropathy, however, indicated promising results using rituximab, a chimeric 
monoclonal that targets B-cells, in which anti-MAG titers decay with clinical improvement 
(31-34). Interestingly, most clinical improvement was reported in patients with the lowest 
baseline anti-MAG titers (31), further illustrating the clinical relevance of a sensitive 
technique to demonstrate anti-MAG antibodies. Our study shows that the ELISA can be used 
as a sensitive and reliable screening method for determining anti-MAG antibodies. 
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Supplementary Figure e-1. Comparison of MAG preparation used in ELISA and myelin preparation used in 
western blot. 
Coomassie staining of MAG preparation used in ELISA (lane 1) and myelin preparation used WB-b (lane 2). 
No additional bands are visualized in MAG antigen used in ELISA.
Supplementary Figure e-2. Binding of antibodies to the MAG preparation used in anti-MAG ELISA and the 
myelin preparation used in western blot. 
Immunoblotting with monoclonal antibody Leu-7 (Becton Dickinson, NJ, USA) recognizing the HNK-1 epitope in 
MAG (lanes 1 and 4) reveals a band at 100 kD both in the blot with the MAG preparation used in ELISA (lane 1) and 
the myelin preparation used in WB-b (lane 4). No band was seen after incubation with serum from a healthy control 
(lanes 2 and 5). Serum from a patient with a demyelinating polyneuropathy and IgM monoclonal gammopathy 
showed a single band with the ELISA MAG preparation (lane 3), and several bands, including the 100 kD band, with 
the myelin preparation used in WB-b (lane 6).
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GENERAL DISCuSSION
GBS is often a devastating disease for which currently limited effective treatment is 
available. Artificial respiration for several weeks or months is required in 20% of patients. 
Around 5% of patients are hospitalized for more than a year and require years of rehabilitation 
for their residual deficits. This prolonged process involves an extraordinary patience and 
endurance of patients and their relatives. The severity of the disease varies considerably 
and is related to the type of preceding infection and genetic background of the patient. 
The most severe forms of GBS are particularly associated with antecedent C. jejuni infections. 
How does an infection caused by C. jejuni, which usually leads to a self-limiting and mild 
gastroenteritis, in exceptional cases (1:1,300) trigger the onset of GBS? The challenge for 
performing the research described in this thesis was to further unravel the etiology and 
pathogenesis of GBS in order to improve the prognosis, especially for the grave subgroup 
with C. jejuni-related GBS. 
In this thesis we aimed to dissect the factors involved in the interaction between 
C. jejuni and other specific pathogens and the hosts (the patients) that determines the aberrant 
immune response preceding the development of GBS. We addressed whether the risk of 
developing GBS in The Netherlands is related to the demography and seasonality of C. jejuni 
infections and to what extent infections caused by CMV may be involved in triggering GBS. 
For investigating the mechanisms that determine the outcome of host-pathogen interactions, 
we especially focused on C. jejuni because this is the predominant preceding infection in 
GBS and is relatively best characterized within GBS pathogenesis. Molecular techniques to 
characterize epitopes in the LOS structure of C. jejuni were used and related to the specificity 
of anti-ganglioside antibodies and clinical symptoms in GBS patients. Furthermore, the 
serum cross-reactivity to new molecular targets in C. jejuni LOS composed of combinations 
of ganglioside mimics or ganglioside complexes was determined. The clinical relevance of 
these targets was addressed by determining the diagnostic value of anti-neural antibodies in 
GBS patients as well as in other immune-mediated neuropathies. Furthermore, we assessed 
whether the immune response is modulated by these targets and by interactions between 
human dendritic cells (DCs) and C. jejuni. We also addressed the hypothesis that genetic 
variation in CD1 molecules expressed by DCs is related to a higher risk of developing GBS. 
These comprehensive objectives were addressed in the studies that are described in 
chapters 2 to 5 by using one of the largest GBS datasets currently available in the world. 
In this chapter the results of these studies will be outlined and discussed in relation to available 
literature. In addition, suggestions for further research will be put forward where applicable. 
METHODOLOGICAL PERSPECTIVE AND EPIDEMIOLOGy OF 
PRECEDING INFECTIONS IN GBS 
Investigating GBS in relation to the objectives of this thesis requires patient material and 
clinical data preferably from a large number of patients to strengthen the general applicability 
of its observations. GBS is a relatively rare disease with an incidence of approximately 
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1 per 100.000 persons per year (1). As a consequence, well-organized and large-scale clinical 
studies that systematically include GBS cases and recruit patient materials are required. 
At the Erasmus MC, in the past twenty-five years several clinical trials and national survey 
studies have been coordinated, which has resulted in the presence of a large bio-bank with 
serum, DNA, cerebrospinal fluid samples and extensive clinical information from more 
than 500 GBS patients. In addition, more than 25 GBS-related C. jejuni isolates have been 
assembled between 1986 and 2005 from efforts by various microbiologists and neurologists 
in The Netherlands (2-6). Control samples from healthy individuals but also from patients 
with other neurological illnesses and C. jejuni-related gastroenteritis were also collected. 
The studies performed in the past have identified several important host- as well as pathogen-
related factors involved in the etiology of GBS and showed the efficacy of various treatment 
regimens (3-7). The extensive body of data obtained during these studies was available for 
performing the research described in thesis and constituted a unique opportunity to address 
the objectives stated in the Introduction.
Detection and epidemiology of preceding infections in GBS
The most commonly identified triggers for GBS found in case-control studies are preceding 
infections caused by C. jejuni, CMV, EBV and Mycoplasma pneumoniae (8). Combined, 
these infections explain only about half of the cases, despite the fact that GBS is generally 
considered to be a post-infectious disease. Determining the frequency of preceding infections 
is complicated by the fact that in many GBS cases, infections lead to mild symptoms or 
remain subclinical. In addition, most GBS patients have already cleared their infection by the 
time they develop neurological symptoms, making it often impossible to isolate the pathogen 
causing the infection. These factors explain that preceding infections are not detected in a 
large proportion of GBS patients. Possibly the techniques to identify these infections are 
not sensitive enough, or these negative patients have other types of preceding infections. 
Improvement of techniques to detect and study the epidemiology of preceding infections in 
GBS is relevant because the type of preceding infection may determine the GBS variant and 
clinical outcome. For example, diarrhea in GBS is associated with poorer prognosis and the 
AMAN variant is highly associated with preceding C. jejuni infections (9-11). In addition, the 
type of infection may also determine the mechanism leading to development of GBS. 
In a recent Austrian report a highly sensitive PCR technique was used showing that 40% 
of GBS patients of a small cohort (n=42 patients) contained CMV DNA in cerebrospinal 
fluid whereas only 12% had positive IgM serum reactivity to CMV (12). This could suggest 
that CMV plays a more significant role in AIDP, the predominant form of GBS in European 
countries, than the 15% as previously considered based on case-control studies (8,12). CMV 
infections are thought to induce GBS as a result of a cross-reactive immune response to neural 
targets such as GM2 (13-15). The detection of CMV DNA in cerebrospinal fluid samples 
suggests that either a local reactivation of CMV or a primary CMV infection in peripheral 
nerves directly causes nerve dysfunction. Because GBS patients show no symptoms of central 
nervous system dysfunction, the presence of CMV DNA in cerebrospinal fluid may represent 
passive transfer of CMV across a damaged blood nerve barrier or retrograde transport from 
peripheral nerves. The finding of a highly frequent associated pathogen for GBS in Europe, 
perhaps in analogy to the situation of C. jejuni and AMAN, requires further attention and 
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suggests that new sensitive PCR techniques play an important role in identifying potential 
new clinical subgroups. In contrast, we describe in Chapter 2.1 that only one out of 
170 GBS patients (<1%) displayed CMV DNA in cerebrospinal fluid, whereas 22 patients 
(14%) had positive IgM serum reactivity (16). Remarkably, a similar PCR technique was used 
and both studies were performed in reference laboratories for detection of CMV infections. 
We accordingly could not identify a new relevant clinical subgroup associated with CMV 
infections. 
Possible explanations for this discrepancy include selection bias, geographic difference 
in circulating genotypes of CMV and poor specificity of the PCR technique (16). Molecular 
techniques such as PCR have the advantage of being highly sensitive but their specificity 
for CMV has been estimated 76% (17). Even when CMV is cultured from cerebrospinal 
fluid, this does not rule out the possibility that this occurred in absence of active disease as 
is seen in CMV viraemia (18). The cross-reactivity of CMV induced anti-GM2 antibodies 
from GBS patients and clinical homogeneity in CMV IgM seropositive GBS patients are 
highly suggestive of a causal relationship (13-15,19). Although these observations clearly 
indicate that CMV can trigger GBS, the use of PCR techniques to demonstrate CMV DNA in 
cerebrospinal fluid samples from GBS patients did not contribute to a better understanding of 
the significance of this infection in terms of relative frequency yet.
 In general, the detection of CMV infections and distinction between recent infection, 
active disease and reactivations of CMV is difficult. To discriminate primary CMV infections, 
advanced serological assays that determine the avidity of IgG antibodies to CMV could be 
applied in large groups of GBS patients (20,21). New developments in assays to detect CMV 
viraemia such as the NASBA pp67 RNA assay (22), which is more specific but less sensitive 
than the real-time PCR currently used, should be validated in specific clinical situations 
such as GBS. Since it is likely that most if not all AIDP or GBS patients have preceding 
(subclinical) infections that trigger the disease, it is recommended to search for new pathogens 
and, in compliance with the molecular mimicry model for C. jejuni-related GBS, focus on 
those known to express neural antigens. Screening for new pathogens could be performed by 
random PCR amplification strategies known as RAP-PCR that enables obtaining sequence 
information on unknown viruses (23-25). More information about the frequency of CMV 
infections and of other types of infection in GBS is important to identify new epitopes present 
in pathogens that may induce a cross-reactive immune response. Further characterization of 
the mechanism and involved immune response may subsequently lead to development of new 
therapies.
In addition to increasing our knowledge about the frequency and type of infection preceding 
GBS, describing the epidemiology of specific infections could lead to identification of new 
risk factors by empirical cause and effect analysis. One of the crucial questions remains why 
only 1 in 1,000 to 5,000 individuals develops GBS after enteritis caused by C. jejuni (26,27). 
Host-, pathogen- but also environmental factors may be involved in this exceptional outcome 
of C. jejuni infection. GBS occurs more frequently at older age and a male predominance 
is found, which could be related to acquired immunity to C. jejuni and riskier practices as 
regards to food handling in men causing more frequent infections by C. jejuni compared to 
women (1,28). It has been suggested that in the industrialized world, handling fresh poultry 
is the most common cause of infection by C. jejuni (29). Seasonal changes may influence 
175
General Discussion
the predominance of specific circulating strains of C. jejuni that could be more pathogenic 
(30,31). Comparing the demography and seasonality of C. jejuni-related gastroenteritis and 
GBS could lead to identification of possible environmental risk factors. 
In Chapter 2.2 the demography and seasonality of culture proven C. jejuni-related 
gastroenteritis (n=16,621) and GBS patients (n=26) as well as serology-proven C. jejuni-
related GBS patients (n=128) was compared. Interestingly, a striking inverse seasonal pattern 
of C. jejuni-related GBS and gastroenteritis was found. This study suggests that C. jejuni 
infections occurring during the winter season seem to have a higher risk for the post-infectious 
development of GBS (Chapter 2.2). In The Netherlands a higher chance of becoming infected 
does apparently not correlate to a higher chance of developing GBS. We also found that 
C. jejuni infections in GBS patients occurred more often in age groups above 60 years in 
contrast to C. jejuni-related gastroenteritis, a pattern that was also independent of changes in 
age pyramids of the general population during 1986-2006 (1). Accordingly, older people have 
a higher risk to develop GBS after C. jejuni infections than young people, possibly as a result 
of encountering rare serotypes or by becoming sensitized (32). 
The collecting process of GBS patients and gastroenteritis patients limit concise statistical 
comparisons by confounding selection bias. However the strong inverse patterns that were 
observed justifies speculation about the causes of the discrepancy between the seasonality 
and age distribution of C. jejuni-related GBS and gastroenteritis. It is possible that subclinical 
infections occurred more frequently in the serologically proven C. jejuni-related GBS patients 
compared to the C. jejuni-related gastroenteritis patients as medical help for diarrhea was sought 
and stools were taken for examination in the C. jejuni-related gastroenteritis group. Therefore 
we determined whether clinical differences between culture-proven and serologically proven 
C. jejuni-related GBS cases biased our observations but could not demonstrate significant 
discrepancies between these two groups. The culture-confirmed C. jejuni-related GBS cases 
are limited in number but worldwide provided a unique set of isolates, which has been 
thoroughly investigated for several genetic and phenotypic features of C. jejuni probably 
involved in GBS pathogenesis (Chapter 3.1).
A potential association was demonstrated between specific C. jejuni serotypes and 
Pulsed Field Gel Electrophoresis (PFGE) restriction profile types during winter and summer 
months in New Zealand, Sweden and the North West of England (33-35). Application of 
universal typing methods such as multilocus sequence typing (MLST) for seasonality of 
C. jejuni infections should be encouraged to confirm these interesting observations (36). 
New functional studies that investigate the pathogenicity of C. jejuni strains and compare 
strains isolated during winter or summer may identify new intrinsic virulence factors for 
C. jejuni with possible relevance for medical treatment, especially in the elderly. During winter 
months, the pathogenicity of C. jejuni is possibly influenced by the local flora at mucosal 
surfaces and due to dual hit infections may lead to a boost of immune responses. Comparing 
immune responses to antigens between GBS patients with both diarrhea and upper-respiratory 
tract infections and a control group hit by the same infections but who did not develop GBS, 
may indicate whether such a boost of immune response likely occurs in GBS. New detection 
methods for demonstrating recent infections, including PCR based molecular techniques and 
serological assays for C. jejuni or other pathogens, may also increase the chance of finding 
multiple infections occurring at the same time (37-39). A nationwide survey study that is 
Chapter 6
176
designed to identify each GBS patient after a positive C. jejuni culture will promote functional 
studies and increase the number of available GBS-related C. jejuni isolates (40). 
In conclusion, new developments in techniques to detect infections are important for 
understanding the pathogenesis of GBS and for defining new subgroups of patients. Moreover, 
investigating the demography and seasonality of these subgroups may help to determine new 
risk factors of developing GBS after common infections. 
CROSS-REACTIVITy, SPECIFICITy AND CLINICAL 
RELEVANCE OF ANTI-NEuRAL ANTIBODIES 
The expression of ganglioside mimics in C. jejuni LOS has been reported in several case-reports 
of C. jejuni-related GBS patients and has been associated with the presence of pathogenic 
cross-reactive anti-ganglioside antibodies (41-43). More convincing evidence supporting this 
molecular mimicry theory is obtained by chemical characterization of ganglioside mimics 
in series of C. jejuni isolates from GBS patients and relating these to clinical symptoms and 
host-related antibody responses. Identification of the genetic mechanisms that are involved in 
the variation of expression of ganglioside mimics in LOS also increases our understanding of 
host-pathogen interactions that determine why patients develop GBS after a C. jejuni infection 
(Chapter 3.1).
Using mass spectrometry we found a high frequency of mixtures of ganglioside mimics 
such as GM1- and GD1a-like LOS, which was found in 36% of 26 GBS-associated C. jejuni 
isolates, an association which was also later confirmed in a Japanese report (44,45). Remarkably, 
Kaida et al. recently reported patients having antibody responses to ganglioside complexes 
formed by mixtures of two gangliosides (46,47). In combination, both observations suggest 
that the mixtures observed in LOS are related to induction of ganglioside complex antibodies. 
Next, we searched for anti-ganglioside complex antibodies in the C. jejuni culture positive 
group of GBS patients and found 4 of 26 patients with anti-GM1/GD1a or anti-GQ1b/GD1a 
complex antibodies that all cross-reacted with LOS from the autologous isolated C. jejuni 
strain, expressing similar ganglioside mimics in three of these isolates (48). These results 
indicate that mixtures of ganglioside-like epitopes in LOS form conformational epitopes and 
induce anti-ganglioside complex antibodies in GBS (Chapter 3.2). The clinical relevance of 
ganglioside complex antibodies in GBS patients and other immune-mediated neuropathies 
requires further exploration. 
2.1. Clinical relevance and detection and of anti-neural antibodies
Several combinations of ganglioside mimics were identified by mass spectrometry, which in 
part correlated with specific clinical variants (Chapter 3.1). For example, in GBS patients 
with ophthalmoplegia and MFS patients the presence of GD1c-like LOS was predominantly 
found. In addition, the presence of GM1/GD1a complex antibodies was associated with a pure 
motor form of GBS and the presence of GQ1b/GD1a ganglioside complex antibodies with a 
GBS overlap syndrome with ophthalmoplegia (Chapter 3.2). Likewise, ganglioside complex 
antibodies to GM1/GD1b, GQ1b/GD1a, GQ1b/GM1 and GalNAc/GD1a are associated 
with distinct forms of GBS characterized by specific neurological deficits (46,47,49). It will 
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be interesting to asses if antibodies to different types of combinations of ganglioside and 
glycolipids or glycoproteins exist and to determine which combinations are immunogenic 
and have a clinical correlate. The detection of anti-ganglioside complex antibodies is intricate 
because the environment in which these glycolipids reside influences the avidity or capacity 
of antibody binding by masking the antigenic epitope on glycolipids (50). This concept of new 
anti-neural targets formed by complexes of glycolipids in immune-mediated neuropathies, 
demands a critical look at diagnostic assays for antibody detection.
Previous studies have reported variable frequencies of anti-ganglioside antibodies in 
different immune-mediated neuropathies and other diseases using different techniques, which 
has caused uncertainty about the clinical relevance and correlates of these antibodies (51,52). 
In general, most immune-mediated neuropathies may be diagnosed also without determining 
anti-neural antibodies. However, it can be difficult to discriminate an immune-mediated cause 
of polyneuropathy from other causes of disease, especially at the onset of disease. Since 
these polyneuropathies are often progressive, cause a significant amount of disability and are 
treatable, sensitive and robust assays are required for early detection of antibodies that should 
be validated by testing large groups of patients and controls.
In Chapter 5.2 we validated the European standardized INCAT ELISA technique by 
testing more than 1,000 patients and showed that antibodies to GM1 were highly specific 
for GBS (IgG and IgM 13-14%) and other inflammatory neuropathies such as MMN (IgM 
44%) (51,53). A typical illustration of the diagnostic value of this ELISA is shown in 
Chapter 5.1. Here we present a case with MFS and high titers of IgG to GQ1b that after 
follow-up developed a clinically similar episode of dysarthria and ataxia but was in this case 
caused by a brainstem infarction with negative GQ1b serology. In line with our observations 
the gain of positive high titers (>1/640) IgM anti-GM1 serology for correctly diagnosing MN 
patients was recently reported in Italy (54). This study used an identical assay technique and 
addressed the diagnostic value of IgM antibodies to gangliosides and other neural antigens, 
including myelin-associated glycoprotein (MAG), in chronic forms of immune-mediated 
neuropathy (54). What we may learn from these studies is that in patients with reasonable 
doubt about the cause, IgG and high titers of IgM antibodies to GM1 strongly increases the 
chance that an immune-mediated cause defines the type of neuropathy. There is a rationale for 
starting or adjusting immunomodulating treatment for such patients although further research 
is required (55,56). 
One of the hallmarks of anti-GM1 serology is that in spite of the generally low sensitivity 
the assay is highly specific with a specificity up to 100% (53). Developments in using 
synthetically produced gangliosides for immunoadsorption therapies with ganglioside coated 
columns (57,58), also emphasize the importance of adequate detection of anti-ganglioside 
antibodies without identification of false-positives for individual patients. If such therapies 
become available antibody titers should also be monitored accurately. This requires clinically 
validated, robust and reproducible assays. At present the INCAT ELISA complies best for 
these demands. 
At Erasmus MC, the department of Immunology collaborates closely with the clinical 
Neurology department and has collectively set up a Neuroimmunology unit, which is 
specialized in the development and validation of anti-neural antibody assays. As part of this 
initiative we have also invested in evaluating the diagnostic value of the anti-MAG serum 
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antibodies in polyneuropathies associated with monoclonal gammopathies. The typical 
clinical picture of anti-MAG polyneuropathy is a slowly progressive distal weakness with 
sensory deficits and ataxia, predominantly occurring in the elderly. Electrophysiology mainly 
shows a demyelinating form of polyneuropathy with marked prolonged distal latencies. This 
study shows that 72% of patients with polyneuropathy associated with an IgM monoclonal 
gammopathy have IgM anti-MAG antibodies when tested in ELISA compared to 44-54% 
when tested using two different western blot techniques (Chapter 5.3). We propose to use 
ELISA as a first screening method because it is a much less laborious and robust technique 
that identifies patients with a similar clinical picture of a slowly progressive sensory-motor 
demyelinating polyneuropathy (59). 
In light of emerging new therapies such as rituximab for this group of patients, which 
specifically target B-cells, these findings have practical implications as well (60-62). For 
example, antibody levels can be monitored accurately by ELISA which could be relevant for 
follow-up of patients treated by rituximab (61,63,64). The identification of patients with a 
non-demyelinating polyneuropathy with anti-MAG antibodies in ELISA also suggests that a 
broader clinical spectrum is associated with anti-MAG antibodies (Chapter 5.3). Given the 
high sensitivity we may need to extend the indication for testing these antibodies beyond only 
patients with polyneuropathy associated with an IgM monoclonal gammopathy, also to further 
determine the specificity of anti-MAG antibodies (59). Professional experience, centralization 
and standardization of the experimental methods for demonstration of anti-neural antibodies 
are important to improve our ability to recognize these treatable diseases. 
With respect to the origin of anti-MAG antibodies, it is possible that a clonal B-cell 
population during B-cell development aberrantly expands and produces monoclonal antibodies 
reactive to peripheral nerve antigens. It has also been suggested that these antibodies arise in 
response to bacterial antigens as is the case in C. jejuni-related GBS (65). Future studies 
should confirm whether CMV infections or other infections play significant roles in these 
patients (66,67). 
This thesis emphasized the afferent phase during the immune response in GBS, highlighting 
the origin and detection of anti-neural antibodies. During the efferent phase, in which anti-
ganglioside antibodies bind to peripheral nerves, complement activation through the classical 
pathwayplays or via the lectin pathway plays a crucial role in disruption of motor nerve 
terminals (68,69). Inhibition of complement activation is a potential therapeutic option and its 
efficacy in mice and rabbit models has recently been shown (70,71). Further demonstrating 
the pathogenicity of anti-ganglioside complex antibodies in complement-mediated nerve 
injury strengthens the clinical implication of the detection of these antibodies (72). 
Accurate (diagnostic) assays to detect antibodies to neuronal targets composed of 
glycolipids, glycoproteins or combinations of these are desirable. With the extending 
number of possible targets formed as ganglioside complexes, ELISA techniques become 
impractical because only a limited number of combinations can be tested in a single run. 
Glycan microarray techniques have been developed in which antibody binding 
to hundreds of glycolipids covalently bound to glass slides can be assessed (73). This attractive 
approach could be adapted for detection of anti-ganglioside complex antibodies for 
patients with immune-mediated neuropathies. One has to keep in mind the that solid 
phase environments of assays, which in the case for ELISA (polystyrene) is highly negatively 
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charged, limits the flexibility and as a consequence the accessibility for antibody binding 
of masked epitopes formed by complexes of gangliosides (74). Recently, a glycolipid array 
for antibody detection to ganglioside complexes has been developed that makes use of an 
automated thin-layer chromatography system in a non-solid phase polyvinylidine fluoride 
environment. This assay enables antibody binding to ganglioside complexes in a non-
immobilized fashion and showed interesting differences between ELISA results for antibody 
specificity of serum from GBS patients (74). Validation of these methods in groups of patients 
with immune-mediated neuropathies is necessary to evaluate the value of these new assays in 
clinical practice.
C. jejuni mimicry and specificity of anti-ganglioside antibodies in GBS
Previous serological studies indicated a strong relationship between antibody specificity to 
gangliosides in GBS patients and ganglioside mimics in LOS from autologous C. jejuni. 
Remarkably, we observed that the overlap between antibody specificity in patients and 
the ganglioside mimics found by mass spectrometry in C. jejuni LOS was not complete 
(Chapters 3.1 and 3.2). In addition, in 6 of 26 GBS-related C. jejuni strains no ganglioside 
mimics were found at all. This study provides molecular evidence that ganglioside mimics 
in LOS induce anti-ganglioside antibodies, which is in accordance with indirect observations 
from the previous serological reports (44,75). The LOS biosynthesis class A LOS locus was 
associated with GBS and the expression of GM1-like structures, whereas the class B LOS 
locus was associated with MFS and the expression of GQ1b-like structures. Mechanisms that 
explain the observed discrepancy and genetic pathways in this process have been addressed 
in Chapter 3.1. Specific base deletions and frame-shift mutations in sialyltransferase genes 
of the LOS biosynthesis cluster in three strains without ganglioside mimicry were found that 
may have occurred during colonization or culture. Alternatively, a different C. jejuni strain 
may have been isolated from patients that were infected by multiple strains (76). Interactions 
between hosts and pathogens during colonization and the immune response could be involved 
in this process. 
Relating the anti-ganglioside antibody specificity to the LOS carbohydrate composition 
in terms of the number of carbohydrate molecules and attached sialic acid groups is an 
oversimplification of the actual interactions between host receptors, bacterial epitopes and 
antibodies. For example, the presence of bacterial GD1c-like LOS is highly associated with 
induction of anti-GQ1b antibodies. This can be explained because GD1c and GQ1b share 
the presence of terminal di-sialylated carbohydrates. Nevertheless, GD1c and GQ1b are not 
identical structures (Table 2, Introduction). A different example is that a proportion of serum 
anti-GM1 antibodies bind to cryptic GM1 which is only accessible after the unmasking of 
neighboring gangliosides such as GD1a (50). Gangliosides reside within glycosynapses in 
which nearby factors such as other adjacent glycolipids or (glyco-) proteins alter electrostatic 
charge and hydrophilic interactions and modulate signaling pathways (77). The proximity 
of different gangliosides in membranes enables the formation of so called conformational 
epitopes that are comprised of contiguous but physically discontinuous components of the 
immunogenic molecule. The presence of such conformational epitopes in the C. jejuni cell 
wall could well explain the presence of ganglioside complex antibodies in a subgroup of GBS 
patients (78). Chemical characterization of the exact molecules to which anti-ganglioside 
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complex antibodies bind in C. jejuni LOS or in immunoassays may be essential to further 
demonstrate this and would be supplementary to the observed serum cross-reactivity described 
in chapter 3.2. Whether the cellular wall of C. jejuni and the host cell membrane forms a 
so called glycosynapse and coordinates downstream signaling events should be determined. 
Carbohydrate microarrays and synthetically produced glycolipids are essential new tools that 
can be exploited to investigate this hypothesis (58,79). Revealing new host and pathogen 
interactions, possibly at the level of a glycosynapse, increases our understanding of bacterial 
strategies for survival and infection and could lead to new therapeutic or preventative 
developments.
Although the mimicry function of C. jejuni to express gangliosides may have evolved to 
evade immune recognition, in GBS it seems to result in an exaggerated immune response to 
self-structures (80). Several host-pathogen interactions, as listed in the Table, may interfere 
with recognition of pathogens during the aberrant immune response in GBS. Underlying 
mechanisms such as adherence and entry of pathogens, dissemination of infection, 
multiplication and immune evasion or modulation all involve specific interactions between 
host and pathogen (81). Sialylation of bacterial or host surfaces plays a critical role in these 
mechanisms and is an interesting field for further research. Epithelial cell invasion by C. jejuni 
depends on sialylation of LOS and sialylation is involved in the pathogenicity of various other 
bacteria and viruses such as Neisseria meningitidis and Influenza viruses (82-84). Haemophilus 
Influenza, also thought to be involved in triggering GBS in a substantial proportion of GBS 
patients (85), incorporates host-derived sialic acids into its LPS increasing its virulence (86). 
Pathogen-derived sialidases also modulate immune responses by freeing the pathogen from 
host surfaces (83). In addition, variation in sialidase gene transcription leads to a modulation 
of the capacity of antigen presenting cells to stimulate B-cells through IL-4 (87,88). 
Thus, variation in genes encoding sialidases with a functional relevance for sialidase activity 
could theoretically modulate immune responses at mucosal surfaces to C. jejuni and additionally 
lead to differences in the self repertoire of gangliosides in the nervous system. Comparing 
SNPs in genes encoding sialidases in GBS patients and healthy individuals therefore is an 
interesting approach to assess whether such SNPs increase host susceptibility to develop GBS 
(87). Given the crucial role of sialic acid in various host-pathogen interactions it is interesting 
to further determine the effect of sialylation of C. jejuni and other GBS-related pathogens in 
human immune responses to understand how cross-reactivity is induced in GBS.
In conclusion, the presence of microbial targets consisting of more than one molecule has 
been demonstrated in LOS of a unique set of 26 GBS-related C. jejuni strains and were found 
to induce ganglioside-complex antibodies. Variability of antibody responses and clinical 
symptoms could be related to variable expression of ganglioside mimics in LOS due to 
genetic changes in C. jejuni. Interactions between pathogens and hosts in which multiple risk 
factors simultaneously influence the chance of inducing a cross-reactive immune response 
may determine the development of GBS. Further studies that characterize these interactions 
may lead to new targets for prevention or treatment of GBS.
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HOST IMMuNE RESPONSE TO GANGLIOSIDE MIMICS IN GBS-
RELATED C. jejuNI
Interactions between host and pathogens take place at several stages during immune responses 
and because the innate immune response is defined as the host’s first barrier for entry of 
pathogens, studying innate responses to C. jejuni may be of particular interest for understanding 
GBS pathogenesis. Innate immunity has evolved to swiftly respond to evolutionary conserved 
microbial structures such as lipid A, also present in C. jejuni LOS, and coordinates suitable 
types of adaptive immune responses (95). The characterization of the adaptive immune 
response and identification of cross-reactive serum antibodies and relationship with antecedent 
infections in GBS has received much attention during the past two decades but the host-related 
receptors, cells and pathways involved in this aberrant immune response are largely unknown. 
Reducing this gap in our understanding of GBS pathogenesis may have general implications 
for understanding other post-infectious diseases. 
An important cell type of innate immunity is the dendritic cell (DC), a professional 
antigen-presenting cell (APC) type abundantly present underneath the epithelial cell layer 
in the gut. In our focus on C. jejuni-related GBS this anatomical localization is of particular 
interest and gut DCs are presumably one of the first immune cells to interact with invading 
pathogens such as C. jejuni (96). DCs can directly interact with B-cells providing signals to 
class switch antibody isotype without T-cell help (96,97). As such, these important features 
position DCs at a critical checkpoint for interactions between host and pathogen that could 
be of relevance for the induction of the aberrant immune response in GBS. Accordingly, we 
aimed to construct an in vitro model for humans, which would enable to study functional 
interactions between DCs and C. jejuni in relation to host- (i.e. antigen presentation) as well 
as pathogen- (LOS sialylation) related factors in GBS pathogenesis.
Sialylation of C. jejuni LOS boosts human immune response
In chapter 4.2 we investigated the human DC response to C. jejuni, the influence of LOS 
Table. Examples of factors that may interfere with host-pathogen recognition during host immune response 
to pathogen. 
Process References
Double infection with additional C. jejuni strain or microorganism with different pathogenicity (76)
Genetic changes in LOS locus during colonization, influencing the expression of ganglioside 
mimics in C. jejuni 
(44,89)
Bacterial invasiveness and pathogen-pathogen interactions influencing local flora and inflammatory 
environment
(84,90)
Uptake of sialic acids or secretion of sialidases influencing receptor-ligand interactions between 
pathogen and host or between pathogens
(86,87)
Variability between individuals in distribution and self-repertoire of ganglioside expression (91-94)
Clustering of gangliosides and receptors that change the composition in microdomains of lipid rafts (77)
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sialylation and whether DCs provide signals to B-cells in relation to stimulation with 
C. jejuni LOS. We found that C. jejuni strains from GBS patients activated DCs and showed 
that highly purified LOS from these strains activated DCs at very low concentrations. 
This activation of DCs was partly mediated by signaling through TLR4, a pattern recognition 
molecule that binds to lipid A, which is present in both LOS and LPS. Sialylation of LOS 
had strong immunomodulatory effects on DCs; enhanced DC cytokine release was found 
when DCs were stimulated with sialylated LOS from a C. jejuni strain obtained from a 
GBS patient compared to a genetically mutated strain lacking sialic acid (cst-II knockout 
mutant strain). A tenfold higher concentration of the non-sialylated mutant strain compared 
to the wild-type was required in order to obtain similar cytokine levels secreted by DCs after 
stimulation with LOS (Chapter 4.2). In addition, we found that supernatant from C. jejuni-
stimulated DCs contained soluble factor(s) that increased human naïve B-cell proliferation. 
The immunomodulatory effect of sialic acid on DC activation correlated with increased B-cell 
proliferation. These results indicate that sialylation of C. jejuni LOS causes a boosting of the 
in vitro immune response, rather than functioning as a scavenger molecule for evasion of 
immune recognition (80). This boost of the immune response may lead to improper antigen 
presentation and a cross-reactive B-cell response, which in susceptible hosts might cause 
GBS. In the next paragraphs three possible pathways related to this process are discussed and 
related to available data and literature.
Receptor-mediated uptake of sialylated glycolipids
The correct balance of the amount of sialic acid expression by pathogens appears crucial 
for immune detection by host cells sensing sialylated surfaces by specialized receptors 
called lectins (98). Antigen presenting cells also express several receptors such as TLRs that 
recognize microbial conserved structures and trigger cell activation. We observed that DC 
activation by C. jejuni LOS was partly inhibited when TLR4 signaling was prevented by a 
blocking mAb. In addition, a significantly lower response in HEK/TLR4 cells after enzymatic 
removal of sialic acid residues from LOS was shown, indicating a potential role for TLR4 
in the differential activation of DCs by sialylated LOS. In line with these findings it was 
found that gangliosides, containing sialic acid residues by definition, alter TLR4 expression 
in astrocytes and trigger inflammatory responses (99). However, the mechanism by which 
sialic acid may alter TLR4 binding or the configuration of the lipid-A carbohydrate complex 
is unknown. In analogy to the situation in which functional units are formed by TLR4 and 
either MD-2 or CD14, which subsequently binds to smooth or rough LPS, conformational 
and electrostatic differences in sialylated LOS may cause that binding to TLR4 occurs in a 
different functional unit or context (100). 
Such functional units for LOS binding may be formed by specific sialic acid binding 
lectins called Siglec’s (sialic acid binding Ig-like lectins) and other calcium dependent 
C-type lectins. These receptors bind to carbohydrate molecules and theoretically may bind 
ganglioside mimics in LOS. Siglec’s are thought to be involved in monitoring self-antigens by 
detecting changes in expression of sialylated proteins- and glycolipid rich surfaces (101-103). 
Two subsets of Siglec’s have been characterized that differ in the presence of an anchored 
cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) that suppresses immune 
activation, or the absence of this motif such as seen in Siglec-14, -15 and -16 (98,104). 
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Binding of C. jejuni LOS expressing ganglioside mimics to Siglec-7 has been demonstrated 
but the functional effects on DCs and the immune response is unknown (105). 
Siglec’s contribute to endocytosis of antigens after trans interactions (interactions with 
ligands on other cells) with pathogens (82,98,106). In theory, activation of DCs through TLR4 
by LOS may lead to unmasking cis interactions (interactions with ligands on the same cell 
surface) of endogenous sialic acids with Siglec’s, which can facilitate access or binding of 
sialylated LOS to Siglec’s and as a result increase endocytosis of C.  jejuni by DCs. Interestingly, 
a link between Siglec’s and TLRs has been suggested for Siglec-H which associates with 
immunoreceptor tyrosine-based activation motif (ITAM) through DAP12 adapter molecules 
after stimulation with TLR-9 agonists (107) (108). Whether functional units formed by TLRs 
and Siglec’s may explain our observed modulation of TLR-4 signaling by sialylated LOS is 
unknown but would be an interesting question for further research. Unraveling these complex 
mechanisms for activation of DCs by LOS helps to elucidate the question of how immune 
responses are boosted by sialylated LOS and how this leads to a derailed co-stimulation of 
auto-reactive B-cells in GBS. 
Antigen presentation of ganglioside-like LOS
After antigen uptake by innate immune cells such as DCs, one of the crucial events during the 
immune response is the presentation of these microbial antigens to other immune competent 
cells. Antigen presentation is a molecular process in which self- and non-self antigens are 
continuingly processed by molecules including the major histocompatibility complex (MHC) 
system and CD1 group and is designed to prevent harmful auto-reactive immune responses. 
It has been shown that dendritic cells expressing CD1 induce proliferation of GM1-restricted 
γ-δ T-cells when stimulated by C. jejuni (109). Moreover, dendritic cells secrete de novo 
produced self-gangliosides upon stimulation with C. jejuni, possibly further recruiting 
surrounding GM1-specific T- or B-cells. Because CD1 molecules present glycolipids including 
GM1 (110), the aberrant immune response to C. jejuni in GBS may be due to an inaccurate 
antigen presentation by CD1 molecules in particular. 
Genetic studies in GBS patients mainly identified disease modifying factors influencing 
the severity of the disease and outcome (Table 3 in the Introduction) but the host-factors that 
determine the susceptibility to develop GBS after antecedent infections are poorly defined and 
could be related to an aberrant presentation of antigens (111). In support of this hypothesis, a 
recent study in an Italian GBS cohort consisting of 65 patients showed an increased susceptibility 
for GBS associated with CD1A and CD1E SNPs (112). This association also seemed specific 
for GBS because it could not be found in other immune-mediated neuropathies (113). 
These results implicate that an important host-related factor was identified for development of 
GBS. Reproducing these results in a different GBS cohort was therefore relevant especially 
when using a much larger cohort, enabling subgroup analysis for patients with anti-ganglioside 
antibodies and antecedent C. jejuni infections. 
In chapter 4.1, the genetic variation in CD1 molecules was studied in currently the largest 
cohort of GBS patients in the world assembled in The Netherlands (n=312), in which the 
association between CD1A and CD1E SNPs and GBS susceptibility could not be replicated 
(114). This difference was probably related to sample size differences. The last study was 
five times larger and consequently has a stronger statistical power. A definite role for CD1A 
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and CD1E SNPs in GBS susceptibility cannot be claimed. Larger databases of GBS patients 
are required, which can only be established by extensive international collaborations and 
platforms (115).
A functional role for CD1 could also not be established in an elegant study using CD1d 
knockout mice (110). Cross-reactive anti-ganglioside antibodies (IgG1, IgG2b, and IgG3 
isotypes) in response to C. jejuni infection were similar in wild-type mice and in CD1d 
knockout mice, suggesting that at least this group of CD1 molecules are not critically 
involved. In contrast to humans, mice do not express CD1e (110). Further addressing the 
role of this molecule in GBS is recommended because this intracellular protein processes 
complex glycolipids and is involved in loading glycolipids onto CD1b in late endosomes 
and lysosomes. Although it has not been demonstrated yet that CD1e transports gangliosides, 
crystallographic imaging showed the presence of GM2 within the binding groove of the CD1b 
molecule (116,117). Interestingly, mutations in CD1E have been reported with functional 
effects on antigen presentation, supporting the suggestion that sequencing CD1E genes from 
groups of GBS patients may reveal unknown but possibly relevant mutations (118). Exploring 
the functional effects of such mutations by siRNA methods, which enables switching off single 
genes, could be an interesting alternative for in vitro cell culture systems with C. jejuni strains 
from GBS patients. These studies help to answer the question whether cross-reactive immune 
responses to C. jejuni are caused by a host-dependent aberrant presentation of ganglioside-
like antigens through CD1. 
Coordination of the adaptive immune response
The boost of the immune response elicited by sialylated C. jejuni LOS was also reflected 
in enhanced B-cell proliferation in the presence of supernatant from stimulated DCs 
(Chapter 4.2). In order to determine how B-cell proliferation is regulated by DCs, the role of 
B-cell activating molecules such as IL-6 and IL-12, which were also present in supernatant 
of stimulated DCs (119,120), was studied by using neutralizing antibodies. These cytokines 
were not found to be critical for boosting the B-cell response in our model, which was in 
contrast to results from a previous study that investigated the DC and B-cell response to 
E. coli LPS, however the study protocol in that case included T-cell help (120). Since anti-
ganglioside antibodies induced by C. jejuni LOS are often isotype-class switched antibodies 
(IgA,IgG), which is uncommon for antibodies to carbohydrate antigens that are mostly T-cell 
independent, an alternative stimulation of B-cells by DC-derived secreted factors may be 
involved.
Factors secreted by DCs such as BAFF, APRIL, and C4b binding protein (C4BP) are 
known to induce isotype-class switch without T-cell help and TLR agonists may also synergize 
and deliver direct signals to B-cells for isotype-class switching (97,121-124). Increased serum 
BAFF levels occur in autoimmune diseases such systemic lupus erythematosus, primary 
Sjogren’s syndrome and rheumatoid arthritis and are associated with increased serum anti-
nuclear antibodies (125). Likewise, the induction of auto-reactive anti-ganglioside antibodies 
by antecedent infections in GBS may be associated with increased circulating levels of BAFF 
and APRIL, which are mainly secreted by DCs but also other cell types such as gut epithelial 
cells (126). C4BP is a regulator component of the classical complement pathway and can bind 
to CD40 on B-cells, is upregulated by monocytic cells and could reduce the amount of CD40L 
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needed to activate and class-switch B-cells (121,122,127,128). The number of other possible 
soluble interacting factors that modulate the B-cell response in relation to DCs stimulated by 
C. jejuni or other GBS-associated pathogens is daunting. In addition, it is unknown whether 
the observed effects only lead to a general impulse for B-cells or whether this may also lead to 
detectable (auto-reactive) antibody production. From a strategic point of view, implementing 
screening methods that diminish the number of possible causative factors like dialysis 
and microarray techniques is desirable. Results from such studies possibly bring us closer 
to the cause of the breakdown of B-cell tolerance, sometimes occurring after a relatively 
benign infection in GBS, but more generally leading to more long-lasting antibody-mediated 
autoimmune diseases such as anti-MAG polyneuropathy, MMN or Sydenham’s chorea. When 
GBS patients develop their neurological symptoms the production of auto-reactive antibodies 
may be an ongoing process, as the titers of antibodies in some patients decay after several 
months whereas the half-life of antibodies is shorter. Investigating the regulation of auto-
reactive B-cells or plasma cells by DCs may lead to new therapeutic developments that may 
be implemented in the earliest stages of disease.
Experimental limitations and directions for future studies
Other pathogens than C. jejuni are involved in GBS, which were not addressed in the current 
study (Chapter 4.2). Further limitations related to the conclusions of this study are caused 
by the methodology and use of an in vitro model to study a human disease. The monocyte-
derived DC used is an artificial cell type that is skewed by exogenous cytokines and growth 
factors and may function differently than DCs present in the lamina propria of the gut (129). 
The advantage however, is that the results are less likely to depend on variation in DC 
phenotypes existing for example in peripheral blood or in the gut. The human tonsillar naïve 
B-cells used in the study also represent an approximation of mucosal B-cells but included 
relevant cell types such CD5+ B1 cells responding to thymus-independent antigens. 
Elegant and suitable animal models with rabbits have been developed that can in part 
overcome these shortcomings but require laborious and intensive protocols (130,131). Earlier 
studies by different groups failed to induce weakness in C. jejuni immunized mice, rats and 
rabbits (132-135). The advantage of applying an animal model is that it enables investigation 
of pathological changes at several anatomical localizations such as peripheral nerves and 
the intestine. For example, it would be interesting to use fluorescently traceable C. jejuni 
strains for infecting these rabbits and to investigate by fluorescence light-microscopy methods 
the localization, spreading and surrounding immune cells of C. jejuni invasion. This could 
answer the question whether cross-reactive C. jejuni responses arise in the gut or as a result 
of a systemic infection in secondary lymphoid tissues. However, caution should be taken in 
extrapolating the results from animal studies to the human situation, especially in relation to 
human B-cell responses to carbohydrate antigens in which important species differences exist 
(136-138). Therefore the development of a human experimental system in which host- and 
pathogen related factors could be addressed is an additional relevant method for studying the 
pathogenesis of GBS.
The next step forward would be to obtain DCs from GBS patients and compare immune 
responses with healthy individuals or gastroenteritis patients that did not develop GBS after 
C. jejuni infections. Ideally, assessment of DC responses to autologous C. jejuni isolates from 
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GBS patients is performed by using DCs isolated from the lamina propria or DCs generated 
from peripheral blood from GBS patients (during the acute stage of disease and after 
recovery). These studies could identify whether constitutional differences in GBS patients 
exist regarding functional DC responses to ganglioside-expressing microbes explaining 
their susceptibility of developing a cross-reactive immune response. Less than 5% of GBS 
patients have recurrences, an interesting subgroup for further study in this context (139). 
Characterization of the intra-cellular pathways by micro-array techniques may subsequently 
lead to strategies for developing new therapies.
CONCLuSION 
GBS is preceded by infections and pathogen-related factors in part cause the disease. 
Host-related factors such as the induction of cross-reactive anti-ganglioside antibodies cause 
damage of peripheral nerves. It is important to consider that GBS is a heterogeneous disease 
triggered by different pathogens that are incompletely characterized. The most important 
infection is caused by C. jejuni during the winter months. Combinations of ganglioside-
like structures in C. jejuni LOS form conformational epitopes and induce cross-reactive 
anti-ganglioside complex antibodies. The clinical relevance of these antibodies has been 
validated and may become clearer by developing new diagnostic assays to detect anti-
ganglioside antibodies. An important functional interaction between host and pathogen was 
observed in which sialylation of C. jejuni LOS results in boosting of DC and subsequent 
B-cell responses. Characterization of the pathways involved in this process (Figure 1) could 
contribute to the development of new therapies for GBS. Progress in understanding the 
pathophysiology of the different variants and levels of severity of GBS depends critically 
on further unraveling the mechanisms of interactions between pathogens and patients.
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Figure 1. Hypothetical model of host-pathogen interactions in GBS. 
Conformational epitopes present in the outer cell wall of C. jejuni LOS induce cross-reactive antibodies leading 
to GBS. C. jejuni invades intestinal epithelium from the lumen of the intestine. Pattern recognition receptors and 
sialic-acid binding Ig-lectins (siglec’s) on DCs may bind to LOS and induce an inflammatory response and enhance 
B-cell proliferation. The conformation of the mimics present in C. jejuni LOS are related with the clinical variants of 
GBS. TLR4: Toll-like receptor 4, BAFF: B-cell activating factor, APRIL: a proliferation inducing ligand, C4BP: C4b 
binding protein, *: Putative pathways.
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Guillain-Barré syndrome (GBS) is a neurological disorder characterized by rapid progressive 
and symmetrical limb muscle weakness and loss of tendon reflexes. Sensory deficits and cranial 
nerve involvement is observed to a variable extend. Some patients have additional weakness 
of respiratory miscles for which they may require prolonged ventilation at an intensive care 
unit. The disease is caused by a post-infectious immune mediated polyradiculoneuropathy 
and has a monophasic course with a variable and often incomplete recovery. The Miller 
Fisher syndrome (MFS) is a variant of GBS that is characterized by double vision, inability 
to coordinate movements and loss of tendon reflexes. Campylobacter jejuni is the most 
frequent cause of preceding infection in GBS and MFS, and is identified in 20-50% of 
patients. Preceding C. jejuni infections are associated with a more severe clinical course 
and poorer outcome. Other infections that can precede the development of GBS include 
Mycoplasma pneumoniae and viruses such as cytomegalovirus and Epstein-Barr virus. 
An immune response orchestrated to eradicate these infections follows an aberrant course 
in GBS, which eventually leads to destruction of peripheral nerves and muscle weakness. 
It has been shown that C. jejuni isolated from individual GBS patients bear specific structures 
on the outer surface that resemble structures (gangliosides) present on human nerves. 
This resemblance is called molecular mimicry and is held responsible for the induction of 
antibodies that cross-react to C. jejuni and peripheral nerves.
Previous studies identified several host-related factors associated with GBS, including 
demographic features, variation in genes of the immune system and presence of serum 
antibodies to gangliosides. Other studies found pathogen-related factors involved in the 
pathogenesis of GBS, including distinct types of antecedent infection, such as C. jejuni, and 
of molecular mimicry with gangliosides. The aim of the research described in this thesis was 
to identify mechanisms by which these host and pathogen factors induce GBS and delineate 
the clinical relevance of these factors.
First, the epidemiology of specific infections associated with GBS are investigated. 
In Chapter 2.1 we assessed whether CMV infections are as frequent as C. jejuni in GBS as 
was suggested in a previous study performed by another research group based on analysis 
of cerebrospinal fluid samples from patients using a sensitive molecular technique to detect 
the virus genome. A large set of cerebrospinal fluid samples from Dutch GBS patients was 
tested for comparison using a similar technique. In contrast to the previous report, only 3 of 
171 samples were found positive for a recent CMV infection. Therefore, it is too early to suggest 
that CMV plays a similar important role as C. jejuni preceding the development of GBS. 
The difference between our results and previous published data may be related to the selection 
of patients and the tested material. 
The remaining chapters focus on the most frequent preceding infection in GBS caused 
by C. jejuni. Food products, especially from chicken and shell fish, may contain these gut 
bacteria and cause gastroenteritis, with severe diarrhea, or remain unnoticed. In Chapter 2.2 it 
is described whether age and season of infection by C. jejuni are risk factors for development 
of GBS. A striking inverse pattern was observed when the age distribution of patients with or 
without development of GBS after a C. jejuni infection was compared. Similarly, an inverse 
pattern was also observed for the season of becoming infected. C. jejuni-related GBS patients 
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tended to be older and more frequently infected during winter months suggesting that both 
environmental and host-related factors may play a role for the risk to develop GBS after a 
C. jejuni induced gastroenteritis which processes underlie this phenomenem are unknown.
In Chapter 3.1 the combined results are described from molecular and genetic studies 
of a set of 26 C. jejuni strains, which were isolated from or associated with GBS patients. 
Never before a large group of C. jejuni strains was available for such an extensive investigation 
of the molecular mimicry theory. The compilation of strains and patients now also enabled the 
possibility to investigate the clinical relevance of the presence of ganglioside-like structures 
on the outer surface of C. jejuni. We found that a majority of the C. jejuni strains express 
combinations of ganglioside-like motifs although strains without ganglioside-like motifs 
were also found. Genetic mechanisms responsible for the lack of ganglioside expression were 
found in part of these strains. In Chapter 3.2 is described that four of these GBS patients 
had antibodies to combinations of gangliosides, so called ganglioside complex antibodies, 
which were also induced by similar combination of ganglioside-like structures present in 
these bacteria.
In Chapter 4 we move forward to the role of host-related factors in the development of 
GBS. We investigated whether variation in CD1 genes is a susceptibility factor for GBS. CD1 
binds to certain gangliosides and is amongst others expressed by dendritic cells, a specific 
antigen-presenting cell of the innate immune system and is one of the major coordinators 
of the type of required adaptive immune response. A previous study in a cohort of 65 Italian 
patients with GBS reported that specific variations occurring in two genes of CD1 (CD1A and 
CD1E) increase the chance to develop GBS. This important association for understanding the 
susceptibility to develop GBS was also studied in the Dutch cohort of almost 400 patients, 
but these variations were not associated with specific subgroups of patients (Chapter 4.1). 
This inconsistency illustrates that genetic association studies for diseases like GBS need large 
number of patients and well defined cases records and strict guidelines for performing such 
studies. The role of dendritic cells as possible coordinator of the aberrant immune response 
in GBS is addressed in Chapter 4.2. Here we investigated whether sialic acid, present in 
the outer membrane of C. jejuni and an important constituent of gangliosides, influences the 
extent of activation of dendritic cells. It was found that C. jejuni strains expressing sialic acid 
were 10 times more efficient in activation of dendritic cells compared to genetically mutated 
strains lacking the expression of sialic acids. In addition, dendritic cells activated by C. jejuni 
were found to secrete factors that enhance the growth of B-cells, precursor cells of antibody 
producing plasma cells. The involvement of specific receptors in activation of dendritic cells 
was investigated and the possible mechanisms related to the activation of dendritic cells, 
growth of B-cells and modulation by sialic acids are highlighted in the general discussion. 
These results contribute to the understanding of the initial steps in the pathogenesis of GBS 
and may eventually lead to the development of new preventative strategies or therapies.
Chapter 5 is dedicated to the detection of antibodies to peripheral nerve carbohydrate 
structures, including glycolipids and glycoproteins, and the role that antibody detection may 
have in clinical practice. Antibodies to gangliosides are mainly found in GBS but also in 
other immune-mediated diseases of peripheral nerves. For example, antibodies of the IgM 
isotype to the GM1 ganglioside are frequently found in multifocal motor neuropathy, a 
progressive disease with asymmetric weakness in limb muscles, especially of the arms, with 
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a patchy distributed lesion of the peripheral nerves, causing a slow but severe functional 
decline. In Chapter 5.2, a technical validation of the ELISA technique used for detection 
of anti-ganglioside antibodies is performed. Next, an analysis of more than 1,000 patients 
tested for anti-ganglioside antibodies is done in which the diagnostic value was assessed by 
comparing test results between patients with immune-mediated causes of polyneuropathy 
and different control groups. Although antibodies to gangliosides are found infrequently, an 
additional diagnostic value was especially found for patients with a low a priori chance of 
an immune-mediated cause for their neuropathy. In Chapter 5.1, a typical example of the 
diagnostic value of antibodies to the GQ1b ganglioside is described in a patient with recurrent 
symptoms resembling Miller Fisher syndrome but seemed to be mistaken for a brainstem 
infarction. In Chapter 5.1, a typical example is presented that illustrates the diagnostic 
value of the detection of antibodies to the GQ1b ganglioside. The patient had two episodes 
with very similar neurological symptoms. The first episode was caused by the Miller Fisher 
syndrome and serum obtained at that time point contained high titers of IgG antibodies to 
GQ1b. After this the patient showed an almost complete recovery. In the second episode 
these antibodies were absent and an MRI scan of the brain identified a brainstem infarction. 
In Chapter 5.3, a new technique was validated to test sera for the presence of antibodies to 
myelin-associated glycoprotein (MAG). This antibody is not related to GBS, but to another 
distinct form of immune-mediated neuropathy in which patients have a slowly progressive 
form of loss of sensation, weakness, often causing severe problems in walking and other 
coordinating intended movements. This new ELISA technique was compared to the existing 
golden standard technique of Westernblotting, and showed that ELISA detected anti-MAG 
antibodies more frequently in patients with this neurological phenotype and is a more sensitive 
diagnostic assay. 
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Het Guillain-Barré syndroom (GBS) is een neurologische aandoening die wordt gekenmerkt 
door snel progressieve symmetrisch verdeelde spierzwakte in ledematen en verlies van 
peesreflexen. Gevoelsstoornissen en betrokkenheid van hersenzenuwen komt ook in 
een variabele mate bij patiënten voor. Sommige patiënten hebben een additionele zwakte 
van de ademhalingspieren waardoor zij soms langdurige kunstmatige beademing nodig 
hebben op een intensive care unit. De ziekte wordt veroorzaakt door een post-infectieuze 
polyradiculoneuropathie en heeft een monofasich beloop met een variabel en meestal 
incompleet herstel. Het Miller Fisher syndroom (MFS) is een variant van GBS die wordt 
gekenmerkt door dubbelzien, onvermogen om bewegingen te coördineren en verlies van 
peesreflexen. GBS wordt meestal voorafgegaan door een infectie waarvan Campylobacter 
jejuni de frequentste oorzaak is. C. jejuni komt voor bij 20-50% van de patiënten en is 
geassocieerd met een ernstiger klinisch beloop en een slechtere uitkomst. Andere infecties 
die voorafgaan aan de ontwikkeling van GBS zijn Mycoplasma pneumoniae en virussen 
zoals het cytomegalovirus en Epstein-Barr virus. Een storing in de afweerreactie welke in 
gang wordt gezet om deze infecties te bestrijden, leidt in GBS patiënten tot destructie van 
perifere zenuwen en spierzwakte. Het is aangetoond dat C. jejuni geïsoleerd uit individuele 
GBS patiënten specifieke structuren bevat die lijken op structuren (gangliosiden) aanwezig 
op de menselijke zenuwen. Deze gelijkenis of moleculaire mimicry wordt verantwoordelijk 
gehouden voor de ontwikkeling van antilichamen tegen C. jejuni die kruisreacties geven met 
perifere zenuwen en in dit proces ernstige schade aanrichten. 
Patiënten met GBS fungeren als gastheer voor bacteriën en andere pathogenen. 
Vanuit dit concept is uit eerdere studies gebleken dat verschillende gastheer-gerelateerde 
factoren, met inbegrip van demografische kenmerken, variatie in genen van het immuunsysteem 
en de aanwezigheid van antilichamen tegen gangliosiden, een rol spelen bij het ontstaan en 
beloop van GBS. In verschillende studies werd gevonden dat pathogeen-gerelateerde factoren 
betrokken zijn bij de pathogenese van GBS, waaronder de verschillende soorten voorafgaande 
infecties, zoals C. jejuni, en de moleculaire mimicry met gangliosiden. De doelstelling van 
dit promotie-onderzoek was het identificeren van mechanismen waarmee deze gastheer- en 
pathogeen-gerelateerde factoren GBS veroorzaken waarbij getracht is de klinische relevantie 
van deze factoren af te bakenen. 
Als eerste wordt de epidemiologie van specifieke infecties die geassocieerd zijn met GBS 
beschreven. In Hoofdstuk 2.1 wordt behandeld of CMV-infecties net zo frequent voorkomen 
in GBS als C. jejuni, zoals onlangs werd gesuggereerd in een studie uitgevoerd door een 
andere onderzoeksgroep en was gebaseerd op een analyse van hersenvocht monsters uit 
patiënten waarin gebruik werd gemaakt van een gevoelige moleculaire techniek om het 
virus genoom aan te tonen. Een grote verzameling monsters van hersenvocht afkomstig van 
Nederlandse GBS patiënten werd ter vergelijking door ons getest met een identieke techniek. 
In tegenstelling tot het eerdere rapport, was in deze studie 1 van de 171 monsters positief voor 
CMV. Hoewel er bewijzen zijn dat in ongeveer 15% van de GBS patiënten CMV infecties 
een rol spelen, kunnen we de suggestie dat CMV een vergelijkbare rol speelt als C. jejuni 
(ongeveer 30-40% van alle GBS patiënten) voorafgaand aan het ontstaan van GBS nog niet 
onderbouwen. Het verschil tussen onze resultaten en de eerdere gepubliceerde gegevens kan 
te maken hebben met de selectie van patiënten en het geteste materiaal. 
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In de overige hoofdstukken wordt de aandacht gericht op de meest voorkomende 
infectie voorafgaand aan GBS die wordt veroorzaakt door C. jejuni. Voedselproducten, 
voornamelijk kippenvlees en schaaldieren, kunnen deze darm geassocieerde bacteriën 
bevatten en veroorzaken een gastro-enteritis die met ernstige diarree gepaard kan gaan maar 
ook onopgemerkt kan verlopen. In Hoofdstuk 2.2 wordt beschreven of leeftijd en het seizoen 
waarin een infectie door C. jejuni ontstaat risicofactoren zijn voor het ontwikkelen van GBS. 
Een opvallend omgekeerd patroon werd waargenomen voor seizoen om besmet te raken en 
leeftijd bij het vergelijken van een grote groep patiënten met C. jejuni-gerelateerde gastro-
enteritis met en zonder GBS. C. jejuni-gerelateerde GBS patiënten waren doorgaans ouder 
en werden vaker besmet tijdens de wintermaanden. Dit suggereert dat zowel omgevings- en 
gastheer-gerelateerde factoren een rol kunnen spelen in de ontwikkeling van GBS na C. jejuni 
veroorzaakte gastro-enteritis. Welke processen hieraan ten grondslag liggen is vooralsnog 
onduidelijk. 
In Hoofdstuk 3.1 worden de gecombineerde resultaten beschreven van moleculaire 
en genetische studies uit een reeks van 26 C. jejuni stammen, die werden geïsoleerd uit of 
samenhang hadden met GBS patiënten. Nooit eerder was een groep van C. jejuni stammen 
beschikbaar voor een dergelijk uitgebreid onderzoek naar de moleculaire mimicry theorie en 
de klinische relevantie ervan. Dit laatste bleek uit associaties tussen specifieke ganglioside-
achtige structuren op de buitenkant van C. jejuni en uitvalsverschijnselen bij besmette patiënten. 
Verder werd gezien dat een meerderheid van de C. jejuni stammen uitdrukkelijke combinaties 
van ganglioside-achtige motieven bevatten, hoewel ook stammen zonder ganglioside-achtige 
motieven werden gevonden. De genetische mechanismen die verantwoordelijk zijn voor het 
ontbreken van deze ganglioside-achtige motieven werden geïdentificeerd in een deel van 
deze stammen. In Hoofdstuk 3.2 wordt beschreven dat sommige van deze GBS patiënten 
antilichamen hadden tegen combinaties van gangliosiden, de zogenaamde antilichamen tegen 
ganglioside complexen. Door middel van kruisreactie experimenten werd bewezen dat deze 
antilichamen werden veroorzaakt door besmetting met een C. jejuni stam met een vergelijkbare 
combinatie van ganglioside-achtige structuren aanwezig in deze bacteriën. 
In Hoofdstuk 4 wordt gekeken naar de rol van gastheer-gerelateerde factoren in de 
ontwikkeling van de GBS. Onderzocht werd of het hebben van specifieke variaties in CD1 
genen een rol speelt in het risico voor het ontwikkelen van GBS. CD1 moleculen kunnen 
binden aan bepaalde gangliosiden en worden onder andere gevonden in en op dendritische 
cellen, een specifieke antigeen-presenterende cel van het immuunsysteem en een belangrijke 
coördinator als het gaat om het aansturen van het type immuun-respons voor verschillende 
lichaamsvreemde gevaren. Een eerdere studie in een Italiaans cohort van 65 GBS patiënten 
toonde aan dat specifieke variaties in twee genen van CD1 (CD1A en CD1E) een verhoogd 
risico gaven om GBS te krijgen. Deze belangrijke associatie voor het begrijpen van de 
gevoeligheid om GBS te krijgen, werd in onze Nederlandse database van bijna 400 GBS 
patiënten niet gevonden en kon ook niet geassocieerd worden met specifieke subgroepen van 
patiënten (Hoofdstuk 4.1). Deze inconsistentie illustreert dat genetische associatie studies 
voor ziekten als GBS, grote groepen patiënten met goed gedefinieerde gevallen en strikte 
richtlijnen voor het uitvoeren van dergelijk onderzoek vereisen. De rol van dendritische cellen 
als mogelijke coördinator van de afwijkende immuunrespons bij GBS wordt behandeld in 
Hoofdstuk 4.2. Hiervoor is onderzocht of siaalzuur, aanwezig in het buitenste membraan van 
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C. jejuni en een belangrijk bestanddeel van gangliosiden, de mate van activatie van dendritische 
cellen beïnvloedt. Er werd vastgesteld dat C. jejuni stammen die siaalzuur bevatten 10 keer 
efficiënter zijn in activatie van dendritische cellen in vergelijking met genetisch gemuteerde 
stammen die geen siaalzuur bevatten. Daarnaast vonden we dat door C. jejuni geactiveerde 
dendritische cellen factoren afscheiden die de groei van B-cellen bevorderen; voorlopercellen 
van antilichaam producerende plasmacellen. De betrokkenheid van specifieke receptoren 
bij de activatie van dendritische cellen werd onderzocht en de mogelijke mechanismen met 
betrekking tot de activatie van dendritische cellen, de groei van B-cellen en modulatie door 
siaalzuur is gemarkeerd in de algemene discussie (Hoofdstuk 6). Deze bevindingen geven 
inzicht in de eerste stappen in de pathogenese van GBS en kunnen uiteindelijk leiden tot de 
ontwikkeling van nieuwe preventieve strategieën of therapieën. 
Hoofdstuk 5 is gewijd aan de rol van antilichamen die binden aan perifere zenuw 
koolhydraatstructuren, waaronder glycolipiden en glycoproteïnen, en de rol van antistof 
detectie voor de klinische praktijk. Antilichamen tegen gangliosiden worden voornamelijk 
gezien in GBS maar ook in andere immuun-gemedieerde ziekten van perifere zenuwen. 
Zo worden antilichamen van het IgM isotype tegen het GM1 ganglioside vaak gevonden 
in multifocale motorische neuropathie, een progressieve ziekte met zwakte in verschillende 
spieren met een fragmentarische distributie die langzame maar functioneel ernstige 
achteruitgang veroorzaakt. Hoofdstuk 5.2 beschrijft de uitvoering van een technische 
validatie van de ELISA-techniek gebruikt voor de detectie van anti-ganglioside antilichamen. 
Vervolgens werd een analyse verricht, in meer dan 1000 patiënten die getest zijn op anti-
ganglioside antilichamen, waarin de diagnostische waarde beoordeeld is door vergelijking van 
de testresultaten tussen patiënten met immuun-gemedieerde polyneuropathie en verschillende 
controle-groepen. Hoewel antistoffen tegen gangliosiden niet vaak worden gevonden, 
werd een extra diagnostische waarde vooral gezien in patiënten met een lage a priori kans 
op het hebben van een immuun-gemedieerde oorzaak voor hun ziekte. In Hoofdstuk 5.1 
wordt een typisch voorbeeld gepresenteerd dat de diagnostische waarde van detectie van 
antilichamen tegen het GQ1b ganglioside illustreert. De patiënt had twee episoden met 
zeer vergelijkbare neurologische symptomen. De eerste episode werd veroorzaakt door het 
Miller Fisher syndroom en serum monsters verkregen op dat moment bevatte hoge titers van 
IgG-antistoffen tegen GQ1b. Hierna bleek de patiënt bijna volledig hersteld te zijn. In de 
tweede episode waren deze antistoffen afwezig en toonde een MRI-scan van de hersenen een 
hersenstaminfarct. In Hoofdstuk 5.3 is een nieuwe techniek gevalideerd om sera te testen 
op de aanwezigheid van antilichamen tegen myeline-geassocieerde glycoproteïne (MAG). 
Dit antilichaam is niet gerelateerd aan GBS, maar aan een andere bijzondere vorm van immuun-
gemedieerde neuropathie waarbij patiënten een langzaam progressieve achteruitgang hebben 
van het gevoel en zwakte ontwikkelen die vaak ernstige problemen met lopen veroorzaakt 
en daarnaast problemen hebben met het coördineren van juiste bewegingen. Deze nieuwe 
ELISA-techniek werd vergeleken met de huidige gouden standaard techniek, Westernblotting, 
en liet zien dat ELISA vaker deze anti-MAG antilichamen kon detecteren bij patiënten met dit 
neurologische fenotype en een gevoeliger diagnosticum is.
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LIST OF FREQuENTLy uSED ABBREVIATIONS IN THESIS
Abs   Antibody
APRIL   A Proliferation Inducing Ligand
BAFF   B-cell activating factor
BAFF-R   Receptor for B-cell activating factor
TACI Transmembrane activator and calcium-modulator and cyclophilin 
ligand interactor
BLyS   B-cell activating factor
C. jejuni   Campylobacter jejuni  
CE-ESI-MS  Electrospray ionization mass spectrometry
CIAP   Chronic idiopathic axonal polyneuropathy
CIDP   Chronic inflammatory demyelinating polyneuropathy
CMV   Cytomegalovirus
CSF   Cerebrospinal fluid
cst-II   Campylobacter sialyltransferase II
DC   Dendritic cell
DNA   Deoxyribonucleic acid
EBV   Epstein-Barre virus
ELISA   Enzyme-Linked Immuno Sorbent Assay
F-score   GBS disability score 
GBS   Guillain-Barré syndrome
H. Influenza  Heamophilus Influenza
INCAT   Inflammatory Neuropathy and Treatment
I-PNP    Other inflammatory polyneuropathy 
LOS   Lipo-oligosaccharide
LOS locus  LOS biosynthesis gene locus
LPS   Lipo-polysaccharide
M. pneumoniae  Mycoplasma pneumoniae
MAG   Myelin-associated glycoprotein
mDC   Monocyte-derived dendritic cell
MFS   Miller Fisher syndrome
MMN    Multifocal motor neuropathy 
MND    motor neuron disease
MRC    Medical Research Counsil sumscore
MS   Mass spectrometry
MS    Multiple sclerosis
OD    Optical density
OND    Other neurological diseases
orf   Open reading frame
PCR   Polymerase Chain Reaction
PNP   Polyneuropathy
PP-PNP   Paraprotein-related polyneuropathy
PRR   Pattern-recognition receptor
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RNA   Ribonucleic acid
SGPG   Sulfate-3-glucuronyl paragloboside
SNPs   Single Nucleotide Polymorphisms
STARD   Standards for Reporting of Diagnostic Accuracy
TLR-4   Toll-like receptor 4
TNF   Tumor necrosis factor
WB   Western blot
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APPENDIX 1.
Diagnostic criteria of Guillain-Barré syndrome
Required for the diagnosis
Progressive motor weakness of more than one limb1. 
Areflexia or marked hyporeflexia in very weak muscles (< grade 3 MRC)2. 
Features strongly supportive of the diagnosis
Progression over days to a maximum of four weeks1. 
Relative symmetry2. 
Mild sensory signs or symptoms3. 
Cranial nerve involvement4. 
Onset of recovery 2-4 weeks after progression stops5. 
Autonomic dysfunction6. 
Initial absence of fever7. 
Elevated CSF protein after the first week of symptoms8. 
CSF cell counts of 10 or fewer mononuclear leucocytes/mm9. 3
Abnormal electrodiagnostics with conduction slowing or block10. 
No other identifiable cause11. 
Feautures that rule out the diagnosis
A current history of hexacarbon use1. 
Abnormal porphyrin metabolism2. 
A history or finding of recent diphtheric infection3. 
Lead intoxication4. 
The occurrence of a purely sensory syndrome5. 
Diagnosis of poliomyelitis, botulism, hysterical paralysis or toxic neuropathy6. 
Adapted from the revised version of the diagnostic criteria for GBS, set up by the National 
Institute of Neurological Disorders and Stroke. Asbury AK, Cornblath DR. Assessment of 
diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 1990 (suppl); 27:21-24.
Appendices
204
APPENDIX 2. 
STARD checklist for reporting of studies of diagnostic accuracy 
(version January 2003)
Section and Topic Item # On page #
TITLE/ABSTRACT/
KEYWORDS
1 Identify the article as a study of diagnostic accuracy (recommend 
MeSH heading ‘sensitivity and specificity’).
INTRODUCTION 2 State the research questions or study aims, such as estimating 
diagnostic accuracy or comparing accuracy between tests or across 
participant groups.
METHODS
Participants 3 The study population: The inclusion and exclusion criteria, setting 
and locations where data were collected.
4 Participant recruitment: Was recruitment based on presenting 
symptoms, results from previous tests, or the fact that the participants 
had received the index tests or the reference standard?
5 Participant sampling: Was the study population a consecutive series 
of participants defined by the selection criteria in item 3 and 4? 
If not, specify how participants were further selected.
6 Data collection: Was data collection planned before the index test 
and reference standard were performed (prospective study) or after 
(retrospective study)?
Test methods 7 The reference standard and its rationale.
8 Technical specifications of material and methods involved including 
how and when measurements were taken, and/or cite references for 
index tests and reference standard.
9 Definition of and rationale for the units, cut-offs and/or categories 
of the results of the index tests and the reference standard.
10 The number, training and expertise of the persons executing and 
reading the index tests and the reference standard.
11 Whether or not the readers of the index tests and reference standard 
were blind (masked) to the results of the other test and describe any 
other clinical information available to the readers.
Statistical methods 12 Methods for calculating or comparing measures of diagnostic 
accuracy, and the statistical methods used to quantify uncertainty 
(e.g. 95% confidence intervals).
13 Methods for calculating test reproducibility, if done.
RESULTS
Participants 14 When study was performed, including beginning and end dates of 
recruitment.
15 Clinical and demographic characteristics of the study population 
(at least information on age, gender, spectrum of presenting 
symptoms).
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16 The number of participants satisfying the criteria for inclusion who 
did or did not undergo the index tests and/or the reference standard; 
describe why participants failed to undergo either test (a flow 
diagram is strongly recommended).
Test results 17 Time-interval between the index tests and the reference standard, 
and any treatment administered in between.
18 Distribution of severity of disease (define criteria) in those with the 
target condition; other diagnoses in participants without the target 
condition.
19 A cross tabulation of the results of the index tests (including 
indeterminate and missing results) by the results of the reference 
standard; for continuous results, the distribution of the test results 
by the results of the reference standard.
20 Any adverse events from performing the index tests or the reference 
standard.
Estimates 21 Estimates of diagnostic accuracy and measures of statistical 
uncertainty (e.g. 95% confidence intervals).
22 How indeterminate results, missing data and outliers of the index 
tests were handled.
23 Estimates of variability of diagnostic accuracy between subgroups 
of participants, readers or centers, if done.
24 Estimates of test reproducibility, if done.   
DISCUSSION 25 Discuss the clinical applicability of the study findings.
This checklist was developed by the STARD (STAndards for the Reporting of Diagnostic accuracy studies) group and 
published as Bossuyt PM, Reitsma JB, Bruns DE Gatsonis PP, Glasziou PP, Irwig LM, Moher D, Rennie D, De Vet 
HC, Lijmer JG; Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting of diagnostic 
accuracy: explanation and elaboration” in 2003 by two journals: Clin. Chem. 2003;49:7-18 and Ann. Intern. Med . 
2003:138:W1-12. Checklist and directions can be found at http://www.stard-statement.org. 
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APPENDIX 3. 
Antistoffen tegen myeline-geassocieerd-glycoproteïne (MAG)
Geschreven door M.L. Kuijf en B.C. Jacobs en verschenen als hoofdstuk in “Handboek 
medische laboratoriumdiagnostiek”; Prelum uitgevers, mei 2009, ISBN10:9085620139.
Doel
Diagnostiek bij verdenking op een gammopathie-gerelateerde polyneuropathie.
Benodigde klinische informatie
Standaardinformatie bij aanvraag laboratoriumonderzoek (o.a. identificatie, leeftijd, geslacht, 
klinische gegevens/vraagstelling).
Beschrijving methodes
IgM antistoffen tegen myeline-geassocieerd-glycoproteïne (MAG) worden bepaald door 
middel van een Enzyme-Linked Immuno Sorbent Assay (ELISA). Sera worden daarbij getest 
in ELISA platen waarvan de wells vooraf zijn gecoat met humaan MAG, zodat in het serum 
aanwezige anti-MAG antistoffen kunnen binden. De gebonden antistoffen worden vervolgens 
aangetoond door middel van geconjugeerd anti-humaan IgM antiserum en een enzymatische 
reactie, waarna een kleuromslag optreedt die gemeten wordt met een ELISA reader. De hoogte 
van de antistofreactiviteit tegen MAG welke wordt berekend aan de hand van een standaard 
calibratie curve en uitgedrukt in titer-units. Indien deze antistofreactiviteit hoger is dan de 
grenswaarde is het serum positief voor deze antistoffen.  
Belasting voor de patiënt 
Venapunctie. 
Voorbereiding patiënt 
Geen specifieke voorbereiding; afname kan op elk tijdstip van de dag plaatsvinden. 
Materiaalafname/Fixatie
Afname van bloed middels een venapunctie (stolbuis). De bepaling wordt bij voorkeur 
uitgevoerd in serum. Scheiding van serum door middel van centrifugeren. Indien de bepaling 
plaatsvindt binnen vijf dagen kan het serum worden bewaard bij 2-8°C. Indien de bepaling 
later plaatsvindt kan het serum beter worden bewaard bij -20°C of -80°C. Verzending van 
serum naar een extern laboratorium kan bij kamertemperatuur.
Mogelijke toepassingen
Diagnostiek bij verdenking op een gammopathie-gerelateerde polyneuropathie.
Contra-indicaties
Geen.
Complicaties
Geen.
207
Appendices
Interpretatie
Bij ongeveer de helft van de patiënten met een IgM gammopathie-gerelateerde polyneuropathie 
wordt in het serum IgM antistoffen tegen MAG gevonden. Patiënten met deze antistoffen 
zijn meestal ouder dan 60 jaar en hebben meestal last van distale sensibele stoornissen, met 
name in de vorm van sensore ataxie van de benen. De polyneuropathie is in het algemeen 
langzaam progressief. Bij electrofysiologisch onderzoek wordt in het beginstadium van de 
polyneuropathie kenmerken gevonden van demyelinisatie. Indien bij deze gammopathie een 
maligniteit is uitgesloten, wordt er gesproken van een “monclonal gammopathie of unknown 
significance” (MGUS). MAG speelt een belangrijke rol bij de myelinisatie van zenuwen en 
IgM antistoffen tegen dit glycoproteïne van 100 kD lijken een directe rol te spelen in de 
pathogenese van gammopathie-gerelateerde polyneuropathie. 
Sensitiviteit/specificiteit
De sensitiviteit van anti-MAG antistoffen is 40-75% bij patiënten met een IgM gammopathie-
geassocieerde polyneuropathie. De specificiteit is 99%.
Valkuilen
Geen.
Vergelijking andere methodes
Anti-MAG antistoffen kunnen ook worden bepaald door middel van immunoblotting. 
Deze techniek heeft een hoge specificiteit, maar mogelijk een lagere sensitiviteit dan de recent 
ontwikkelde ELISA voor het aantonen van deze antistoffen. Soms wordt er voor de diagnostiek 
gebruik gemaakt van een combinatie van beide technieken. De gevonden antistoftiters met 
deze twee methoden vertonen echter een matige correlatie. 
Referentiewaarden
Titer-units boven de 1500 worden niet gevonden bij gezonde individuen. 
Zie ook
Antistoffen tegen gangliosiden.
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APPENDIX 4.
Antistoffen tegen gangliosiden
Geschreven door M.L. Kuijf en B.C. Jacobs en verschenen als hoofdstuk in “Handboek 
medische laboratoriumdiagnostiek”; Prelum uitgevers, mei 2009, ISBN10:9085620139.
Doel
Diagnostiek bij verdenking op immuun-gemediëerde polyneuropathie.
Benodigde klinische informatie
Standaardinformatie bij aanvraag laboratoriumonderzoek (o.a. identificatie, leeftijd, geslacht, 
klinische gegevens/vraagstelling).
Beschrijving methodes
Antistoffen tegen gangliosiden worden bepaald door middel van een Enzyme-Linked Immuno 
Sorbent Assay (ELISA) volgens het gevalideerde protocol van de Inflammatory Neuropathy 
Cause and Treatment (INCAT) groep (1;2). Sera worden daarbij getest in ELISA platen 
waarvan de wells vooraf zijn gecoat met gangliosiden (gesialydeerde glycolipiden) zodat in 
het serum aanwezige anti-ganglioside antistoffen kunnen binden. De gebonden antistoffen 
worden vervolgens aangetoond door middel van geconjugeerd anti-humaan IgM en IgG 
antisera en een enzymatische reactie, waarna een kleuromslag optreedt die gemeten wordt 
met een ELISA reader. De sterkte van de verkleuring is een maat voor de hoogte van de 
antistofreactiviteit tegen gangliosiden in het serum. Indien deze antistofreactiviteit hoger 
is dan de grenswaarde is het serum positief voor deze antistoffen. Door middel van een 
verdunningsreeks van het serum kan ook de antistoftiter worden bepaald als maat voor de 
hoogte van de antistofreactiviteit.  
Belasting voor de patiënt
Venapunctie.
Voorbereiding patiënt
Geen specifieke voorbereiding; afname kan op elk tijdstip van de dag plaatsvinden. 
Materiaalafname/Fixatie
Afname van bloed middels venapunctie (stolbuis). De bepaling wordt bij voorkeur uitgevoerd 
in serum. Scheiding van serum door middel van centrifugeren. Indien de bepaling plaatsvindt 
binnen vijf dagen, dan kan het serum worden bewaard bij 2-8°C. Indien de bepaling later 
plaatsvindt kan het serum beter worden bewaard bij -20°C of -80°C . Verzending van serum 
naar een extern laboratorium kan bij kamertemperatuur.
Mogelijke toepassingen
Diagnostiek van immuun-gemediëerde en mogelijk behandelbare vormen van 
polyneuropathie.
Contra-indicaties
Geen.
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Complicaties
Geen.
Interpretatie
In het serum van patiënten met een immuun-gemediëerde polyneuropathie kunnen IgM en 
IgG antistoffen tegen diverse gangliosiden worden gevonden. Gangliosiden zijn gesialydeerde 
glycolipiden die in hoge concentraties aanwezig zijn in neurale celmembranen. Voor de 
diagnostiek kunnen de antistoffen tegen de gangliosiden GM1, GD1a en GQ1b van belang zijn 
(zie tabel). Deze antistoffen lijken een directe rol te spelen bij het ontstaan van deze vormen 
van neuropathie (3). In het algemeen worden antistoffen tegen GM1 en GD1a gevonden bij 
patiënten met een belangrijke motore uitval, terwijl antistoffen tegen GQ1b voorkomen bij 
patiënten met een sensore ataxie en/of oogbolmotoriekstoornissen. Het isotype van de anti-
ganglioside antistoffen is soms gerelateerd aan het type neuropathie. Deze antistoffen kunnen 
met verschillende technieken worden aangetoond, maar alleen van de ELISA volgens het 
INCAT protocol zijn gevalideerde studies beschikbaar (1;2). 
De multifocale motore neuropathie (MMN) is sterk geassocieerd met de aanwezigheid 
van IgM antistoffen tegen GM1. MMN is een chronisch progressieve neuropathie die klinisch 
wordt gekenmerkt door het optreden van een asymmetrische spierzwakte in armen of benen en 
wordt veroorzaakt door een demyeliniserende neuropathie van perifere motore zenuwen (4). 
De patiënten hebben geen of slechts minimale sensore uitval. MMN kan worden behandeld 
met intraveneus toegediende immuunglobulinen (4). 
Het Guillain-Barré syndroom (GBS) is een postinfectieuze acute polyneuropathie. Het 
GBS is een opvallend heterogene aandoening, die kan worden onderverdeeld in diverse 
subgroepen met een typische klinische en electrofysiologische presentatie. Er is er een 
associatie tussen deze subgroepen, het type voorafgaande infectie en de specificiteit van de 
anti-ganglioside antistoffen. Bij patiënten met een voorafgaande gastro-enteritis of andere 
aanwijzingen voor een infectie met de Campylobacter jejuni worden in de acute fase in het 
serum vaak IgG en/of IgM antistoffen tegen GM1, GD1a en GQ1b gevonden (5;6). Bij deze 
patiënten zijn de antistoffen primair gericht tegen het lipo-oligosaccharide van de C. jejuni, 
maar door moleculaire mimicry kunnen deze antistoffen kruisreageren met gangliosiden op 
humane perifere zenuwen (7). De antistoffen tegen GM1 en GD1a zijn geassocieerd met 
ernstige motore uitval, vaak zonder uitval van sensore- of hersenzenuwen. De antistoffen 
tegen GQ1b zijn sterk geassocieerd met de aanwezigheid van oogbolmotoriekstoornissen 
(waaronder ophthalmoplegie). Antistoffen tegen verschillende combinaties van gangliosiden 
kunnen ook voorkomen. Daarnaast worden antistoffen tegen gangliosiden gezien na andere 
typen infecties, waaronder bovenste luchtweg infecties met Haemophilus influenzae (3;6). 
Het GBS is behandelbaar met o.a. intraveneus toegediende immuunglobulinen (8). Meestal is 
er een monofasisch ziektebeloop, soms met ernstige restuitval. De anti-ganglioside antistoffen 
verdwijnen bij patiënten met GBS vrijwel altijd binnen enkele maanden uit het serum. 
Serum IgG en IgM antistoffen tegen GQ1b zijn ook sterk geassocieerd met het Miller 
Fisher syndroom (MFS), dat wordt beschouwd als een variant van het GBS. Het MFS wordt 
gekenmerkt door het klinische trias oogbolmotoriekstoornissen, ataxie en areflexie (9). 
Overige aandoeningen waarbij anti-GQ1b antistoffen kunnen voorkomen zijn de Bickerstaff 
encefalitis en CANOMAD. Bickerstaff encefalitis is een fulminant verlopende ontsteking 
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van de hersenstam die gepaard gaat met bewustzijnsveranderingen (3). CANOMAD is een 
chronische neuropathie gekenmerkt door ataxie, ophthalmoplegie en de aanwezigheid van 
een IgM paraproteine tegen GQ1b en andere disialosyl-gangliosiden (10). Antistoffen tegen 
GM1 en GD1a kunnen ook voorkomen bij enkele andere zeldzame vormen van inflammatoire 
polyneuropathie. 
In typische gevallen kan bij de meeste van deze aandoeningen de diagnose worden gesteld 
op basis van de klinische kenmerken en de bevindingen bij electrofysiologisch en overig 
aanvullend onderzoek. In atypische gevallen echter kan het bepalen van deze anti-ganglioside 
antistoffen een bijdrage leveren aan de diagnostiek. Het klinische belang van het stellen van 
de juiste diagnose is gelegen in het feit dat veel van deze antistof-gerelateerde vormen van 
neuropathie behandelbaar zijn, o.a. met intraveneus toegediende immuunglobulinen (4;8).  
Sensitiviteit/specificiteit
De sensitiviteit voor de verschillende aandoeningen wordt weergegeven in onderstaande tabel. 
IgG antistoffen zijn specifieker dan IgM antistoffen en worden vrijwel uitsluitend gezien bij 
GBS en zuiver motorische vormen van inflammatoire polyneuropathie.
Valkuilen
Sera met een hoge achtergrondactiviteit kunnen vals negatief zijn. 
Vergelijking andere methodes
De resultaten zijn sterk afhankelijk van de gebruikte methode. Alleen van de ELISA volgens 
het INCAT-protocol zijn momenteel gevalideerde resultaten bekend (1;2).
Referentiewaarden
Sera met een antistof-titer van 1:100 of hoger zijn positief (2). 
Zie ook
Antistoffen tegen MAG.
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Tabel. Frequentie van serum IgM en IgG antistoffen tegen de gangliosiden GM1, GD1a en GQ1b in relatie 
tot neuropathie.
GM1 GD1a GQ1b
IgM IgG IgM IgG IgM IgG
MMN1 40-60% - - - - -
GBS2 10-20% 10-20% 5-10% 5-10% 1-5%3 1-5%3
MFS4 - - - - 20–50% >90%
Bickerstaff encefalitis - - - - 10-30% 60-70%
CANOMAD5 - - - - 100% -
Inflammatoire motore PNP6 <5% <5% <5% <5% - -
Gezonde bloeddonoren7 - - - - - -
-, aanwezig bij <0.3% van deze patiënten of personen. 
1 Multifocale motore neuropathie.
2 Guillain-Barré syndroom.
3 Bij GBS met ophthalmoplegie bij > 90 %.
4 Miller Fisher syndroom.
5  Chronische Atactische Neuropathie met Opththalmoplegie, M-proteïne, koude Agglutininen en antistoffen tegen  
Disialyl-gangliosiden.
6  Chronisch inflammatoire demyeliniserende polyneuropathie (CIDP), polyneuropathie (PNP) geassocieerd met  
paraproteïnen, mononeuritis multiplex, andere chronische vormen van inflammatoire PNP.
7  Gebaseerd op een studie van 110 gezonde bloeddonoren uit regio Rotterdam (2).
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Dit proefschrift maakt deel uit van een lange reeks van eerder gepubliceerde Rotterdamse 
proefschriften over het Guillain-Barré syndroom (GBS), waaraan talloze onderzoekers, clinici 
en bovenal honderden patiënten meewerkten. Ook bij de totstandkoming van dit proefschrift 
zijn veel mensen betrokken geweest. Voor hun onmisbare bijdrage wil ik hen zeer bedanken. 
Verder gaat mijn dank in het bijzonder uit, ten eerste naar mijn promotor prof. dr. P.A. van 
Doorn die het tot stand komen van mijn proefschrift heeft mogelijk gemaakt. Beste Pieter, ik 
herinner me nog als de dag van gisteren dat ik op aanraden van Mathieu van der Jagt jouw 
kamer betrad om te praten over onderzoek. Spoedig volgde op jouw initiatief een afspraak 
met Bart Jacobs. Je terugkerende opmerkingen met betrekking tot “de link naar de kliniek” 
kon ik niet altijd gemakkelijk verwerken in mijn mechanistische onderzoek, maar hebben er 
uiteindelijk toe geleid dat er een geïntegreerd geheel ontstond. Je hebt me altijd betrokken 
bij klinische taken, bijeenkomsten en internationale contacten, wat ik erg gewaardeerd heb. 
Het laten regelen van vliegtickets door mij als één van je AIOS bleek niet helemaal zonder 
risico’s te zijn maar mede dankzij jouw flexibiliteit is ook dat goed gekomen! 
Het was voor mij een grote eer om dr. B.C. Jacobs als co-promotor te hebben. Beste Bart, 
door de jaren heen ben je voor mij een groot leermeester geweest. Ik wil je graag bedanken 
voor de ruime aandacht en tijd die je altijd voor me hebt vrijgemaakt. De zorgvuldigheid 
waarmee je vliegensvlug mijn stukken beoordeelde heeft zeker als voorbeeld gediend en 
heeft zijn weerslag gehad op zowel mijn wetenschappelijke als klinische werkzaamheden. 
Jouw humor die alles relativeert was op de werkvloer en daarbuiten een noodzakelijke en 
prettige strategie voor het oplossen van mijn soms wat zwaarmoedige stemming, waarmee 
ik je wel eens heb bestookt. Door het delen van gemeenschappelijke interesses mochten we 
elkaar ook buiten het werk regelmatig treffen waarbij we dit jaar samen zelfs een literair 
lustrum konden vieren. Dat haring met champagne een uitstekende combinatie is neemt niet 
weg dat we ook het oestermes uit Normandië binnenkort eens een keer van pas moeten laten 
komen!
Veel dank ben ik verschuldigd aan de leescommissie te weten prof. dr. J.D. Laman, 
dr. E.E.S. Nieuwenhuis en prof. dr. A. van Belkum. Beste Jon, intrigerende en vaak nuttige 
informatie bereikten regelmatig mijn postvak waarbij je betrokkenheid altijd tastbaar was 
door het vinden van mijn naam boven aan het artikel in jouw kenmerkende handschrift. 
Beste Edward, min of meer vanaf het prille begin heb jij het proces gevolgd. Tijdens de 
wekelijkse dinsdagochtend besprekingen waren je lovende woorden vaak stimulerend en 
wist je snel nieuwe bevindingen in perspectief te plaatsen. Kennisoverdracht speelde een 
centrale rol waarbij het adagium “ask the expert and you know it” van grote betekenis was. 
Beste Alex, ik laat het visjes voeren en het volume niveau van je muziek op je werkkamer 
even voor wat het is, maar je bent een geweldige organisator en ik heb met veel plezier met 
je samengewerkt. 
Een beslissend moment voor mij in de afgelopen jaren was de komst van dr. J.N. Samsom 
uit de VU Amsterdam naar het Laboratorium Kindergeneeskunde van het Erasmus MC. 
Beste Janneke, met veel voortvarendheid gaf jij het cellulaire onderzoek een cruciale nieuwe 
impuls. Met gezwinde spoed bedacht je pragmatisch steeds een nieuw plan en had je een 
inhoudelijke scherpe bijdrage. Ook ben ik je dank verschuldigd voor je hulp bij het geven van 
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presentaties en heb ik je persoonlijke betrokkenheid bij het reilen en zeilen van een thans meer 
onthaaste promovendus erg gewaardeerd.
Honderden experimenten werden opgezet, uitgevoerd en geanalyseerd door de analisten 
Wouter van Rijs en Anne Tio-Gillen van de afdelingen Neurologie en Immunologie. Wouter, 
maar een enkele keer heb ik je in de stress weten te krijgen wanneer ik weer met verkeerde 
berekeningen kwam of de verkeerde buis materiaal overboord gooide. Dankzij jouw precisie 
in pipetteren en sterk analytisch denken is een belangrijk deel van het proefschrift tot stand 
gekomen. Anne, een sterk ontwikkeld geweten was onontbeerlijk voor de validatie studies 
die hard nodig waren en waar we nu de vruchten van plukken. De patiënt met GBS op de 
achtergrond was altijd voelbaar wanneer ik met je werkte en dat gaf een speciale band voor 
het werk dat we samen deden. Jouw ervaring en inzicht hielpen mij altijd verder tijdens 
momenten van twijfel. Geen goede publicaties zonder grondig onderzoek vooraf en geen 
gronding onderzoek zonder goede samenwerking tussen analisten en promovendus. Anne en 
Wouter, veel dank!
Dank ben ik ook verschuldigd aan de collega’s van het Laboratorium Kindergeneeskunde, 
in het bijzonder aan Lisette van Berkel, Lianne Ruiter, Ytje Oosterhuis, Rolien Raatgreep, 
Dicky Lindenbergh-Kortleve, Jeroen Hol, Pieter van Lierop, Fleur du Pré, Sylvia Brugman en 
Colin de Haar. Tijdens de presentaties op de vele dinsdagochtenden wanneer ik de resultaten 
die ik samen met Wouter had geboekt mocht laten zien, werden door jullie altijd nuttige 
aanvullingen gedaan. Dank dat jullie telkens weer de moeite namen om die bacterie stammen 
met verschillende siaalzuur configuraties uit elkaar te houden.
Op de afdeling Immunologie wil ik graag alle collega’s van de ‘sleuf’ bedanken. In de 
sleuf, een geïmproviseerde smalle uitwerkruimte voor experimenten en tevens dienstdoend als 
koffiekamer, werd mijn onhandigheid en onwetendheid altijd op tactvolle wijze behulpzaam 
opgelost. Ruth Huizinga wil ik in het bijzonder danken voor haar nuttige bijdrage tijdens de 
laatste fase van het DC onderzoek. De perfecte secretariële ondersteuning van Wendy van 
Netten en Marcia IJdo-Reintjes heeft enorm bijgedragen aan de gewenste presentatievorm 
van dit proefschrift.
De langlopende en goede samenwerking met de medisch microbiologen is van essentieel 
belang geweest voor het GBS onderzoek in het Erasmus MC. Graag wil ik Hubert Endtz 
bedanken voor zijn snelle en zinvolle bijdrage aan manuscripten en Wim Ang voor zijn 
betrokkenheid bij lopende GBS studies en algemene adviezen over richting en hypotheses 
in het GBS-veld. Mathijs Bergman wil ik bedanken voor de onderhoudende besprekingen in 
de trein over Siglec’s. Peggy Godschalk, Astrid Heikema en Rogier Louwen bedank ik voor 
de prettige samenwerking en de assistentie bij het opkweken van de bekende Campylobacter 
jejuni stammen. 
Apart wil ik enkele woorden besteden aan de 22e verdieping en kamer Ee-2230. Ik vond 
het een verademing na mijn 1e dampige jaar als zwoegend AGNIO vanaf zo hoog te kunnen 
werken en uitkijken over Rotterdam en omstreken, in een betonnen cel waar de waterleidingen 
en kabels bloot aan het plafond hingen. Ik kwam er toch op een bepaalde manier tot rust. 
Het idee bestond toen nog bij mij dat wetenschap vanzelf naar je toe zou komen als je maar 
voldoende ontspande en tijd nam om te lezen en te schrijven. Wellicht door toedoen of in 
elk geval in medeplichtigheid van enkele collega’s werd dit concept in het eerste jaar goed 
getoetst op zijn negatieve waarde voor wetenschappelijke vooruitgang. Koffie pauzes werden 
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wel eens koffie-uurtjes en een lunchpauze een heus drie gangen menu. Toch heeft dit alles 
een basis gelegd voor een creatieve en betrokken groep collega’s die allen zeer gedreven 
aan hun doelen bezig zijn en waarvan sommigen ongetwijfeld nu de vruchten plukken van 
die rust uit de beginjaren. Enkele namen van collega’s die de afgelopen jaren met mij op de 
22e gewerkt hebben en die ik allen dank voor de prettige werksfeer zijn Karin Geleijns, 
Maaike Dirks, Rinze Neuteboom, Marie-Claire de Wit, Eric van Breda, Bas ter Meulen, 
Naghmeh Jafari, Nadine van der Beek, Ilse Hoppenbrouwers, Krista Kuitwaard, Liselotte Ruts, 
Sonja van Nes, Christa Walgaard, Marcel Garssen, Heleen den Hertog, Immy Ketelslegers, 
Juna de Vries, Laura Donkerkaart, Harro Seelaar, Alex Korsten en Karin ter Meulen - Boer. 
Daarnaast wil ik de verpleging van de afdeling Neurologie, alle overige arts-assistenten van 
de afdeling Neurologie en alle neurologen bedanken voor hun flexibiliteit en medewerking 
aan het vervolgen van opgenomen patiënten met GBS die meededen met klinische studies. 
Mijn paranimfen wil ik in het bijzonder bedanken voor hun moed. Joost, dank dat je ook 
vandaag aan mijn zijde wilt staan, zoals je dat doet sinds onze ontmoeting in RSG. Maaike, 
hierboven al genoemd, veel dank voor je betrokkenheid en steun bij al mijn aarzelingen 
en voor je vriendschap. Over niet al te lange tijd sta jij hier ook! Mijn vrienden Masoud, 
Erik en Nils wil ik bedanken voor hun oprechtheid. Veel te lang geleden bereikten we onze 
laatste bergtop gezamenlijk, op de naar de volgende!
Mijn familie wil ik danken voor de vreugde die ik van hen meekreeg. Felix Thijssen sr. 
wil ik postuum eren als aanstichter. Mijn ouders lazen met goede moed altijd het abacadabra 
dat ik hen toestuurde. Lieve Ber, Lies en Linde, veel dank voor jullie steun in de keuzes die 
ik maak en jullie onvoorwaardelijke liefde. Ook de Wamstekers wil ik bedanken voor hun 
betrokkenheid en hulp thuis van de afgelopen maanden op mijn `vrije` vrijdagen.
Mijn levensvreugde dank ik aan Erika, Simon en Basiel. Lieve Erika, het afronden van 
dit proefschrift is ongetwijfeld gelukt dankzij jouw doorzettingskracht. Met grote klasse weet 
je drie mannen in huis te aarden en dit te combineren met een drukke baan. Wie weet is zo’n 
proefschrift ook wel wat voor jou! “Papa gaat werken?”, zullen we nog wel even blijven horen 
van Simon wanneer ik ’s avonds onverwacht mijn schoenen tevoorschijn haal. De nachtelijke 
werkuurtjes mocht ik de afgelopen maanden nu en dan afwisselen met het in slaap wiegen van 
Basiel, hetgeen ook een relativerende invloed had op de werkstress. Mijn ware levensplezier 
deel ik met jullie.
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ABOuT THE AuTHOR
Mark Laurens Kuijf was born on the 1st of February 1977 in Arnhem, The Netherlands. 
After finishing high school he started his training in Medicine in 1995 at the Erasmus 
University of Rotterdam. During that period he worked from 1997 until 2000 as a nurse-
assistant at the department of Neurology of the Erasmus MC and in 2001 completed a 
placement at the Neurology department of the University hospital of Juiz de Fora, Brazil. 
He graduated in 2002 on a research project about the diagnostic value of fine-needle biopsies 
in the rejection of liver transplantation under the supervision of Dr. H.J. Metselaar and 
Dr. J. Kwekkeboom at the department of Gastroenterology of the Erasmus MC, Rotterdam. 
After this he worked from 2002 until 2003 as a medical doctor at the department of Neurology 
of the Erasmus MC. In the winter of 2003 he started his PhD project on Guillain-Barré 
syndrome under the supervision of Dr. B.C. Jacobs and Professor P.A. van Doorn from the 
departments of Immunology and Neurology of the Erasmus MC and started his training for 
neurologist under supervision of Professor P.A.E. Sillevis-Smitt in 2005.
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General courses
Classical methods for Data-analysis
Animal research course according to Law on 
research animals, article 9
2006
2007
5.7
4
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Pre-congress Teaching course, 5th European 
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2005
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2
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Department Journal club and seminars 2004 - 2008 20
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International Congress 
(oral presentation)
European Congress 
International Congress 
(oral and poster presentation)
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oral presentation)
International Congress 
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1
1
1
1
1
1
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